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2016 Statistics 
at a Glance 
EXPORT CERTIFICATES ISSUED – 
1,429 CERTIFICATES FOR MEDICINES 
AND 2,122 FREE SALE CERTIFICATES 
FOR MEDICAL DEVICES
3,551
CLINICAL TRIALS OF HUMAN 
MEDICINES WERE APPROVED TO 
COMMENCE IN IRELAND
108
  
VARIATIONS TO MARKETING 
AUTHORISATIONS ISSUED – 14,207 
FOR HUMAN MEDICINES AND 1,341 
FOR VETERINARY MEDICINES
15,548 
THE TOTAL NUMBER OF NEW HUMAN 
MEDICINES AUTHORISED
637
APPLICATIONS FOR CLINICAL 
INVESTIGATIONS OF MEDICAL 
DEVICES TO BE CONDUCTED IN 
IRELAND
10
NEW MARKETING AUTHORISATION 
APPLICATIONS FOR VETERINARY 
MEDICINES RECEIVED
126
MANUFACTURING LICENCES IN 
PLACE AT YEAR END – 103 FOR 
HUMAN MEDICINES AND 24 FOR 
VETERINARY MEDICINES
127 
THE NUMBER OF EMA SCIENTIFIC 
ADVICE PROCEDURES WHERE 
THE HPRA ACTED AS LEAD 
51
2
EU PSUR SINGLE ASSESSMENT 
PROCEDURES FOR HUMAN 
MEDICINES LED BY THE HPRA
31 
ENFORCEMENT CASES WERE 
INITIATED IN RESPECT OF POTENTIAL 
BREACHES OF HEALTH PRODUCTS 
LEGISLATION
4,054 S
SUSPECTED ADVERSE REACTION 
REPORTS FOR HUMAN MEDICINES 
RECEIVED
3,264
MEDICINE RECALLS CONSISTING 
OF 201 HUMAN MEDICINES AND 8 
VETERINARY MEDICINES
209
EVER HPRA PUBLIC INFORMATION 
CAMPAIGN PROMOTING THE SAFE 
USE OF MEDICINES
MARKET SURVEILLANCE CASES 
INVESTIGATED IN RESPECT OF 
MEDICAL DEVICES
1st 335 
GMP INSPECTIONS CONDUCTED AT 
MANUFACTURING SITES FOR HUMAN 
AND VETERINARY MEDICINES AND 
ACTIVE SUBSTANCES
94
COSMETIC PRODUCTS SENT 
FOR LABORATORY TESTING 
471
MEDICAL DEVICE VIGILANCE 
REPORTS RECEIVED AND 
ASSESSED
2,216 
REPORTS OF SUSPECTED ADVERSE 
REACTIONS ASSOCIATED WITH THE 
USE OF VETERINARY MEDICINES
337
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4It was a great honour to be appointed Chairperson 
of the HPRA and I now have the pleasure of 
presenting the 2016 Annual Report.
2016 was the 50th anniversary of the establishment 
of the National Drugs Advisory Board (NDAB), a key 
milestone in our organisation’s history. The NDAB 
developed over the years to become the Irish Medicines 
Board and eventually the HPRA. In the intervening 
period, the role of this organisation has grown from a 
purely advisory capacity to the Minister for Health for 
medicines, through to the competent authority it is 
today overseeing the regulation of a range of health 
products on the Irish market. Over time, it has secured 
a reputation nationally and internationally for the 
excellence of its regulatory model and approach. 
The year in review is particularly significant in that it 
witnessed the start of the HPRA’s new Strategic Plan 
2016-2020. This follows the successful completion and 
delivery of our last strategy from 2011-2015 which 
elevated the organisation’s work platforms to new levels 
of output and engagement. The new strategy builds on 
this success, setting out a robust roadmap to focus the 
organisation’s activities into the future. It was developed 
after lengthy and detailed consultation with staff and a 
range of external stakeholders, including, importantly 
those who use health products, and is in line with 
Department of Health priorities. The Strategic Plan was 
approved by the Authority at its meeting in December 
2015.
Our role is to continually protect and enhance public 
and animal health. In short, we seek to ensure that the 
health products we regulate are effective and that they 
are as safe as possible for those that rely on the benefits 
they can give. Ours is a broad and extensive remit as 
we act as the competent authority for the regulation of 
human and veterinary medicines, medical devices, blood 
products, tissues and cells, organs for transplantation 
and controlled drugs. We are also responsible for the 
regulation of cosmetic products and for the protection of 
animals used for scientific purposes. The Strategic Plan 
2016-2020, which reflects the key issues and work areas 
highlighted during the consultative process, will enable 
us to continue to deliver on our consumer protection 
role whilst also shaping our organisation to evolve 
as dynamically as the industries and sectors that we 
regulate. It sets out five core strategic goals (as outlined 
below) which are supported by 17 high level actions. 
HPRA Strategic Goals 2016-2020
Chairperson’s 
Statement
Optimised regulatory systems
Keeping pace with product and 
manufacturing developments
Supporting innovation
Providing regulatory support and 
advice to research and 
development centres
Internal capabilities
Ensuring strong internal systems, 
resources and expertise
Access to health products
Enhancing regulatory support to
access
Better informed users
Providing current information to 
inform choices and decisions
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These goals and defined actions will underpin our 
workload for the next four years. As this timeframe is 
long, we must also be ready to adapt to significant 
changes in our operating environment and be flexible 
in terms of renewing our strategic priorities. However, 
we have already completed the first year of an exciting 
journey and 2016 saw the delivery of some key 
highlights and firsts for our organisation. 
We undertook our first ever public information 
advertising campaign across a range of media channels, 
including social media. The focus of our campaign was 
to encourage people taking medicines themselves 
or caring for others to Take 3 Minutes to read the 
information on the label and leaflet that accompanies 
their medicine. It was devised in light of consumer 
research we commissioned which showed that a quarter 
of Irish adults do not read the directions for use that 
comes with the medicines that they take. We will 
relaunch the campaign at various stages during 2017 
to continue to remind people of the vital importance of 
taking care when taking medicines. 
We had another first with the launch of our Innovation 
Office which we established to provide regulatory 
advice and assistance to those entrepreneurs, academics 
and small innovative companies developing novel 
health products or technologies. The Innovation Office 
focuses on directly assisting them in their understanding 
and compliance with EU and national regulations 
at the development stage of their innovations. Our 
dedicated in-house service is managed by a team of 
experienced regulatory and scientific experts who can 
help with queries relating to initial research and design, 
formulation, testing, clinical studies and the manufacture 
of new products or technologies. Ultimately, our goal 
is to facilitate the delivery of innovative products and 
technologies to the market and, by so doing, ensure 
patients have timely access to the most effective and 
safe health products possible. 
Brexit was a major event in 2016. Following the news 
of the UK’s referendum decision to exit the EU in June, 
the HPRA reviewed the potential impact this could 
have on the various aspects of our regulatory work 
and we commenced engagement with our European 
colleagues.The focus of our Brexit planning is clear and 
that is to ensure that patients continue to have access to 
necessary and appropriate health products both during 
and post the exit process. This will be an important part 
of our work in the coming years and will necessitate 
close continued collaboration with our partners 
nationally, with the European Medicines Agency and 
with our colleagues in the other European competent 
authorities for medicines, medical devices and other 
health products.
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Management 
Committee
2016 was my first year as Chief Executive of the 
HPRA, a role that I commenced at the beginning of 
January. I am very proud of what has been another 
year of high performance for the HPRA which 
demonstrates again our absolute commitment to the 
protection and enhancement of public and animal 
health.
At the start of the year, the organisation launched its 
Strategic Plan 2016-2020 which outlines our goals, 
objectives and high-level strategic actions for this 
period. The plan was prepared in consultation with staff 
and a range of external stakeholders including those 
who use health products, and in line with Department 
of Health priorities. 
The strategic goals are:
1. Optimised regulatory systems;
2. Better informed users;
3. Access to health products;
4. Supporting innovation;
5. Internal capabilities.
The actions and activities identified in our strategic 
plan provide a clear roadmap for the future focus and 
development of the HPRA. It involved an extensive 
analysis and consultation process through which we 
gained an important insight into how our environment 
will evolve over the coming years. We are committed 
to acting upon this to ensure continued regulatory 
excellence. 
However, it must be acknowledged that the year 
passed has presented unanticipated developments, 
which may have an impact on our priorities. The most 
notable being the outcome of the United Kingdom’s 
European Union membership referendum, which has 
potential consequences for our role in the regulation 
of medicines, medical devices and cosmetics. These 
also extend to the continuity of the European networks 
within which we operate for these products. One direct 
consequence of the UK’s decision to leave the EU is 
that the European Medicines Agency (EMA) will have 
to move from London. During 2016, a key focus for 
the HPRA has been supporting the Irish Government 
in its bid to relocate this Agency, with its crucial role 
in the authorisation and monitoring of medicines, 
to Dublin. As an organisation, we can be confident 
in our demonstrated ability to adapt and evolve to 
changing needs and we will embrace and overcome 
the challenges that lie ahead to ensure the continued 
protection of public and animal health.
The regulatory role of the HPRA continues to evolve 
and grow in line with new national and European 
legislation, and in response to other changes and 
developments in our operating environment. I would 
like to take this opportunity to highlight a number of 
specific initiatives where we have made significant 
progress this year and where our work will enhance the 
support we are providing to our valued stakeholders. 
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New Developments for Patients and 
Animal Health
2016 saw our organisation make significant 
advancements in our approach to supporting 
innovation. Key to this was the establishment of the 
HPRA Innovation Office. The office provides regulatory 
support and advice to individuals, academics, 
small and medium enterprises, pharmaceutical and 
medical device companies, and other groups in the 
development of a novel concept, idea or approach 
into a prototype, product or technology. The aim is to 
provide real and practical benefits for patients, health 
providers and the life sciences sector spanning from 
early stage development to post-authorisation research 
and monitoring. 
The HPRA holds at its core protection of the health 
of those who use and benefit from the products we 
regulate. Patient engagement is therefore of immense 
importance to the HPRA and an area in which we 
continue to expand our focus. An example of this was 
our commitment in 2016 to support the Irish Platform 
for Patient Organisations, Science and Industry (IPPOSI) 
in their initiative to develop a national expert patient 
training programme. Graduates of the programme 
will bring invaluable patient expertise and insight 
throughout the entire medicines development process.
Another important development, which will directly 
benefit Irish patients, is our commitment to taking 
on a new and expanded role in the co-ordination 
and management of medicines shortages in order to 
ensure, insofar as possible, uninterrupted supplies of 
medicines. Collaboration with those already involved in 
the management of shortages at a national level as well 
as interaction with our European counterparts will be 
key to the success of this initiative. 
The last year saw a number of significant legislative 
developments in the finalisation of new medical device 
legislation, which will provide a new framework in 
Europe focused on better public health protection 
through enhanced requirements for the safety and 
performance of devices. We also continued our work 
on the implementation of the new Clinical Trials 
Regulation, which aims to enhance the number of 
clinical trials conducted in Europe for the direct benefit 
of patients. 
Network Participation
During the year, we continued with our absolute 
commitment to the European regulatory networks. Of 
particular significance, was the unanimous election of 
our colleague Dr David Murphy as Chair of the EMA 
Committee for Medicinal Products for Veterinary Use 
(CVMP) in June. 
Our network participation goes beyond involvement at 
a European level; we continue to be strong participants 
within the International Collation of Medicines 
Regulatory Agencies and the International Medical 
Device Regulators Forum. The HPRA continues to 
play leadership roles in both of these forums through 
our membership of their executive committees. This 
work plays a vital role in bringing about greater 
harmonisation and convergence of regulatory 
approaches at a global level to the benefit of regulators 
and our stakeholders. 
Parliamentary Affairs 
The HPRA engaged significantly with elected 
representatives and government officials throughout 
2016. We responded to 53 parliamentary questions 
during the year while a further 116 requests for 
information were received from the Department of 
Health, other Government departments and members 
of the Oireachtas. 
In November 2016, the Minster for Health requested 
the HPRA to provide scientific advice in respect of the 
potential medical use of cannabis. The HPRA convened 
an expert working group to assist with its review of this 
matter. ‘Cannabis for Medical Use - A Scientific Review’, 
which outlines the key findings and conclusions of 
the working group, was published by the Minister in 
February 2017. We also addressed the Oireachtas Joint 
Committee on Health on 24 November of 2016 on this 
matter. 
Stakeholder Engagement and 
Communications
As an organisation, we value the importance of 
engagement with healthcare professionals, patients, 
industry and other key stakeholders. We have strived to 
achieve this through active communication and events 
throughout the year. One of the highlights included 
our information day for medical devices while we also 
hosted a range of seminars and training events. 
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I am particularly proud of the work our communications 
team completed in 2016 which brought about new 
mechanisms to facilitate this engagement through 
social media and our first ever national public 
information campaign, entitled ‘Take 3 Minutes’. The 
focus of these initiates was to develop a greater public 
awareness of the HPRA and our role. 
Organisational Management
In this year, we have also enhanced our focus on the 
development of internal capabilities including the 
progression of a major infrastructure project through 
the development of a new consolidated workflow 
system. Other key initiatives include the launch of 
our first HR strategy focused on many key talent 
management objectives, and the development of 
systems to enhance our knowledge management 
capabilities.
The HPRA is largely self-funded by a system of fees 
which are approved annually by the Minister for Health, 
following a public consultation. This approach is in 
line with the typical funding model of health products 
regulation worldwide. We are committed to the 
highest standards of independence and governance 
so as to ensure quality of service combined with value 
for money and we continued in 2016 to successfully 
manage the affairs of the HPRA in line with our 
statutory obligation that income at least meets costs.
The Future
2016 was also a significant milestone for the HPRA 
in that we celebrated the 50th anniversary of the 
establishment of our organisation. We have had 
an incredible journey over that timeframe bringing 
us to the point today where we now regulate nine 
distinct classes of health products. As a health product 
regulator we have one of the widest remits of any 
agency operating in this area on a global basis. We 
are also well placed to continue on our development 
trajectory. Our investment in innovation, stakeholder 
engagement and building internal capabilities position 
us well as we continue on our journey to meet the 
challenges of being a regulator of the future. 
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Medicines
It is the role of the HPRA to ensure that medicines 
are as safe as possible and do what they are 
intended to do. We grant licences for medicines 
subject to a review of their safety, quality and 
effectiveness and continuously monitor their use 
once they become available on the Irish market. 
We also approve and monitor clinical trials, inspect 
and license manufacturing sites and wholesalers, 
and investigate activities associated with the illegal 
supply, manufacture, wholesale or advertising of 
medicines.
Authorisation and Registration
Scientific Advice
Scientific advice is a pre-authorisation activity which 
assists product and technology innovation and 
development.
European Scientific Advice
The European Medicines Agency (EMA) operates 
a scientific advice system for innovative medicinal 
products (medicines) which may ultimately be 
the subject of applications under the centralised 
authorisation system. During 2016, the HPRA acted 
as lead in 51 EMA scientific advice procedures for 
medicines proposed for the treatment of a broad range 
of conditions. Areas of focus included medicines to 
treat respiratory disorders, auto immune inflammatory 
diseases, cancers and blood disorders, monoclonal 
antibodies and biosimilar medicines. 
National Scientific Advice 
A new national scientific and regulatory advice 
procedure was established by the HPRA in July 
2016. Advice is issued to applicants to assist in the 
development of new or existing human medicines for 
commercial and non-commercial entities. Advice can 
be sought from the HPRA on preclinical, quality and 
specific clinical areas as well as regulatory issues. A 
guideline, template request form and fee structure were 
developed and published on the HPRA website. By 
the end of 2016, we had received 13 enquiries under 
this procedure. We issued national scientific advice in 
respect of four applications while in nine cases scientific 
advice was not required.
Borderline Product Classification
For products for human use, a classification service 
is operated for products which are on the borderline 
between medicines and other products such as food 
supplements, cosmetics and medical devices. Requests 
for classification, whether external or internal, are 
presented to an internal, multidisciplinary classification 
committee. This committee met six times in 2016 
considering a total of 49 new products and revisiting 
five products from pre-2016.
The committee has a close working relationship with 
the Food Safety Authority of Ireland (FSAI). During 
the course of 2016, the FSAI notified the HPRA of 185 
products which had been brought to its attention and 
which it considered to fall more appropriately under 
the HPRA’s remit. Where this turned out to be the case, 
these products were followed up by the HPRA.
Clinical Trials
The role of the HPRA is to assess applications from 
sponsors to conduct clinical trials in Ireland. Sponsors 
include pharmaceutical companies and academic 
research institutions. The HPRA approves the clinical 
trial protocols which describe in detail how each trial 
is to be conducted and outlines the steps that will be 
taken to protect the health of subjects.
In 2016, 108 clinical trials were approved to commence 
in Ireland. The same number of trials was approved in 
the previous year.
Voluntary Harmonisation Procedures
A voluntary harmonisation procedures (VHP) is a 
co-ordinated work-sharing assessment procedure 
for multinational clinical trials. This procedure was 
established by the national competent authorities for 
clinical trials across the European Union. The VHP is 
similar to the approval process for clinical trials under 
planned new legislation, which is expected to come 
into force in 2019. For this reason, it is popular with 
sponsors wishing to gain experience and the HPRA 
continues to actively participate in this procedure. 
The HPRA participated in 22 VHPs for clinical trials 
during 2016, compared with 15 during the previous 
year. The HPRA acted as lead Member State for the 
assessment of eight of these VHPs in 2016.
Medicinal Product Authorisations
New Marketing Authorisation Applications 
Prior to a new medicine being placed on the Irish 
market, it must be assessed and authorised (licensed) 
by the HPRA or by the European Medicines Agency 
(EMA) in conjunction with the European Commission. 
The assessment involves establishing that a medicine’s 
health benefits outweigh its known risks. Where this is 
the case, it may be granted a marketing authorisation.
There are a number of routes through which a medicine 
can be authorised by the HPRA. These include the 
national procedure, the mutual recognition procedure 
(MRP) and the decentralised procedure (DCP). Both 
MRP and DCP involve the simultaneous submission of 
applications in a number of EU Member States. The 
assessment involves the input from all of the relevant 
competent authorities in evaluating the benefit-risk of 
the medicine. The DCP route differs from the MRP in 
that the medicine has not previously been authorised 
within the EU.
The following applications were assessed by the HPRA 
during 2016: 
– 71 new national applications; 
– 55 applications made under the MRP; 
– 322 applications made under DCP. 
The HPRA acted as reference (lead) Member State for 
the assessment of three of the MRPs and nine of the 
DCPs.
The centralised route is another mechanism whereby 
medicines can be authorised in Ireland. In this 
procedure, the assessment is carried out by Member 
States appointed as lead assessor (rapporteur), joint 
lead assessor (co-rapporteur) and peer reviewer, with 
input also from all other Member States. A centralised 
procedure is coordinated by the EMA with authorisation 
granted by the European Commission. The centralised 
route involves the submission of a single application to 
the EMA, and the authorisation once granted is valid 
in all Member States. In 2016, the HPRA was allocated 
five rapporteurships, nine co-rapporteurships and 
six procedures as peer reviewer by the Committee 
for Medicinal Products for Human Use (CHMP) at 
the EMA. These included treatments for respiratory, 
musculoskeletal, dermatological, gynaecological and 
orphan diseases. A number of these applications were 
for biological medicines.
The total number of new medicines authorised in 2016 
was 637. This figure includes 169 medicines authorised 
through the centralised route where the HPRA was 
neither rapporteur nor co-rapporteur. In overall terms, 
the number of medicines authorised decreased relative 
to 2015 when the total number of new medicines 
authorised was 806.
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Parallel Product Authorisations
A parallel imported medicine is a product which is 
equivalent to one already authorised on the Irish 
market and imported from an EU Member State or 
from a European Economic Area (EEA) country, by 
someone other than the importer appointed by the 
marketing authorisation holder of the product on the 
Irish market. A total of 57 parallel product applications 
were authorised by the HPRA in 2016.
Traditional Herbal and Homeopathic 
Medicinal Products
During 2016, nine traditional herbal medicinal products 
(THMPs) were authorised by the HPRA. This is a 
simplified registration scheme which takes into account 
the tradition of use of these medicines. Legislation 
requiring registration for THMPs came into effect in full 
in 2011. The number of applications received by the 
HPRA since that time has remained low. A total of 49 
THMPs are now authorised for sale in Ireland. 
One homeopathic medicine was granted a marketing 
authorisation during 2016. There were no homeopathic 
medicines authorised under the simplified rules 
scheme. As a result, the total number of these 
medicines registered at year end was 99.
Transfer Applications 
The HPRA processed a total 209 human medicine 
transfer applications in 2016. Of these, 187 related to 
the transfer of an existing marketing authorisation to a 
new marketing authorisation holder while the balance 
related to a transfer of a marketing authorisation holder 
prior to authorisation.
Variations 
After a medicine has been authorised, the terms of its 
marketing authorisation may need to be changed and 
the process whereby such changes are implemented is 
known as a ‘variation’. Examples of variations include 
the addition of a new indication, a new potential side 
effect, or updates to the company’s manufacturing 
or contact details. In the past year, the HPRA issued 
14,207 variations to marketing authorisations for 
medicines authorised through the national or MR 
procedures. The figure compared with a total of 15,691 
variations during the previous year. The HPRA also 
issued 576 work-sharing variations in 2016 through 
national procedures. For 28 of these procedures, the 
HPRA acted as lead Member State.
Articles 45 and 46 - Variations to Update Product 
Information
During the past 12 months, the HPRA acted as 
rapporteur for one paediatric Article 45 procedure 
which included five medicines and 12 procedures 
relating to Paediatric Investigational Plans (PIPs). 
These are important procedures from a public health 
viewpoint as they increase the availability of medicines 
specifically indicated for use in children.
Renewals 
A total of 351 renewals to marketing authorisations for 
medicines authorised through national (33) and MR/
DC (318) procedures were assessed during 2016. While 
the number of renewals can vary from year to year, in 
general the trend is downwards, reflecting the reduced 
number of medicine authorisation applications.
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Interchangeable Medicines
Following commencement of the Health (Pricing and 
Supply of Medical Goods) Act in June 2013, the HPRA 
was tasked by the Minister for Health with publishing 
a list of interchangeable medicines to facilitate generic 
substitution by pharmacists and to allow for the 
introduction of a reference pricing system by the Health 
Service Executive (HSE). By the end of 2016, the list 
included a total of 51 active substances.
Legal Classification of Medicines
Medicines are classified, in law, as prescription or 
non-prescription. Since 2014, the HPRA has taken a 
proactive approach to the reclassification of the legal 
status of medicines, with the aim of increasing the 
number of medicines available without prescription, 
where it is safe to do so. The HPRA has identified 
medicines which we consider could be safely made 
available without a prescription in pharmacies, or made 
more widely available in general retail outlets such as 
supermarkets, and has invited the industry to make 
applications to have these medicines reclassified. A 
number of reclassification applications were completed 
in 2016 and further progress is anticipated during 2017.
Authorisation / Licensing of Sites and 
Facilities
The authorisation / licensing of manufacturers and 
wholesalers of human medicines and the approval of 
contract laboratories permits those facilities to carry 
out specified activities. The authorisation is based on 
satisfactory outcomes to HPRA inspections (see also 
under Safety and Quality) during which adherence to 
relevant European guidance is evaluated.
The total number of licences / authorisations in place, 
at year end, for the past five years is presented by 
category in the accompanying table. 
Number of Licences/
Authorisations (Sites)
2012 2013 2014 2015 2016
Manufacturers of 
medicines for human 
use
87 89 92 95 103
Investigational 
medicinal products for 
human use
47 49 53 52 55
Wholesalers of 
medicines for human 
use
258 269 272 287 318
Additionally, there were 11 contract laboratory 
approvals in place at year end, an increase of one 
compared with 2015.
Variations to Authorisations / Licences
We regularly process applications from authorisation 
and licence holders to vary the information on which 
the authorisation / licence is based. These variations, 
including updates and amendments, are classified as 
either administrative or technical. 
In respect of human medicines, there were 565 
variations associated with manufacturers, 248 
associated with wholesalers and 230 related to 
investigational products. There was also one variation 
to a laboratory approval.
Registrations for Active 
Pharmaceuticals Ingredients and 
Brokers of Medicinal Products 
Under amendments (via the so-called ‘Falsified 
Medicines Directive’) to the Medicines Directive, 
2001/83/EC, that came into force at the beginning 
of 2013, manufacturers, importers and distributors 
of active substances are required to register with the 
HPRA. 
The numbers of registrations in place at year end is 
outlined by category in the accompanying table. 
Number of Registrations 
for Active Pharmaceuticals 
Ingredients
2013 2014 2015 2016
Manufacturers 22 22 22 21
Importers 35 37 37 41
Distributors 38 36 37 49
Brokers of medicines for human use are also required 
to register with us. During 2016, three new broker 
registrations were issued, meaning that there was a 
total of five registrations in place at year end.
Annual Updates and Variations to 
Registrations 
There were 26 annual updates to registrations 
processed across the three categories of manufacturers, 
importers and distributors. This was in addition to five 
variations.
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Export Certificates 
Export certificates are required by health authorities in 
many so-called third country markets as an indication 
that a product registered, authorised and / or 
manufactured in the country of origin is of appropriate 
quality. The inspection and authorisation / registration 
programmes that we operate form the basis on which 
certificates are issued. 
During 2016, there were 1,274 certificates issued in 
respect of human medicines which was down from a 
figure of 1,646 in the previous year.
Exempt Medicines Programme
Where no equivalent product is authorised or available, 
a registered medical practitioner is permitted to 
prescribe unauthorised medicines for individual 
patients under her / his direct responsibility in order to 
fulfil the special needs of those patients. Such products 
are referred to in Irish law as ‘exempt medicinal 
products’. Wholesalers and manufacturers are obliged 
to notify certain information to our database in relation 
to any exempt medicinal products that they source. 
This information facilitates, when required, the effective 
recall of any defective exempt medicine from the Irish 
market.
In 2016, 1,827,047 packs of exempt medicines were 
notified to us compared to 1,639,312 packs during 
2015. In addition, we responded to approximately 200 
queries related to the programme.
The HPRA continued to work with key stakeholders to 
encourage the submission of applications for marketing 
authorisations for high volume and other important 
exempt medicines supplied to the Irish market.
Safety and Quality
Pharmacovigilance 
The HPRA, in co-operation with pharmacovigilance 
professionals primarily across the EU network, monitors 
adverse reaction reports to look for new types of 
reactions or changing trends in reporting. If there 
appears to be a new and serious risk emerging, the 
issue must be assessed to determine the impact on the 
overall benefit-risk profile of the medicine concerned 
and consideration is given as to how any new risks 
should best be managed and communicated to 
healthcare professionals and patients.
During 2016, the HPRA received a total of 3,264 
reports of new adverse reaction reports occurring in 
Ireland associated with the use of human medicines. 
This represents a 15% increase in overall reporting rates 
compared with 2015. 
In addition, 3,242 follow-up reports were also received 
during the past 12 months with any duplicate case 
reports reconciled with previously submitted cases and 
invalid / nullified reports managed appropriately.
Source of Suspected New Adverse Reaction 
Reports
%
Pharmaceutical Company 69
Patient / Consumer 10
Community Pharmacist 4
General Practitioner 3
Nurse 3
Community Care Doctor 3
Hospital Pharmacist 3
Hospital Doctor / Specialist 2
Healthcare Professional - Other 2
Clinical Trial Reports 1
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Adverse Reaction Reports
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As in previous years, the majority of adverse reaction 
reports were notified to the HPRA by pharmaceutical 
companies in the context of their regulatory reporting 
obligations. It is important to note that these reports 
will have initially been received by the companies from 
healthcare professionals, patients or consumers. 
Medicines subject to additional monitoring accounted 
for 29% of the reports submitted during 2016. Such 
medicines are identifiable by a black inverted triangle 
which is included on the accompanying package leaflet 
(PL) and the summary of product characteristics (SmPC).
The medicines most frequently included in reports 
to the HPRA accounted for some 76% of the adverse 
reaction reports received during 2016 (see table). It is 
important to note that the place of a medicine on this 
list cannot be taken as an indicator of safety or risk. The 
number of reports received cannot be used as a basis 
for determining the incidence of a reaction as neither 
the total number of reactions occurring, nor the number 
of patients using a medicine, is known. 
Suspect Medicine(s) /    
Class of Medicines
Number of 
Reports*
Antineoplastics, including 
immunomodulating medicines, monoclonal 
antibodies and endocrine medicines
589
Immunosuppressants 500
Psycholeptics 287
Vaccines 285
Respiratory medicines 181
Anti-infective medicines, including 
antibacterials, antimycotics and antivirals 179
Antithrombotics 137
Cardiovascular medicines, including 
antihypertensives and lipid lowering agents 117
Analgesics and anti-inflammatory 
medicines 107
Medicines for the treatment of bone 
disease 91
Reports submitted to the HPRA in many instances arise 
from suspicions occurring during observation of an 
unexpected and / or unwanted event, in the context of 
use of a medicine. They also include adverse reactions 
known to occur in association with medicines, such as 
those described in the product information.
Of the new adverse reaction reports received by the 
HPRA in 2016, 161 patients were reported to have died 
while on treatment. The accompanying table outlines 
the medicines / class of medicines associated with the 
highest number of reports.
In many of these cases, the patients concerned had 
significant underlying illness and were treated with 
multiple medicines and/or surgery, which may also have 
contributed to the outcome. In addition, many of these 
cases were influenced by disease progression or other 
complications unrelated to the medicine. The majority 
were associated with medicines used in the context of 
products subject to close monitoring, those used in the 
management of severe underlying medical conditions, 
in patient support programmes and special patient 
monitoring programmes. 
Suspect Medicine(s) /    
Class of Medicines
Number of 
Reports*
Antineoplastics, including 
immunomodulating medicines and 
monoclonal antibodies
45
Antithrombotics 29
Psycholeptics 27
Immunosuppressants 14
Anti-infective medicines, including 
antibacterials, antimycotics and antivirals 12
Analgesics and anti-inflammatory 
medicines 11
Cardiovascular medicines, including  
anti-arrhythmics and antihypertensives 9
Systemic hormones, including steroids 7
Antidepressants 6
Medicines for the treatment of bone 
disease 4
*Please note that in some cases treatment may have 
involved more than one medicine from the above groups.
Online and Electronic Reporting 
The online reporting system, available to healthcare 
professionals and patients / consumers, accounted for 
44% of reports received throughout the year. 
Monitoring Compliance with 
Pharmacovigilance Obligations
Company/sponsor compliance with pharmacovigilance 
obligations continued to be monitored throughout 
2016, with follow up and feedback provided as 
appropriate. See Inspections and Audits on page 22 for 
details of the associated inspection programme.
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Vigilance Assessment and Risk 
Management
The HPRA plays a key role in monitoring the safety 
of medicines available on the Irish market. In co-
operation with our EU counterparts, we regularly assess 
signals and emerging safety issues, and carry out 
routine and urgent benefit-risk evaluations. We also 
proactively participate in evaluating and approving risk 
management plans for medicines so that appropriate 
studies are carried out to gain more knowledge about 
their safety and efficacy. In addition, we serve as a 
key source of advice and information on the safe and 
effective use of medicines. 
The HPRA is represented at a European level on 
the Pharmacovigilance Risk Assessment Committee 
(PRAC) and works continuously with the EMA and other 
Member States within the EU to ensure robust and 
timely decision-making on safety-related issues.
Signal Management Activities
Signal detection and management activities are 
focused on the real-time detection of new or changing 
safety issues relating to medicines ensuring availability 
of the most up-to-date information on benefits and 
risks. These activities allow for more rapid action 
when necessary to protect public health. Throughout 
2016, the HPRA continued its participation in the 
work-sharing initiative for signal detection within the 
EU acting as lead Member State for the monitoring 
of 54 nationally-authorised active substances. Serving 
as PRAC rapporteur, the HPRA was also responsible 
for the further management of any signals detected 
in relation to 40 centrally authorised medicines 
(containing 27 active substances / combination of active 
substances). Labelling changes were also implemented 
for nationally authorised medicines during the past 
year following PRAC recommendations thus ensuring 
improved and up-to-date medicines information was 
provided to healthcare professionals and patients. 
We continued our participation during 2016 in the 
Signal Management Review Team at the EMA which 
focuses on improving tools, methods and processes for 
signal detection as well as developing methodological 
guidance.
Periodic Safety Update Reports
Periodic safety update reports (PSURs) are 
pharmacovigilance documents submitted by marketing 
authorisation holders at defined time points following 
the authorisation of medicines. PSURs are intended to 
provide a continuous cumulative update and analysis 
on the benefit-risk profile of a medicine throughout its 
lifecycle. The outcome of these procedures may lead to 
automatic harmonised regulatory action if considered 
necessary such as a variation, suspension or revocation. 
During the year in review, the HPRA continued its 
active contribution to the EU PSUR single assessment 
(PSUSA) procedure, contributing to the evaluation of 
1,059 PSURs and leading the single EU assessment for 
31 of these procedures. We consistently rank in the top 
10 for appointments as lead Member State for PSUSA 
evaluation for nationally authorised medicines at EU 
level.
Additionally in 2016, the HPRA worked with the EMA 
and other Member States to ensure the successful 
delivery of a centralised European repository for 
PSURs and their assessment reports as well as to 
ensure successful integration into our national 
business processes. Under EU pharmacovigilance 
legislation, there was a legal requirement for the EMA 
to set up the repository so as to enhance access to 
data and information, thereby supporting benefit-
risk assessments of medicines. Use of the repository 
became mandatory in June 2016. 
Safety Referrals
Safety referrals are used to resolve issues around the 
safety or benefit-risk balance of a medicine or class of 
medicines. The EMA conducts a scientific assessment 
of a particular medicine or class of medicines 
through the PRAC on behalf of the EU. The PRAC, 
on which all Member States are represented, makes 
a recommendation for a harmonised position across 
the EU which is ultimately implemented nationally 
by the HPRA. The HPRA participated as Concerned 
Member State in eight newly initiated safety referrals in 
2016 and a further six safety referrals which reached a 
conclusion during the year. The HPRA ensures that the 
final outcomes of referrals are implemented nationally 
and communicated to stakeholders.
Risk Management Plans and Post-
Authorisation Safety Studies 
All new applications for marketing authorisations now 
include a risk management plan (RMP) documenting the 
proposed risk management system to be implemented 
once a marketing authorisation is granted. During 2016, 
the HPRA contributed to the review of 305 RMPs (newly 
approved or updated) submitted via national, mutual 
recognition, decentralised and centralised procedures. 
We ranked 12th amongst the EU member states for 
PRAC rapporteurship / co-rapporteurship appointments 
for RMP evaluations relating to initial marketing 
authorisation applications. These medicines include 
treatments for orphan diseases including cystic fibrosis 
as well as other innovative products. 
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The HPRA also provided assessment input to 331 post 
authorisation safety study (PASS) procedures (protocols, 
reports and other post authorisation safety-related 
measures). A PASS is used to further evaluate the safety 
and benefit-risk profile of a medicine in the post-
authorisation phase, or to measure the effectiveness of 
risk minimisation activities that have been introduced. 
Sampling and Analysis Programme
The HPRA’s risk based sampling and analysis 
programme is part of our monitoring of the quality 
and safety of medicines on the Irish market or which 
are manufactured in Ireland for export. It involves the 
analytical testing of products and / or examination of 
their packaging and labelling. It applies to medicines, 
active substances, borderline medicines / non-
medicines and enforcement-related samples. A total of 
404 samples were taken for analytical testing and / or 
examination in 2016. 
Examination of Packaging and Labelling 
The packaging and labelling of 132 medicines 
and other products available on the Irish market 
were examined. This included checks on the safety 
information contained in package leaflets. All were 
examined for signs of falsification and tampering but 
none was found.
The following table outlines the type of examinations 
that were carried out:
Categories of products examined for 
packaging and labelling attributes
Number 
of samples 
examined
Authorised medicines (including samples 
for Braille compliance checks) 97
Authorised parallel imported and parallel 
distributed medicines 27
Borderline products (medicines / food 
supplements) 5
Product supplied via the exempt medicines 
route 2
Products for export 1
Total 132
Analytical Testing
A key element of our sampling and analysis programme 
is the analytical testing of medicines. While the majority 
of testing is carried out by governmental laboratories 
in Ireland, a number of samples are also sent to 
governmental laboratories in other countries as part of 
European working-sharing arrangements. In total, 255 
medicines and other product samples for human use 
were sent for analytical testing during the past year. 
Approximately 44% were authorised medicines, 39% 
related to enforcement cases while 17% were active 
substances and intermediate materials. A breakdown 
of the types of products tested is outlined in the 
accompanying table.
Product categories selected for analytical 
testing in 2016
Number 
of samples 
analysed
Physico-chemical Analysis / Biological 
Analysis:
Enforcement-related products 104
Nationally authorised medicines 42
MRP/DCP authorised medicines 28
Biological/biotechnological products 23
Compounded products 18
Parallel imported medicines 12
Products supplied via the exempt medicinal 
products route 9
Centrally authorised medicines for human 
use 7
Other products (manufactured for export) 6
Active substances / intermediate 
pharmaceutical ingredients 5
Borderline medicinal / non-medicinal 
products 1
Total 255
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255
medicines and other 
product samples sent for 
analytical testing
Participation in EU Co-ordinated Market 
Surveillance Activities
We are an active participant in EU in the Official 
Medicines Control Laboratory (OMCL) network which 
is co-ordinated by the European Directorate for the 
Quality of Medicines and Healthcare (EDQM). Work 
completed during 2016 included:
- Centrally authorised medicines: Samples of four 
human medicines were sent for testing at OMCLs 
in other member states. Samples of five human 
medicines were received for testing at the HPRA’s 
OMCL (the Public Analyst’s Laboratory in Galway). 
- MRP/DCP medicines: Two MRP / DCP medicines 
for human use were sampled in Ireland and tested 
at other member state OMCLs. 
- Other products: A number of other products were 
tested for the HPRA by OMCLs in other member 
states.
Principal Findings
Laboratory Analysis
While the majority of the samples tested were 
compliant with their specifications, a number of 
out-of-specification results were also obtained. The 
most frequent of these was appearance not being in 
accordance with the specification. Eight deficiencies 
were also identified in the analytical methods and/or 
specification documents used by the manufacturers. 
Appropriate follow-up actions were taken in each case. 
Packaging and Labelling
A total of 28 non-compliances were identified. These 
included: 
- braille-related issues; 
- product packaging and labelling that did not 
comply with the marketing authorisation;
- key safety information that had not been updated 
after a variation.
Again, appropriate follow-up actions were taken in each 
case. 
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Quality Defects and Recalls
The quality defect and recall programme investigates, 
on a risk basis, reports of suspected quality defects in 
medicines and in their related active substances. It also 
co-ordinates recalls from the Irish market.
Quality Defects
Quality defects pertaining to 835 medicines for human 
use were reported or identified. The risk classifications 
that were assigned, along with the corresponding 
figures for the previous year, are outlined in the 
accompanying table.
Year 2015 2016
Critical quality defects 213 119
Major quality defects 218 331
Minor quality defects 301 382
Number of reports not justified 5 3
Total Number Quality Defects 737 835
Stability, defects relating to CMC / artwork and non-
compliance with specification were the three largest 
defect categories. In addition, 22 reports relating to 
falsified medicines detected in other countries were 
considered, primarily because the genuine medicines 
were manufactured in Ireland. In none of these cases 
was the falsified product detected on the Irish market 
nor was the genuine manufacturer found to have had 
any part in their manufacture.
In respect of the sources of quality defect reports, 
pharmaceutical companies and other competent 
authorities again accounted for the majority of reports 
received.
Source of Reports Human 
Medicines
Companies (manufacturers, distributors 
and/or authorisation holders) 596
Other competent authorities 171
Community pharmacists 43
HPRA staff members 42
Other health care professionals 42
Hospital pharmacists 18
Patients and/or other members of the 
public 3
Competitor companies 1
Recalls of Human Medicines 
In certain cases, in order to protect public or animal 
health, it is deemed necessary to withdraw, or 
recall, medicines from the Irish market. During the 
year in review, 201 medicine recalls occurred which 
representing an 83% increase when compared to 
2015. This increase is due mainly to a significant rise 
in the number of medicines that were recalled due to 
distribution issues. Overall, the most common causes of 
recalls during 2016 recalls were:
Source of Reports Human 
Medicines
Erroneous distribution 99
Cold-chain 34
Stability 14
Lack of sterility assurance 9
SPC/printed artwork component 9
CMC/Artwork variation 8
Non-compliance with GMP 7
Product preparation/administration 7
Non-compliance with specifications 6
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Retail Sales Monitoring 
General Retail Sale Monitoring
The sale of consumer healthcare products by retail 
outlets such as grocery shops, health food shops and, 
where necessary, pharmacies, is monitored by the 
HPRA using a proactive and reactive, risk based, retail 
monitoring programme. During 2016, 53 cases, some 
of which involved multiple products, were investigated. 
Of these, 22 related to the sale of medicines that did 
not carry a valid registration number or authorisation 
number for the Irish market. An additional 31 cases 
related to the sale of medicines that had been 
incorrectly classified as non-medicines by those placing 
them on the market while one case related to the 
sale of a pharmacy-only medicine by a non-pharmacy 
retailer. A total of 218 products that did not carry a 
valid registration or authorisation for the Irish market 
were removed from sale.
Regulatory Compliance Inspections 
These risk-based inspections are carried out at the 
premises of marketing authorisation holders. The 
inspection seeks to determine the level of compliance 
with the legal requirements for the marketing and 
advertising of medicines. Four inspections were carried 
out, and a number of non-compliances, including 
15 major deficiencies, were identified. These were 
followed up and we monitored the implementation of 
corrective actions at the companies concerned. This 
inspection activity is linked to the HPRA’s advertising 
compliance programme with three of the major 
deficiencies identified directly related to advertising 
activities.
Advertising Compliance Programme
It is the role of the HPRA to monitor and review 
advertising and promotion activities by the industry 
for compliance with the requirements of the Medicinal 
Products (Control of Advertising) Regulations, 2007. 
Some 213* advertisements were reviewed during 2016. 
Non-compliances, including both major and minor 
issues, were identified in respect of 112 of these. The 
major issues included misleading advertisements and 
advertisements that were not in line with the approved 
product information. Five advertisements were recalled. 
The key data relating to the five main components of 
the programme are shown in the accompanying table.
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Total Advertisements 
Reviewed
Non-Compliances Identified
Proactive Monitoring:   
Pre-planned Projects
14 144 72 individual advertisements were non-compliant.
Proactive Monitoring: Includes 
Randomly Selected Projects
21 33 11 individual advertisements were non-compliant.
MAH Inspections Performed 4 Multiple Three major deficiencies related directly to 
advertising activities.
Complaints Received 12 18 17 advertisements in total were non-compliant. 11 
of the complaints were upheld as being valid. 
Queries Received 29 18 12 advertisements were non-compliant.
*Note: Some of these figures are approximate. They may include website advertisements, and each page of a website is 
counted as one advertisement, because multiple pages can have multiple advertisements. Additionally, the data excludes 
advertisements that were reviewed during the regulatory compliance inspections work. Numerous advertisements were 
reviewed during those inspections.
Inspections and Audits 
As part of our regulatory role, the HPRA is focused on 
ensuring industry compliance with relevant standards 
and legislation. During 2016, we carried out an 
extensive programme of work which incorporated a 
range of inspections and audits in respect of human 
medicines.
Good Clinical Practice (GCP) Inspections
The purpose of these inspections is to:
- verify compliance with the approved protocols 
during the conduct of clinical trials;
- ensure that the rights and safety of trial participants 
are protected; 
- ensure the integrity of the data reported from the 
clinical trials that are intended to support marketing 
authorisation applications and post-authorisation 
studies.
Compliance with GCP and applicable regulations is  
also verified.
During the year in review, nine GCP inspections 
were carried out. In connection with the review of 
applications for centralised marketing authorisations, 
we undertook two GCP inspections at the request 
of the EMA. The first of these inspections was at an 
investigator site in South Korea while the second was at 
a sponsor site in the US. There were seven routine GCP 
inspections at investigator sites in Ireland.
Pharmacovigilance Inspections
Pharmacovigilance inspections are performed to 
ensure that marketing authorisation holders comply 
with pharmacovigilance regulatory obligations and to 
facilitate compliance.
Two inspections of pharmacovigilance systems 
were performed in 2016. One of these was of a 
marketing authorisation holder that had not previously 
undergone a pharmacovigilance inspection. The other 
was performed as part of the EMA’s programme of 
inspections related to centrally authorised medicines.
Good Manufacturing Practice (GMP) 
Inspections
GMP inspections are performed to ensure that holders 
of manufacturing and importation authorisations 
comply with GMP guidelines and national regulatory 
obligations, and to facilitate compliance.
A total of 81 GMP inspections were conducted at 
manufacturing sites that produce human medicines 
or active substances in 2016. These included eight 
inspections that were conducted in countries outside 
of the European Economic Area (EEA) incorporating 
seven which were carried out at the request of the 
EMA, relating to centrally-authorised medicines, and 
one which was of an active substance manufacturer. 
Ten sites in Ireland that manufactured active substances 
were also inspected. 
Health Products Distribution Inspections 
The HPRA carried out 129 inspections of wholesalers 
and distributors of medicines to check for compliance 
with EU guidelines on Good Distribution Practice 
(GDP). We also carried out two inspections of 
registered distributors of active substances.
Enforcement 
Illegal activity involving the manufacture, supply and 
sale of medicines can potentially have consequences 
for public health. It is the role of the HPRA to 
investigate potential breaches of human medicines 
legislation and, where necessary, we will take the 
appropriate corrective action, up to and including legal 
proceedings.
Enforcement Cases and Detained 
Medicines
During 2016, 4,054 enforcement cases were initiated, 
compared to 3,677 in the previous year. There were a 
total of 673,906 dosage units detained, down from 1.1 
million units in 2015. While the year-on-year decrease 
in products detained can be partly attributed to the 
ongoing inter-agency approach, both nationally and 
internationally, to combating the illegal supply of 
sedative products onto the Irish market, these products 
still accounted for 40% of all detentions. Anabolic 
steroids and erectile dysfunction medicines accounted 
for 16% and 14% of detentions, respectively. 
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A summary of the HPRA enforcement data is provided in the accompanying table.
Year 2012 2013 2014 2015 2016
Product detained (dosage units) 758,276 919,965 730,056 1,136,494 673,906
Cases Opened 3,911 3,932 3,703 3,677 4,054
Prosecutions 11 9 10 5 6
Voluntary Formal Caution (VFC) 6 27 13 14 13
Inter-Agency Co-operation
The HPRA continues to liaise and work closely with 
other enforcement agencies both nationally and 
internationally, in preventing, detecting and combating 
the unauthorised supply of medicines. The co-
ordinated approach by the HPRA with the Revenue’s 
Customs Service and An Garda Síochána was clearly 
evident during Operation Pangea IX. This operation, 
which is co-ordinated globally by INTERPOL, targets 
the criminal networks behind the sale of falsified and 
illegal medicines via illicit websites. The inter-agency 
approach employed nationally during this operation 
resulted in 60,000 tablets and capsules worth over 
€350,000 being detained. Of note, anabolic steroids 
accounted for over 50% of the products detained in 
Ireland.
The HPRA also actively co-operates with Sport Ireland 
in combating the use of doping substances and with 
the Department of Agriculture, Food and the Marine, 
the Pharmaceutical Society of Ireland (PSI), the FSAI 
and the HSE to address specific offending behaviours 
on the market.
Prosecutions
The HPRA is also responsible for prosecuting cases 
where it considers that there is a significant risk to 
public health. In 2016, six prosecution cases were 
initiated while there were also 13 voluntary formal 
cautions issued. The prosecutions related to the supply 
of products including slimming medicines, anabolic 
steroids, and erectile dysfunction medicines. We 
also support prosecutions brought by the Director of 
Public Prosecutions in relation to the illegal supply of 
medicines.
Legislation and Regulation
New Clinical Trials Regulation 
The new clinical trials legislation (Regulation (EU) No. 
536/2014) was adopted and published in May 2014. 
It will come into effect in Europe in 2018. The new 
Regulation is intended to increase the number of 
clinical trials conducted in Europe and to provide for 
improved transparency. 
The HPRA has been working to progress the 
development of systems and procedures to meet the 
new requirements. The existing voluntary harmonisation 
procedure (VHP) is similar to the approval process for 
clinical trials under the new legislation and we continue 
to increase our involvement in this procedure. 
Falsified Medicines
On 9 February 2016, the European Commission 
published Commission Delegated Regulation (EU) 
No. 2016/161. This Regulation supplements Directive 
2001/83/EC of the European Parliament and of the 
Council by laying down detailed rules for safety features 
that will appear on the packaging of medicines for 
human use. The purpose of the Delegated Regulation 
is to detail the characteristics of the obligatory safety 
features for medicines introduced by the Falsified 
Medicines Directive, 2011/62/EU, the intent of which is 
to prevent the entry of falsified medicines into the legal 
supply chain in the EU.
The safety feature will consist of two elements placed 
on the packaging of a medicine:
- a unique identifier; and
- a device allowing the verification of whether the 
packaging of the medicine has been tampered with 
(anti-tampering device).
The unique identifier can be scanned to authenticate 
a pack at various points in the supply chain but 
particularly at the point of dispensing.
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Supra-national and national repository systems will 
be established across the EU and will retain records 
of operations in relation to the unique identifier. This 
system, which is intended to enable the investigation 
of suspected falsified medicines, will be set up and 
managed by a non-profit legal entity established in 
the EU by manufacturers and marketing authorisation 
holders for medicines bearing the safety features. 
The HPRA has liaised closely with the Irish Medicines 
Verification Organisation (IMVO), the entity which has 
been established in Ireland. The competent authorities 
of the individual EU Member States will have access to 
the repository system located within their territory for 
certain purposes including supervision and monitoring. 
The Delegated Regulation will apply in Ireland, and the 
majority of EU member states, as of 9 February 2019. 
Stakeholders and Partners
Contributing to the European and 
Global Regulatory Network
Europe
The HPRA continues to actively participate across 
the European medicines regulatory network. HPRA 
scientific and technical staff contribute to a broad range 
of committees and working parties, preparing papers 
as appropriate, at the EMA, the European Commission, 
the HMA, and at other fora.
In addition to our regular participation at a European 
level, highlights from the past year included the 
following:
Pharmacovigilance
During 2016, the HPRA continued to contribute 
actively to the work of the PRAC, with the Irish PRAC 
Member continuing to serve as Vice-Chairperson of the 
Committee.
The HPRA continued its work with stakeholders to 
support the implementation of the pharmacovigilance 
legislation. We contributed to the Pharmacovigilance 
Business Team of the EMA / Member State governance 
structure for pharmacovigilance. The Pharmacovigilance 
and Risk Management Lead contributed to the project 
oversight governance through membership of the 
Project Coordination Group and the European Risk 
Management Strategy Facilitation Group. 
The Pharmacovigilance and Risk Management Lead 
contributed to a number of initiatives exploring 
development of the regulatory environment, strategies 
to facilitate access to innovative medicines for patients 
in need and benefit-risk management through the 
product lifecycle. The Pharmacovigilance and Risk 
Management Lead also contributed to a number of 
strategies to support stakeholder engagement through 
participation in routine stakeholder meetings and on 
specialist topics such as risk management planning, 
benefit-risk evaluation, pharmacovigilance impact 
evaluation, post-authorisation efficacy studies and 
pharmacovigilance as an enabler for innovation.
SCOPE
The Strengthening Collaboration for Operating 
Pharmacovigilance in Europe (SCOPE) Joint Action was 
created to support operations of pharmacovigilance in 
Europe following new requirements introduced by the 
European pharmacovigilance legislation that came into 
effect in June 2012. During 2016, the HPRA contributed 
to two main areas:
• The HPRA is the topic lead in respect of carrying 
out an impact assessment of risk communications 
under work package 6 (WP6). This incorporates the 
collection of information on risk communications 
practices in the EU network to better understand 
the communication channels and tools used. 
During 2016, we contributed to and participated 
in the delivery of a two-day risk communication 
workshop which shared relevant research results 
and facilitated discussions with experts from 
patient and healthcare professional organisations, 
and from academia. The workshop focused on 
how EU national agencies can optimise their 
communications on the risks associated with 
medicines. 
• They also contributed as a partner under 
work package 8 (WP8) relating to lifecycle 
pharmacovigilance. Finalised recommendations, 
guidance and training for regulators was delivered 
in 2016 to support EU pharmacovigilance work.
Biosimilars
The HPRA contributed to a number of initiatives 
in 2016 in respect of biosimilar medicines. This 
included chairing the EMA drafting group on quality 
requirements for biosimilar heparins. In addition, the 
HPRA participated as a member of the organising 
committee for EMA assessor training on biosimilars 
and as a member of the EMA drafting group for a pilot 
study on extended scientific advice for biosimilars.
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GMP Inspections
We participated in audit teams as part of the Joint 
Audit Programme (JAP) of GMP inspectorates 
of competent authorities. This also included the 
allied Joint Reassessment Programme (JRP) of the 
Pharmaceutical Inspection Co-operation Scheme 
(PIC/S).
Telematics
During the past year, the HPRA continued to play 
a significant role in the development of European 
telematics strategies, standards and technologies 
through its engagement with programmes at the EMA, 
the European Commission and the HMA forum. We 
continued to be represented on the EU telematics 
management board, the network data board and 
the e-submissions group and led on a number of key 
initiatives relating to single submission portals and data 
standards. The HPRA also participated in meetings 
to assist in the definition of the ICT requirements to 
support the implementation of the new European 
clinical trials legislation.
The HPRA business services team is participating, 
as part of a European consortium, in the European 
Commission’s Horizon 2020 research programme on 
the openMedicine project. During 2016, an annual 
technical review was carried out by the Commission 
in respect of this project. The HPRA presented the 
core work package relating to the Identification of 
Branded Medicinal Products and was commended on 
the deliverable by the Commission review team. The 
project continued throughout 2016, with the HPRA 
participating in a number of other associated work 
packages and representing the project at meetings with 
the FDA and other relevant events.
As part of our continued co-operation with other 
regulatory agencies in Europe, we are assisting the 
Malta Medicines Authority in the development of 
a new regulatory management system for product 
authorisation. The first phase of this project is due for 
completion in 2017.
Common Electronic Submission Portal
A key activity for the HPRA is the ongoing development 
and management of the Common Electronic 
Submission Portal (CESP) on behalf of the wider EU 
regulatory community. We provide technical support 
through the operation of a helpdesk facility and we 
work with all relevant stakeholders throughout the year 
to deliver an optimum solution. Currently, there are 39 
regulatory agencies across Europe using the system 
which is available to accept submissions 24 hours a day. 
Participation and activity levels increased again during 
2016 with the portal now handling more than 390,000 
submissions, compared with 100,000 back in 2013, 
and supporting over 4,000 organisations with 14,000 
users. Of the total number of applications submissions 
received, over 90% related to human medicines. 
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To assist in the end user training, we developed a 
training pack of videos and other materials that can be 
accessed online and provided online training to 560 
participants throughout the year. During 2016, we also 
commenced the development of version three of the 
system with an additional goal to provide the European 
regulatory network with data from online forms based 
on the new ISO Identification of Medicinal Products 
(IDMP) data standards. The first phase of the project is 
due for delivery in 2017.
World Health Organization
The HPRA’s Pharmacovigilance Manager continued to 
represent the World Health Organization (WHO) as a 
member of the Board of the Uppsala Monitoring Centre 
(UMC) and WHO Collaborating Centre for International 
Drug Monitoring during 2016. 
The HPRA participated at the annual meeting of 
national centres participating in the WHO international 
drug monitoring programme in November 2016 
and continued to provide details of reports received 
nationally to the WHO for inclusion on its international 
database. The volume of adverse reaction reports from 
Ireland continued to fall within the top 20 countries 
participating in the programme (currently 125 countries 
with full membership and 28 countries with associate 
membership) with Ireland ranked as the eleventh 
highest reporter (population based) during 2016.
International Coalition of Medicines 
Regulatory Authorities
During 2016, the interim phase (2014-2016) for the 
International Coalition of Medicines Regulatory 
Authorities (ICMRA) ended. As the authority leading 
the Governance working group, the HPRA led the 
development of a new structural model for the coalition 
and the writing of a new Terms of Reference to allow 
for expansion of the ICMRA membership. The agreed 
new structure saw a changeover from the previous 
management committee structure and chair (Canada) 
and vice chairs (HPRA and Japan) to a newly elected 
Executive Committee led by the UK as chair and 
Australia and Mexico as vice chairs along with the 
preceding chair and vice chairs, including the HPRA. In 
line with the new Terms of Reference, ICMRA became 
open for applications for new Associate Members and 
the HPRA took on the role of coordinating applications 
to assist with the work of the ICMRA secretariat. We 
also led on a pharmacovigilance project during 2016, 
which was successfully completed before the end of the 
year, and we participated in the supply-chain integrity 
drafting group. 
Health Systems Strengthening Programme 
The HPRA was part of a successful consortium selected 
to provide ‘Technical Assistance to the Ministry of 
Health and the Zambia Medicines Regulatory Authority 
(ZAMRA)’. This followed a tender process under 
the EU funded Health Systems Strengthening (HSS) 
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programme. Planning for the delivery of regulatory 
and capacity building support by the HPRA to ZAMRA 
began in 2015 while the project itself commenced in 
quarter two 2016. This included the provision of short 
term experts in the areas of clinical assessment and 
risk management in addition to facilitating a week long 
study visit from a ZAMRA delegation to the HPRA.
Contributing to National Health 
Initiatives
Responding to Medicines Shortages
The HPRA works closely with all relevant stakeholders 
to limit the impact of human medicines shortages on 
the Irish market. One of the mechanisms used by the 
HPRA to aid continuity of supply to the market place 
in the event of a shortage includes the granting of 
a temporary authorisation for a batch of a medicine 
known as a ‘batch specific request’. Such applications 
may be appropriate when a medicine in full compliance 
with its registered marketing authorisation dossier is 
temporarily unavailable or where action is proposed 
to bring a batch into compliance with the registered 
details. During 2016, the HPRA reviewed 126 batch 
specific requests to facilitate continuity of supply of 
specific medicines in Ireland and prioritised other 
applications where expedited review was required 
to avoid shortages. We continued to follow up on 
instances of shortage of a particular medicine and 
worked with marketing authorisation holders, including 
suppliers of alternative products, in efforts to mitigate 
and alleviate the effects. 
Emergency Medicines
Legislation (S.I. No. 449/2015) has been introduced to 
allow for trained non-medical persons to administer 
specific prescription-only medicines to a person, 
without a prescription, for the purpose of saving 
their life or reducing severe distress in an emergency 
situation.
During quarter one of 2016, the HPRA launched the 
new Emergency Medicines Registration System to 
support the implementation of this legislation. This 
online system, which was developed in collaboration 
with the Pre-Hospital Emergency Care Council (PHECC) 
and the Pharmaceutical Society of Ireland (PSI), enables 
organisations to notify the HPRA of their intention to 
procure or purchase a specified medicinal product 
from a pharmacy or other supplier for supply and 
administration in an emergency situation.
Information Technology
Throughout 2016, the HPRA’s IT and business services 
team continued to enhance the processes and 
technology interfaces to support the exchange of 
information between stakeholders in areas such as 
the medical products database for both human and 
veterinary medicines, interchangeable medicines for 
the generic substitution programme and data for 
clinical and pharmacy systems. In keeping with the 
government strategy for shared service provision, 
we also provided hosting services to a number of 
organisations and worked closely with other agencies 
on technology related initiatives. In addition, we 
continued in 2016 to contribute to the development of 
data set standards for ePrescribing and an electronic 
medicinal product reference catalogue.
Meetings with Stakeholders 
During 2016, there were a number of meetings held 
with industry representative groups including the 
Irish Pharmaceutical Healthcare Association (IPHA), 
BioPharmaChem Ireland (BPCI), the Healthcare 
Enterprise Alliance (HEA), the Irish Generic Medicines 
Association (IGMA), the Irish Association of Health 
Stores (IAHS) and the Irish Health Trade Association 
(IHTA). Such meetings provide a forum for discussion of 
items of mutual interest. 
Meetings were also held with the PSI, the Irish 
Pharmacy Union (IPU) and the Irish Food Allergy 
Network (IFAN) to discuss issues of medicine availability 
and patient safety. 
In addition, as part of our compliance work programme, 
there was extensive engagement with industry 
stakeholders. This included a large number of meetings 
with existing and prospective manufacturers and 
marketing authorisation holders, and with individual 
entities wholesaling or intending to wholesale 
medicines.
Presentations
As in recent years, the HPRA invested significant time in 
delivering a programme of presentations and talks at a 
range of external stakeholder events such as meetings, 
seminars, conferences and training courses. In addition, 
a programme of presentations was delivered to 
undergraduate and postgraduate students studying 
courses related to the role of the HPRA.
Such presentations contribute to the HPRA goal of 
providing stakeholders such as healthcare professionals 
and regulatory professionals with access to relevant, 
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up-to-date information. The presentations are delivered 
by HPRA staff from across the organisation and cover all 
products and functions under our remit. While some are 
general in nature and primarily focused on explaining 
the role of the HPRA, others are more specific and 
deal with specialist areas and / or new regulatory 
developments. A full list of all presentations delivered 
during 2016 relevant to human medicines is provided in 
Appendix 2.
Regulatory Information Seminars and 
Training 
HPRA information seminars and training events 
provide regulatory guidance and updates to a range 
of stakeholders. The HPRA also partners with other 
regulatory organisations to co-host relevant events.
EU Directive 2011/62/EU on falsified medicines 
introduces the requirement for safety features, 
including a unique identifier, to be added to the outer 
packaging of specified medicines for human use. 
In May, we hosted four workshops for stakeholders 
regarding the implications of this incoming requirement 
for marketing authorisation holders, manufacturers and 
wholesalers of human medicines. The workshops were 
hosted in Athlone, Cork and Dublin (2).
In September 2016, the HPRA hosted a training 
workshop in collaboration with the EU Network Training 
Centre. Approximately 50 people attended this event 
which was focused on benefit-risk training for clinical 
and safety assessors. The EU Network Training Centre 
is a joint HMA and EMA initiative set up to increase 
harmonisation of training within the EU regulatory 
network. 
Advanced Quality Risk Management (QRM) training 
was hosted in the offices of the EMA in September. 
This training was organised jointly by the HPRA and 
the Pharmaceutical Inspection Co-operation Scheme 
(PIC/S).
In October, the HPRA hosted an informal meeting of 
the Committee for Advanced Therapies (CAT). The 
meeting was held on behalf of the Slovakian State 
Institute for Drug Control.
We also provided training in 2016 to industry in relation 
to aspects of controlled drug licensing.
Publications and Information
As part of our on-going commitment to ensuring 
stakeholders have access to information to support 
the safe use of human medicines, the HPRA continued 
during 2016 to publish newsletters, articles and 
important safety updates. We also published updated 
information and guidance for those working in the 
pharmaceutical sector. 
Drug Safety Newsletter
The Drug Safety Newsletter continues to provide 
important safety information to healthcare professionals 
in respect of human medicines and incorporates 
hyperlinks to product information and other relevant 
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documents on the HPRA and EMA websites. Six issues 
of the newsletter were published and distributed to 
registered healthcare professionals, all of which are 
accessible from the HPRA website. A full index of topics 
covered during the past year is included in Appendix 3.
Risk Communications
The HPRA continued to publish educational materials 
and tools for healthcare professionals and patients 
which have been developed by marketing authorisation 
holders (MAHs) as additional risk minimisation measures 
for their medicines. Such materials are approved by the 
HPRA at national level and published on our website. 
Risk minimisation tools for more than 420 individual 
medicinal products are currently available on www.
hpra.ie. During 2016, 77 suites of educational materials 
were approved by the HPRA in addition to 27 direct 
healthcare professional communications (DHPCs). The 
PRAC published monthly agendas, minutes, meeting 
highlights, notifications of safety reviews and signals 
throughout the past year and these were also made 
available via our website.
External Articles
There were 21 articles provided for inclusion in the 
MIMs (Ireland) publication and two articles provided for 
inclusion in the Irish Medicines Formulary. The full list of 
topics covered in these articles is included in Appendix 
3. All articles were also published on the HPRA website.
Guidance Documents
HPRA guidance documents provide stakeholders, 
primarily from the industry sectors we regulate, with 
advice and direction in respect of legislation and 
regulatory requirements. One new publication in 
respect of human medicines, the Guide for National 
Scientific and Regulatory Advice, was published during 
2016. A number of existing documents were also 
updated during the past year. These updated versions 
include tracked changes so that readers can easily 
access the revised content. All of the HPRA guidance 
documents can be accessed via the publications 
section of www.hpra.ie.
Medicinal Products Newsletter 
This newsletter provides regulatory updates for 
those working in the pharmaceutical sector on 
Irish and European legislation, new / revised HPRA 
regulatory publications and stakeholder events such 
as information days. Three editions of the Medicinal 
Products Newsletters were published during 2016. 
Topics covered that were relevant to human medicines 
included:
• The Medicinal Products (Prescription and Control of 
Supply) (Amendment) (No.2) Regulations 2015
• Change to requirements regarding applications 
for certificates of pharmaceutical product and 
certificates of free sale for medicines
• European Commission delegated Regulation for 
safety features on medicinal products for human 
use
• Revision to Annex 16 of the EU GMP guide: 
Certification by a qualified person and batch 
release
• Pseudoephedrine – Implementation of risk 
minimisation measures
• Good practice guide on medication errors
• Parallel importation – Update to variation 
categories
• Introduction of a regulatory contact point for 
marketing authorisation holders
• Sale or supply of traditional herbal medicinal 
products (THMPs) that have been granted their 
certificate of traditional use registration
Oireachtas Joint Committee on Health 
In November, the HPRA was invited to address the 
Oireachtas Joint Committee on Health. The Committee 
met to discuss issues related to the potential use and 
possible legalisation of cannabis for medical use. Earlier 
that month, the Minster for Health requested the HPRA 
to provide scientific advice in respect of this matter. 
We outlined to the Committee our plans to convene 
an expert working group to assist with our review and 
committed to the publication of our deliberations by 
the end of January 2017. 
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It is the role of the HPRA to ensure that veterinary 
medicines are as safe as possible and do what they 
are intended to do. We grant licences for medicines 
subject to a review of their safety, quality and 
effectiveness and continuously monitor their use 
in animals once they become available on the Irish 
market. We also authorise clinical field trials in 
addition to inspecting and licensing manufacturing 
sites.
Authorisation and Registration
Scientific Advice
At a European level, the EMA co-ordinates the 
provision of scientific advice to companies on the 
appropriate tests and studies in the development of a 
veterinary medicine. This is designed to facilitate the 
development and availability of high-quality, effective 
and acceptably safe medicines. During 2016, the HPRA 
acted as co-ordinator for two requests under the EMA 
scientific advice procedure.
Product Classification Requests
As the competent authority, we have an important 
role in deciding which types of products fall within the 
scope of the veterinary medicines legislation. During 
2016, 16 product classification queries were received, 
down from the 21 queries received in the previous year.
Clinical Field Trials
Tests and trials on a veterinary medicine for the 
purpose of generating data to support a marketing 
authorisation, or for other purposes, require a licence 
from the HPRA. We received one application for a 
new clinical field trial in 2016 as well as two variation 
requests for existing trials.
Medicinal Product Authorisations
New Marketing Authorisation Applications 
As with human medicines (see page 12), there are a 
number of routes through which a veterinary medicine 
can be authorised by the HPRA. These include the 
national procedure, the mutual recognition procedure 
(MRP) and the decentralised procedure (DCP).
The following applications were received by the HPRA 
during 2016: 
– 8 new national applications; 
– 62 applications made under the DCP; 
– 26 applications made under MRP. 
We acted as reference (lead) Member State for the 
assessment of four of the MRPs and six of the DCPs.
The MRP may be used after completion of a first 
MRP or a DCP for the recognition of a marketing 
authorisation by other Member States for the same 
veterinary medicinal product. This is referred to as a 
Repeat Use Procedure. We received four applications 
under this procedure in 2016.
Veterinary 
Medicines 
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The centralised route is another mechanism whereby 
veterinary medicines can be authorised in Ireland. The 
centralised route involves the submission of a single 
application to the EMA and the authorisation, once 
granted, is valid in all Member States. In 2016, the 
HPRA was allocated five rapporteurships and six co-
rapporteurships for veterinary medicines. An additional 
14 new medicine applications were received through 
the centralised route where we were neither the 
rapporteur nor co-rapporteur. 
We were also allocated the assessment of one 
maximum residue limit (MRL) application in 2016. 
Before a veterinary medicine intended for food-
producing animals is authorised in the EU, the EMA 
evaluates the safety of its pharmacologically active 
substances and their residues and recommends MRLs. 
Transfer Applications 
A marketing authorisation for a veterinary medicine 
may be transferred from the existing marketing 
authorisation holder to another using a transfer 
procedure. We processed a total 99 veterinary 
medicine transfer applications in 2016. 
Variations 
After a medicine has been authorised, the terms of the 
marketing authorisation may subsequently be varied. 
Examples of variations include the addition of a new 
indication or potential side effect, an alteration to the 
method of manufacture or a change in active substance 
suppliers.
Under European legislation, such variations must 
be notified to the competent authority which must 
evaluate and approve any significant changes. The goal 
is to ensure that medicines are produced in a robust 
and standardised manner, thus safeguarding against 
sub-standard products. This requirement, together 
with a more global manufacturing environment, has led 
to significant numbers of variations in recent years as 
shown in the accompanying graph. 
In 2016, we issued 1,341 variations to marketing 
authorisations for medicines authorised through 
the national (416), MR (768) and centralised (157) 
procedures.
Renewals 
Marketing authorisations are valid for five years from 
the date of first issue. For the authorisation to remain 
valid, it must be renewed at the end of this five-
year period. A total of 100 renewals to marketing 
authorisations were assessed during 2016. Of these, 95 
related to medicines authorised through the MRP with 
the HPRA acting as reference Member State in respect 
of 23 of these applications. There were two renewals for 
medicines authorised through national procedures and 
three for centrally authorised medicines.
Variations Output
1,600
1,400
1,200
1,000
800
600
400
200
0
2012 2013 2014 2015 2016
1,
24
2 1,
36
4 1
,50
2
1,4
31
1,3
41
Authorisation / Licensing of Sites and 
Facilities
The authorisation / licensing of manufacturers of 
veterinary medicines and the approval of contract 
laboratories permits those facilities to carry out 
specified activities. The authorisation is based on 
satisfactory outcomes to HPRA inspections (see also 
under Safety and Quality) during which adherence to 
relevant European guidance is evaluated.
The total number of licences / authorisations in place 
at year end for the past five years is presented by 
category in the accompanying table. 
Number of Licences/
Authorisations (Sites)
2012 2013 2014 2015 2016
Manufacturers of 
veterinary medicines
23 24 25 25 24
Additionally, there were five contract laboratory 
approvals in place at year end, the same number as in 
2015.
Variations to Authorisations / Licences
We regularly process applications from authorisation 
and licence holders to vary the information on which 
the authorisation / licence is based. These variations, 
including updates and amendments, are classified as 
either administrative or technical. 
In respect of veterinary medicines, there were 57 
variations assessed during 2016. 
Export Certificates 
Export certificates are required by health authorities in 
many so-called third country markets as an indication 
that a product registered, authorised and / or 
manufactured in the country of origin is of appropriate 
quality. 
There was a total of 155 certificates issued in respect of 
veterinary medicines in 2016 which was an increase on 
the figure of 99 in the previous year.
Safety and Quality
Pharmacovigilance 
The operation of a national pharmacovigilance system 
which is based on the receipt and review of reports 
of suspected adverse events is a primary role of the 
HPRA. An effective system enables us to monitor the 
continued safety and efficacy of veterinary medicines 
under actual use conditions. Where necessary, 
the HPRA will intervene and introduce new risk 
management measures for a medicine. In so doing, we 
strive to prevent adverse effects in other animals as well 
as in humans exposed to the medicine.
The effectiveness of the system is dependent on the 
submission of reports by veterinarians, pharmacists, 
licensed merchants and others involved in dispensing 
or using the medicines concerned. These reports may 
be submitted either directly to the HPRA or to the 
companies’ marketing the medicines. The companies, 
in turn, must relay the data to the HPRA.
 
Over the course of 2016, we received 337 national 
reports of suspected adverse events to veterinary 
medicines with the vast majority of reports again 
received from pharmaceutical companies. While this 
represents a 23% reduction compared with 2015, 
the long-term trend in the number of reports being 
received on an annual basis is generally upwards. 
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Monitoring Compliance with 
Pharmacovigilance Obligations
Company / sponsor compliance with 
pharmacovigilance obligations is monitored by the 
HPRA. Additional details of the associated inspection 
programme are included under Inspections and Audits 
on page 34. 
Periodic Safety Update Reports
Evaluating periodic safety update reports (PSURs) 
on individual medicines accounts for a significant 
proportion of the HPRA’s overall veterinary medicines 
workload and is evidence of our commitment to the 
ongoing assessment of benefits and risks. Our work 
includes the assessment of individual medicines on the 
market in Ireland as well as a work-sharing initiative 
where we lead, or contribute to, the assessment of a 
class of veterinary medicines for the European Union.
Type of PSUR Number of 
PSURs
National 116
Mutual Recognition 562
Centralised 61
Work-sharing as Reference Member State 1
Work-sharing as Concerned Member 
State
234
Total 974
We completed the evaluation of 974 PSURs in 2016 
which was a decrease on the figure of 1,205 in the 
previous 12-month period.
Use of Veterinary Antimicrobials in 
Ireland
The HPRA collects annual information on the 
consumption of veterinary antibiotics from each 
marketing authorisation holder. This information is 
important as it allows us to benchmark our usage 
rate against those of our European neighbours and 
to follow any developing trends. The data show that 
there are significant fluctuations in consumption levels 
annually and, consequently, that a clear trend is not 
identifiable. This is likely due to a variety of factors, 
such as seasonal disease patterns, fluctuations in the 
classes of antibiotics being prescribed, end of year 
sales activities, the numbers of animals slaughtered and 
exported as well as changes in breeding policy for the 
national herd. 
Consumption 
of Antibiotics 
2009 2010 2011 2012 2013 2014 2015
Tonnes sold 88.3 93.9 85.3 97.4 100.2 90.6 96.7
We continue to work with other EU veterinary 
medicines agencies and the EU Commission to help 
ensure that veterinary antibiotics are used responsibly 
in accordance with their approved conditions of use. 
Sampling and Analysis Programme
The HPRA’s risk based sampling and analysis 
programme is part of our monitoring of the quality and 
safety of medicines on the Irish market or which are 
manufactured in Ireland for export. A key component of 
the programme is the analytical testing of products. 
Analytical Testing
In total, 16 veterinary medicines and other product 
samples were sent for analytical testing during the past 
year. Of these, five were centrally authorised medicines 
while two were MRP / DCP medicines. Of the remaining 
tests, seven related to other medicines (manufactured 
for export), one was of an active substance and one was 
of a biological / biotechnological medicine. 
Participation in EU Co-ordinated Market 
Surveillance Activities
We are an active participant in the EU in the Official 
Medicines Control Laboratory (OMCL) network which 
is co-ordinated by the European Directorate for the 
Quality of Medicines and Healthcare (EDQM). Work 
completed during 2016 included:
- Centrally authorised medicines: One veterinary 
medicine sample was sent for testing at an 
OMCL in another member state. Samples of four 
veterinary medicines were received for testing at 
the HPRA’s OMCL (the Public Analyst’s Laboratory 
in Galway). 
- MRP/DCP medicines: Two MRP / DCP medicines 
for veterinary use were sampled in Ireland and 
tested at other member state OMCLs. 
- Other products: A number of other products were 
tested for the HPRA by OMCLs in other member 
states.
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Quality Defects and Recalls
The quality defect and recall programme investigates, 
on a risk basis, reports of suspected quality defects 
in veterinary medicines, and in their related active 
substances. It also co-ordinates recalls from the Irish 
market.
Quality Defects 
A total of 41 quality defects relating to veterinary 
medicines were reported or identified. The risk 
classifications that were assigned, along with the 
corresponding figures for the previous year, are 
outlined in the accompanying table.
Year 2015 2016
Critical quality defects 1 7
Major quality defects 8 12
Minor quality defects 25 22
Number of reports not justified 1 0
Total number quality defects 35 41
Of the 41 reports received, 26 were determined to 
affect Ireland in that the defective batch or batches 
were either on the Irish market and / or were 
manufactured in Ireland. On investigation, it was 
determined that none of the defects, classified as 
critical, affected medicines on the market here. Product 
stability and defects related to CMC / artwork were the 
two most significant defect categories.
As regards the sources of the quality defects reports, 
24 came from industry, 16 from other competent 
authorities and one from a HPRA staff member. 
Recalls of Veterinary Medicines 
In certain cases, in order to protect animal and / or 
public health, it is deemed necessary to withdraw, or 
recall, a veterinary medicine from the Irish market. In 
2016, eight recalls of medicines occurred compared 
to three in 2015. Of these, seven were recalled due 
to stability issues while one was due to a lack of 
therapeutic efficacy.
Inspections and Audits 
As part of our regulatory role, the HPRA is focused on 
ensuring industry compliance with relevant standards 
and legislation. During 2016, our work programme 
incorporated a number inspections related to veterinary 
medicines.
Pharmacovigilance Inspections
Pharmacovigilance inspections are performed to 
ensure that marketing authorisation holders comply 
with pharmacovigilance regulatory obligations and to 
facilitate compliance.
One re-inspection of the pharmacovigilance systems 
of a marketing authorisation holder was performed in 
2016.
Good Manufacturing Practice (GMP) 
Inspections
GMP inspections are performed to ensure that holders 
of manufacturing and importation authorisations 
comply with GMP guidelines and national regulatory 
obligations, and to facilitate compliance.
During the year in review, 13 GMP inspections were 
conducted at sites in Ireland that are involved in 
manufacturing or testing veterinary medicines, of 
which 10 were routine re-inspections and three were 
non-routine. These included one GMP inspection in a 
country outside the EEA.
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Legislation and Regulation
New Veterinary Medicines Regulation 
New legislation which is intended to enhance the legal 
framework for the authorisation of veterinary medicines 
in the European Union was proposed by the European 
Commission in 2014. The draft framework is aimed 
at improving the health and wellbeing of animals 
by stimulating the development and availability of 
veterinary medicines. The proposal also focuses on the 
growing concerns over antimicrobial resistance.
During 2016, the HPRA continued to provide input 
into the ongoing discussions of the Council Working 
Group in Brussels in respect of the new legislation 
through the provision of comments to the Department 
of Agriculture, Food and the Marine on the impact 
of the proposals on the regulatory procedures. The 
Department participates at European Council meetings.
Stakeholders and Partners
Contributing to the European 
Regulatory Network
The European Regulatory Network is the backdrop 
for reaching a common view on medicines and their 
regulation. Given that most medicines are supplied to 
multiple European markets, it is clear that in order for 
us to maximise our influence, the HPRA must have an 
input in decisions taken at a European level. This we do 
through our involvement across the EU network which 
includes active participation at the EMA and the HMA. 
Of particular note during 2016, was the election of 
Dr David Murphy as Chair of the EMA’s Committee 
for Medicinal Products for Veterinary Use (CVMP). 
Dr Murphy was the Veterinary Assessment Manager 
at the HPRA and served as the Irish member of the 
CVMP for a number of years. The CVMP is responsible 
for preparing European Medicines Agency opinions 
on all questions concerning veterinary medicines. 
In particular, it plays a vital role in the marketing 
authorisation procedures of the European Union 
working to ensure that veterinary medicines that reach 
the marketplace have a positive benefit-risk balance in 
favour of the animal population they are intended for. 
The members of the CVMP, who are nominated by the 
European Union Member States in consultation with the 
EMA’s Management Board, are chosen on the strength 
of their qualifications and expertise with regard to the 
evaluation of medicines.
Also in 2016:
- The HPRA became a member of the steering group 
on veterinary vaccines shortages;
- We became a member of the CMDv taskforce on 
variations. 
- The HPRA delegate was elected Vice-Chair of the 
EMA’s Quality Working Party (QWP) while the co-
opted CVMP member from Ireland was re-elected 
to serve for a further term as a CVMP member. 
- We contributed to the acceptance testing of a 
newly created pharmacovigilance training module. 
Common Electronic Submission Portal
As outlined earlier in this report, a key activity for the 
HPRA is the ongoing development and management 
of the Common Electronic Submission Portal (CESP) on 
behalf of the wider EU regulatory community. 
During 2016, more than 33,000 applications in respect 
of veterinary medicines were submitted through the 
portal. 
Contributing to National Health 
Initiatives
Availability of Veterinary Medicines
Availability of veterinary medicines continues to be 
an issue for many veterinary practitioners tasked 
with treating many different species and conditions. 
Problems of non-availability can arise from a number of 
issues and different solutions are needed depending on 
the issues involved. 
During 2016, in order to better understand the current 
situation, the HPRA carried out a survey amongst 
drug companies and their consultants in respect of 
the drivers and constraints to availability of veterinary 
medicinal products nationally. In addition, we carried 
out a survey in respect of clinical field trials conducted 
in Ireland. Finally, we also authorised a veterinary 
medicine from the so-called AR16 list. Under the 
AR16 licensing procedure, a needed product can be 
imported from another country under licence from the 
Department of Agriculture, Food and the Marine where 
there is no suitable medicine authorised in Ireland. 
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Antimicrobial Resistance
Containment of the development of antimicrobial 
resistance (AMR) is essential for public and animal 
health. AMR is a complex issue and a co-ordinated 
approach from all stakeholders in the human health, 
animal health and agriculture sectors is required to 
address this issue.
The primary responsibility of the HPRA is to ensure 
that only those medicines that meet the EU standards 
of quality, safety and efficacy are authorised, and that 
the benefit / risk assessment of the medicines remains 
positive throughout their life cycle. Through our diverse 
regulatory activities, we collaborate with and support 
the many stakeholders involved in managing AMR, with 
the common goal of enabling and promoting prudent 
and responsible use of antimicrobials.
In January 2016, at the request of the Authority of 
the HPRA, we produced a report on antimicrobial 
resistance which was published online and shared with 
relevant stakeholders. The report references existing 
European and global reports on AMR in bacteria and 
considers their implications for the HPRA in relation 
to our role as the national regulator of human and 
veterinary medicines.
We also participated in two meetings of the National 
Interdepartmental AMR Consultative Committee and 
contributed, in collaboration with the Department of 
Agriculture, Food and the Marine, to a WHO survey on 
AMR.
Meetings with Stakeholders 
We met with the Department of Agriculture, Food and 
the Marine in relation to ongoing matters of mutual 
interest, including medicine shortages and the new 
proposal for the regulation of veterinary medicines.
Presentations
As in recent years, we delivered a programme of 
presentations to veterinarian students and veterinary 
nursing students on the role of the HPRA and the 
promotion of veterinary pharmacovigilance. A full list of 
all presentations delivered during 2016 is provided in 
Appendix 2.
Publications
As part of its on-going commitment to ensuring 
stakeholders have access to informative and up-to-date 
information relevant to the regulation of veterinary 
medicines, the HPRA continued during 2016 to publish 
newsletters, articles and important safety updates. 
Medicinal Products Newsletter
This newsletter provides regulatory updates for 
those working in the pharmaceutical sector on 
Irish and European legislation, new / revised HPRA 
regulatory publications and stakeholder events such 
as information days. Three editions of the Medicinal 
Products Newsletters were published during 2016. 
Topics covered that were relevant to veterinary 
medicines included:
- Mock up submissions to the HPRA 
- Active substance supply
- Future strategy for the regulation of PBT substances
- QP declaration for intermediate sites
- Update on legislative proposal for new EU 
Regulation
- Update to the product literature standard 
- Use of animal test methods for regulatory testing of 
human and veterinary medicines
External Articles
Consistent with our objective to improve stakeholder 
knowledge on the use of veterinary medicines, we 
contributed four articles to the specialist, ‘It’s Your Field’ 
publication. The topics covered were:
- Substantiating the efficacy of a medicine  
- Availability of veterinary medicines  
- Conduct of studies in animals  
- Residue benchmarks for veterinary antibiotics in milk  
Risk Communications
Notices relating to the safety of veterinary medicines 
are published by the HPRA and classified under several 
priority related categories. The issues covered by 
these notices will range from quality defect information 
and medicines safety information through to updated 
information on the appropriate usage of medicines.
During 2016, we published two safety advisory notices 
on the HPRA website. The first notice, published in 
June, related to serious adverse events involving 
recumbency and death in cattle (dairy cows) following 
use of Velactis in Europe. The second notice, which 
was published in December, concerned the safety of 
injectable gentamicin for horses.
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Medical 
Devices
As the competent authority, the HPRA monitors the 
safety of medical devices available in Ireland. Our 
aim is to make sure that these products perform 
as intended and do not compromise the health and 
safety of the patient or the person using them. 
The HPRA also assesses applications for clinical 
investigations, operates relevant registration 
systems, inspects manufacturing sites and monitors 
the performance of notified bodies designated to 
approve medical devices for the European market.
Authorisation and Registration
Product Classification Requests
The HPRA received 40 applications for classification of 
medical devices or other products queried as medical 
devices in 2016. The queries emanated from other 
medical device competent authorities in Europe (60%), 
from medical device manufacturers (20%), notified 
bodies (5%), and users (5%) of medical devices. The 
remainder (10%) resulted from the HPRA’s proactive 
market surveillance activities.
Clinical Investigation Applications
We received 10 applications for clinical investigations 
of a medical device, including three amendments to 
ongoing investigations, to be conducted in Ireland 
in 2016. These clinical investigations were received 
from a range of established manufacturers and device 
innovators. They included medical device software, 
closure devices, cardiac devices and novel devices for 
the management of complications linked to diabetes. 
This level of activity was broadly similar to the previous 
12-month period. During the past year, the HPRA also 
received five applications to use medical devices in 
Ireland on compassionate grounds.
Product Registrations
We received 1,196 notifications of medical devices 
to the medical device register in 2016 representing 
a three-fold annual increase in device registrations 
when compared with the period 2012 to 2015. These 
registrations apply to self-declared class I, in-vitro 
diagnostic and custom made medical devices and to 
system and procedure packs. Registration of these 
devices is required in the Member State in which the 
manufacturer or their authorised representative is 
based. 
Device Registrations
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Organisation Registrations
During 2016, 30 organisations registered with the 
HPRA as Irish-based manufacturers or authorised 
representatives of class I, custom-made, in-vitro 
diagnostic medical devices, as manufacturers of system 
or procedure packs, or as sterilisers of medical devices.
Export Certificates 
The HPRA issued 2,122 certificates of free sale in 2016 
for medical devices manufactured by or on behalf of 
organisations based in Ireland. These certificates are 
required for registration / market access purposes to 
certain non-European countries. This is a reduction on 
the 2,601 certificates issued during the previous year.
Safety and Quality
Market Surveillance
Medical device surveillance activities are focused on 
protecting the health and safety of those who use 
medical devices by seeking to ensure that medical 
devices available in Ireland and Europe are safe and 
perform as intended. This role includes continuous 
surveillance of the market to monitor the regulatory 
compliance of medical devices after they are placed 
on the market. The focus is on ensuring that issues 
detected are appropriately addressed and that there 
is follow up on any issues or learnings relevant to the 
pre-market aspects of the device, such as technical 
standards, design and conformity assessment, to 
minimise the possibility of recurrence.
Surveillance Cases
Since the European Commission’s joint plan for 
immediate actions came into effect in 2012, the HPRA 
has almost doubled the number of cases it assesses 
on an annual basis, with particular focus placed on 
proactive rather than reactive surveillance activities.
During 2016, the HPRA continued to develop 
its lifecycle approach to market surveillance and 
investigated 335 market surveillance cases. In addition, 
we experienced further increases in the number of 
notifications of certificate withdrawals or suspensions, 
and of notifications from other Member States via 
the European Compliance and Enforcement (COEN) 
network.
Other market surveillance activities conducted in 2016 
included: 
– Proactive review of cardiac valve implants;
– Proactive review of certain urogynaecological 
devices;
– Assessment of a variety of medical device 
counterfeit issues;
– Assessment of medical device software products;
– In-vitro diagnostic medical device issues.
The HPRA also initiated plans for a sampling and 
analysis programme for a specific type of medical 
device as part of our proactive surveillance activities.
The accompanying graph shows the annual number of 
market surveillance cases since 2012. From the start 
of 2014, the HPRA changed the way we define market 
surveillance cases and so the figures in the graph have 
been adjusted* by applying the pre-2014 definition to 
allow for comparison with 2012 and 2013 figures. The 
increasing work load in respect of surveillance cases 
during the past five years is clearly shown in the upward 
trend.
38
HPRA Annual Report 2016
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Joint Action on Market Surveillance of 
Medical Devices (JAMS) Project 
During 2016, the HPRA contributed to the 
development of an EU-wide joint action project on 
medical device market surveillance. The project is part 
of the EU Commission’s Health Programme 2014-2020 
and is being led by the UK’s MHRA, the Dutch IGZ and 
the HPRA. The HPRA is participating in all elements of 
the project and is leading a work package on clinical 
resource and development. We are also a contributing 
partner to a work package to establish co-ordination 
and best practice for market surveillance audits of 
manufacturers by regulatory authorities. This project will 
run between 2017 and 2019.
COEN Joint Action Project on Reusable 
Instruments
The COEN Joint Action (JA) 2014 project aims to 
improve the transparency regarding compliance of 
medical devices designed to be re-used such as 
specified surgical instruments. As part of the project, 
technical information for over 30 reusable devices was 
requested from seven manufacturers in Ireland for 
review against an agreed European checklist. 
Certificate Notifications
Certificate notifications from Member State authorities 
relate to certificate refusals, withdrawals and 
suspensions by notified bodies. While the upward trend 
in the number of notifications received continued, the 
2016 total of 1,062 certificate notifications represented 
only a small increase compared to 2015. This levelling 
off in numbers may be a consequence of the joint 
assessment process for notified bodies which has 
increased the consistency and performance of these 
organisations across the EU. The HPRA investigated 
certificate notifications with implications for the Irish 
market, those arising from identified safety concerns 
and major non-compliances, and those arising from a 
reduction in the designation scope or de-designation of 
notified bodies. 
Technical File Reviews
The HPRA continued its increased focus on review of 
technical documentation both in the context of market 
surveillance activities and notified body oversight. 
A total of 21 detailed technical file reviews were 
completed in 2016. 
Clinical Evaluation Reviews
During 2016, the HPRA increased its activities further 
in the assessment of clinical data presented by 
manufacturers to support the safety and performance 
of their devices. A total of 30 clinical evaluation reviews 
were conducted. This work was carried out as part of 
proactive market surveillance activities including in 
some cases as part of broad reviews of specific product 
ranges. Clinical evaluations were also triggered as a 
result of a number of specific device issues. 
Designation and Monitoring of Irish 
Notified Bodies
During 2016, the HPRA conducted its ongoing 
surveillance activities of the National Standards 
Authority of Ireland (NSAI) as a notified body for 
medical devices in Ireland. In addition to the annual 
surveillance assessment (see also Inspections and 
Audits on page 41), a number of observed audits of 
NSAI auditors were conducted as they undertook 
assessments of quality systems at manufacturing sites. 
We also provided technical, clinical and quality system 
experts to support six joint assessments of medical 
device notified bodies in other European countries 
during 2016. We have contributed expert assessors to 
more EU joint assessments than any other European 
authority since the scheme was introduced in 2013.
Vigilance
The medical devices vigilance system which was 
established under European medical device directives 
aims to minimise risks to the safety of patients, users 
and others. Vigilance activities include the following:
• The submission of vigilance reports by 
manufacturers and users to the relevant competent 
authorities (the HPRA in Ireland); 
• The evaluation of reported incidents by the 
competent authorities; 
• The dissemination of information, which may be 
used to prevent recurrence of the incident, or to 
alleviate the consequences of such incidents, in 
cases when it is necessary to do so; 
• A device being updated, modified or taken off the 
market in cases when it is necessary to do so. 
In 2016, we continued to focus our work on the area 
of user reporting and dissemination of HPRA medical 
device safety communications. 
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2016 Reports in Summary 
A total of 2,216 medical device vigilance reports were 
received and assessed representing a slight increase on 
2015. Manufacturers accounted for 56% of all vigilance 
reports received in 2016 while 37% were received from 
other competent authorities. Of the incidents reported, 
38% were as a result of an incident on the Irish market. 
Of the Irish incidents, 23% were related to an ongoing 
field safety corrective action. 
Concerning the regulatory response to the reports 
received, 59% resulted in an action being taken in 
Europe. In Ireland, there were 147 product removals 
conducted in Ireland during 2016.
The HPRA also issued 98 national competent authority 
reports during the past year.
2016 Reports by Product Type
Surgical devices, orthopaedic devices and infusion 
devices accounted for 42% of the total vigilance 
reports. Reports continue to be received relating 
to diagnostic imaging and radiotherapy devices. 
We also continue to receive reports relating to 
revision procedures associated with the ASR Articular 
Surface Replacement and ASR XL Acetabular system 
manufactured by DePuy. 
In addition, 411 were received in respect of in-vitro 
diagnostic (IVD) devices, the majority of which related 
to clinical biochemistry. Field safety corrective actions 
relating to clinical biochemistry reagents and analysers 
continued to have a high impact on the number of IVD 
vigilance cases.
Enhancing the Vigilance System
As part of our focus on strengthening the existing 
regulation of medical devices, the HPRA continued 
in 2016 to focus on improving the functioning of the 
vigilance system both nationally and at an EU level. 
This included the provision of systematic access for 
notified bodies to reports of adverse events as well as 
encouraging healthcare professionals and empowering 
patients to report adverse events. There was also 
enhanced co-ordination in analysing reported incidents 
in order to pool expertise and expedite necessary 
corrective actions.
As regards the dissemination of safety information, the 
HPRA delivered a number of workshops throughout 
the year in conjunction with the HSE. The workshops 
were focused on promoting user reporting, highlighting 
the role of the vigilance liaison officer and raising 
awareness of HPRA safety communications. We also 
circulated a step-by-step guide on adverse incident 
reporting to 121 healthcare centres and developed a 
user engagement page on the HPRA website. 
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The HPRA continues to develop enhanced systems 
for the analysis of vigilance data and is an active 
participant in efforts to promote co-ordination at a 
European level. 
Inspections and Audits 
As part of our regulatory role, we are focused on 
ensuring industry compliance with relevant standards 
and legislation. In respect of medical devices, this 
includes proactive audits of manufacturers of Class I 
devices and ‘for cause’ audits as required, for example, 
as part of the follow-up to a defect. We also carry 
out regular audits of the NSAI, the notified body for 
medical devices that is designated by the HPRA.
Medical Device Audits 
During 2016, 16 audits were performed at both medical 
device manufacturers and authorised representative 
facilities, of which: 
- two were for cause audits, one of which was in the 
US;
- eight were reactive audits based on vigilance / 
market compliance issues; 
- four were audits based on proactive market 
surveillance projects;
- two were of authorised representatives of medical 
device manufacturers.
Notified Body Assessment 
We conducted a full redesignation assessment of the 
Irish notified body, the NSAI. This assessment was also 
performed as part of the joint assessment program 
with the European Commission’s Directorate on Health 
and Food Audits and Analysis and national experts. An 
observed assessment of an NSAI auditor at a class III 
implantable medical device manufacturer based in the 
US was also conducted.
Legislation and Regulation
New Medical Devices Legislation 
In June 2016, a political agreement was reached 
between the European Council, European Parliament 
and the European Commission on the new Regulations 
on medical devices and in-vitro diagnostic devices. This 
agreement followed four years of intense negotiation 
and development of these complex regulatory 
proposals involving close to 100 meetings of the 
European Council’s Working Party on Pharmaceuticals 
and Medical Devices. Throughout the negotiation, the 
HPRA provided regulatory and technical support to the 
Department of Health for the purposes of representing 
the national position at the European Council Working 
Party and in other fora. 
The new legislation has been formally adopted and 
was published in the Official Journal of the European 
Union during Q2 2017. The Regulations replace the 
existing Directives. Some elements will become legally 
binding from the end of 2017 while the remainder will 
be applicable from 2020 for medical devices and 2022 
for in-vitro diagnostic devices. 
During 2016, the HPRA commenced detailed 
planning for implementation of the new legislation at 
organisational and national level. The EU Competent 
Authorities for Medical Devices (CAMD) network 
has, at the request of the HPRA, established a 
taskforce to discuss and co-ordinate implementation 
of the new legislation. This will help prioritise and 
coordinate work at a European level while facilitating 
effective implementation, a consistent approach and 
understanding of the requirements across Europe, and 
clear communication and guidance from EU regulators. 
A critical component of the HPRA’s implementation 
plan will be to provide affected stakeholders with 
guidance and communications relevant to the new 
requirements. This commenced in November 2016 
when we hosted our medical device information day in 
Dublin. 
Ongoing Development of the Existing 
Regulatory Framework
Throughout 2016, the HPRA continued its commitment 
and leadership in the development of the EU regulatory 
system for medical devices to strengthen and improve 
co-ordination and co-operation between medical 
device authorities, the European Commission and 
relevant stakeholders. 
Central to this improved co-ordination is the work of 
the Competent Authorities for Medical Devices (CAMD) 
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network. The HPRA was re-elected to the Executive 
Group of the CAMD in 2016. We also continued to 
provide support across all of the different working 
groups of the European Commission. See Contributing 
to the European and Global Regulatory Network below 
for further details.
National Fees for Medical Devices
In 2016, the HPRA finalised a proposal to the 
Department of Health to introduce a national fee 
model to cover the cost of all of the HPRA’s medical 
device regulatory activities so as to enable the 
HPRA to become self-funding in this area. The new 
EU legislation on medical devices makes specific 
provision for Member States to levy fees to cover 
the costs of their regulatory activities. The HPRA has 
engaged over the last number of years with relevant 
stakeholders and, in particular, the medical device 
industry on the introduction of fees and conducted 
a public consultation in mid-2015 on a proposed 
model. Following on from this, the model was further 
clarified to address concerns raised during the 
consultation process. The fee model was finalised by 
the Department at the end of 2016 to come into effect 
from 1 January 2017. The HPRA has committed to 
complete an annual review of this fee model.
Stakeholders and Partners
Contributing to the European and 
Global Regulatory Network
Europe
During 2016, the HPRA continued its commitment and 
leadership in the development of the EU regulatory 
system for medical devices to strengthen and improve 
coordination and cooperation between medical device 
authorities, the European Commission and relevant 
stakeholders. As the regulatory system for devices 
is decentralised and mutually reliant, it is essential 
that there is consistency and cooperation across the 
European regulatory network.
• Central to this improved coordination EU regulatory 
system for medical devices is the revamp of the 
Competent Authorities for Medical Devices (CAMD) 
network. This network promotes partnership 
and allows for close cooperation between all 
of the regulatory authorities responsible for 
medical devices across Europe and the European 
Commission. It has driven opportunities for joint 
working on medical devices issues between 
authorities, most notably through formal joint 
actions on medical device market surveillance 
issues which fall under the EU health programme 
2014-2020. During 2016, the HPRA was re-elected 
to the Executive Group of the CAMD (along with 
Austria, France, Germany, Sweden, Switzerland and 
the UK).
• The HPRA continued to provide support across 
all of the different working groups of the 
European Commission. During 2016, the HPRA 
was nominated as the co-chair of the Clinical 
Investigation and Evaluation Working Group 
(CIEWG). This adds to our existing co-chair roles at 
the Compliance and Enforcement Working Group 
(COEN) and the Notified Body Operations Group 
(NBOG). During 2016, the HPRA were also key 
contributors to the establishment, development 
and delivery of to two training workshops hosted 
by the European Commission. 
• The HPRA participated in meetings to assist in 
the definition of the ICT requirements to support 
the implementation of the new European medical 
devices legislation.
International Medical Device Regulators 
Forum
Over the past number of years, the HPRA has also been 
contributing to the development of regulatory systems 
for medical devices at international level with a view 
to promoting harmonisation of international regulatory 
systems and consistency and co-operation between 
device regulatory authorities across the globe. 
In 2016, the HPRA continued its membership of the 
Management Committee of the International Medical 
Device Regulators Forum (IMDRF) as part of the 
European delegation (along with France, Germany and 
the EU Commission). 
During this calendar year, the Management Committee 
considered a number of ongoing work items including 
adverse event nomenclature systems, competence and 
training requirements for pre-market reviewers, NCAR 
exchange, and registries for medical devices. Regulated 
product submissions and the requirements for clinical 
evaluation of software as a medical device were also 
discussed.
In March, the Management Committee agreed to 
initiate a new work item: Improving the quality of 
international medical device standards for regulatory 
use. This item will be led by Europe. The Committee 
also approved a number of final documents and 
launched public consultations on a range of others. 
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In addition, the HPRA continued its role as the 
international secretariat for the IMDRF’s NCAR 
Exchange programme. This scheme allows for the 
exchange of information between international 
regulatory authorities on identified or emerging safety 
issues relating to medical devices. During 2016, 18 
reports were exchanged between authorities via this 
system.
Medical Device Single Audit Programme 
The goal of the Medical Device Single Audit 
Programme (MDSAP) scheme is to allow for mutual 
recognition of quality system assessments of 
manufacturers by appointed auditing organisations 
(many of which are EU notified bodies). This scheme 
helps to promote consistency, efficiency and trust 
across regulatory systems.
The HPRA continued its contribution to the MDSAP 
pilot scheme in 2016 while also continuing to 
encourage the EU’s full participation in the scheme 
once the pilot comes to an end. The HPRA acted 
as observers for Europe on MDSAP audits and 
assessment activities. In addition, the HPRA were active 
participants in MDSAP assessments on a bilateral 
basis with the MDSAP consortium (Australia, Brazil, 
Canada, Japan, US). By September 2016, the scheme 
had 126 manufacturing sites participating in MDSAP 
assessments.
 
China Food and Drug Administration 
During 2016, the HPRA hosted a high-level delegation 
from the China Food and Drug Administration (CFDA) 
to discuss medical device regulation in Ireland and 
bilateral relationships. Arising from this meeting, the 
HPRA has held a number of meetings with CFDA 
officials on medical device issues and we were invited 
by the CFDA to participate in their annual national 
conference on medical devices, the China International 
Medical Device Regulatory Forum. We updated this 
conference on the regulation of medical devices in 
Europe and anticipated changes in legislation.
Medical Devices Information Day
In November 2016, the HPRA hosted an information 
day for medical device manufacturers based in Ireland. 
The day provided the HPRA with an opportunity to 
provide an overview of the anticipated requirements in 
the new EU Regulations and to highlight the expected 
implications that these will have for manufacturers. 
The day was attended by over 200 people and was 
officially opened by the Minister of State for Health 
Promotion, Marcella Corcoran Kennedy, TD, who 
spoke about the importance of medical devices 
and the Regulations for Ireland. The meeting also 
was addressed by MEP Mairead McGuinness, Vice-
President of the European Parliament, who played a 
leading role in the discussions of these Regulations 
at the Parliament. The HPRA provided an overview of 
the implications of the new regulations and specific 
technical topics. Invited speakers from the medical 
device industry, from the UK’s MHRA and from the 
German Ministry for Health, also addressed the 
audience on the implications of the new legislation 
for industry, the requirements around unique device 
identification (UDI) and the European database.
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Pictured at the Medical Devices Information Day (l-r): 
Mairead McGuinness MEP, Vice President of the European 
Parliament; Marcella Corcoran Kennedy, TD, Minister of 
State for Health Promotion; and Lorraine Nolan, Chief 
Executive, HPRA.
Meetings with Stakeholders 
During 2016, the HPRA continued its regular liaison 
meetings with the Irish Medtech Association (formerly 
the Irish Medical Device Association). Specific meetings 
were also arranged during the year to discuss the 
medical device regulations and the introduction of 
national fees. The HPRA also participated in a number 
of conferences and events arranged by the Irish 
Medtech Association including its biannual Global 
Access Conference, the CEO Forum, a conference on 
additive manufacturing and a clinical research event 
hosted in RCSI during European Medtech week. 
The HPRA also continued its engagement with the 
Irish Medical and Surgical Trade Association in 2016 
including specific meetings on the introduction of 
national fees and briefings on the new Regulations and 
on the HPRA’s pilot inspection programme for medical 
device distributors.
Presentations
The HPRA continues to deliver a programme of 
presentations and talks at a range of external 
stakeholder events such as meetings, seminars, 
conferences and training courses. In addition, 
a programme of presentations is delivered to 
undergraduate and post graduate students studying 
courses related to the role of the HPRA. A full list of 
all presentations related to the regulation of medical 
devices that were delivered during 2016 is provided in 
Appendix 2.
Publications and Information
Safety Notices 
The HPRA continues to disseminate safety information 
by issuing medical device safety notices and by 
publishing manufacturers’ field safety notices (FSNs). 
In 2016, 46 safety notices concerning medical devices 
were published on the HPRA website and issued to 
subscribers. This represented an increase of 39% on the 
previous year. Safety notices are also circulated through 
the HSE eAlert system. In addition, we published 
476 manufacturers FSNs on our website in 2016 with 
a monthly listing sent to subscribers. A total of 33 
targeted healthcare professional communications to 
raise awareness of certain field safety corrective actions 
were also issued.
Medical Devices Newsletter
This newsletter provides regulatory and safety updates 
for those working in the medical devices sector and 
professionals working in the health area who regularly 
use or purchase medical devices. It provides updates 
on Irish and European legislation, on safety issues as 
well as details of HPRA medical devices publications 
and stakeholder events. 
There were two editions of this publication issued in 
2016. The following were some of the main topics 
covered:
• Clinical investigations 
• Mobile apps – are they medical devices?
• Automated external defibrillators – managing your 
device
• The gift of sound: Clinical benefits of cochlear 
implants
• Cochlear implant research in the Trinity Centre for 
Bioengineering
• Proposals for new Regulations on medical devices 
and in-vitro diagnostics.
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Blood, 
Tissues and 
Organs
The HPRA is responsible for monitoring the safety 
and quality of blood and blood components, tissues 
and cells, and organs intended for transplantation. 
We were designated as the Competent Authority 
responsible for the regulation of blood legislation 
in 2005, for tissues and cells legislation in 2006 and 
joint Competent Authority, with the HSE, for organs 
legislation in 2012.
Authorisation and Registration
Authorisation / Approvals of 
Establishments
The authorisation of blood establishments, tissue 
establishments and organ procurement organisations / 
transplantation centres permits those facilities to carry 
out specified activities. Authorisation by the HPRA is 
subject to the review of supporting documentation 
and inspections during which adherence to relevant 
European guidance is evaluated (see also under Safety 
and Quality).
The total number of authorisations in place at year end 
for the past five years is presented by category in the 
accompanying table. 
Number of 
Authorisations
2012 2013 2014 2015 2016
Blood establishments 3 4 4 3 3
Tissue establishments 21 23 24 24 25
Organ procurement/
transplantation 
0 0 0 4 4
Variations to Authorisations
We regularly process applications from authorisation 
holders to vary the information on which the 
authorisation is based. During 2016, we issued 18 
variations in respect of tissue establishments, six in 
respect of blood establishments and six that related 
to organ procurement organisations / transplantation 
centres. 
Safety and Quality
Haemovigilance
The HPRA is the competent authority for legislation 
concerning blood and blood components. 
Haemovigilance refers to a set of organised surveillance 
procedures relating to serious adverse or unexpected 
events / reactions in donors or recipients and the 
epidemiological follow-up of donors.
Following collaboration with the National 
Haemovigilance Office (NHO), we submitted an annual 
report of serious adverse reactions and events to the 
EU Commission during 2016. The report reflected 
information received by the NHO in 2015 and included 
information on 64 serious adverse reactions and 167 
serious adverse events which met the mandatory 
legislative reporting requirements. 
We continued to work with the Irish Blood Transfusion 
Service (IBTS) and the Department of Health with the 
aim of formalising arrangements for haemovigilance 
activities and to provide for the development of an 
online reporting system, to facilitate simultaneous 
submission of mandatory reports to both the NHO 
and HPRA. Pending finalisation of these formalised 
arrangements, and access to an online reporting 
system, the interim arrangements, first agreed for 
reporting to the HPRA in 2008, continued to operate 
throughout the past year. These arrangements have 
facilitated consistency and timeliness in reporting 
allowing appropriate regulatory oversight.
Tissue and Cell Vigilance
The tissues and cells legislation focuses on standards of 
quality and safety for donations, procurement, testing, 
processing, preservation, storage and distribution of 
human tissues and cells.
We submitted an annual report on serious adverse 
reactions and events associated with tissues and cells to 
the EU Commission during 2016. The report reflected 
information received in 2015 and consisted of some 
55 reports, 42 of which met the legislative reporting 
requirements, including two serious adverse reactions 
and 32 serious adverse events.
Human Organs for Transplantation
We continued to liaise with the HSE lead and 
colleagues from Organ Donation and Transplant 
Ireland in relation to serious adverse reaction and event 
reporting, in accordance with the legislative provisions 
in place. During 2016, the HPRA received six reports of 
serious adverse reactions and events associated with 
organ donation / transplantation.
Inspections of Establishments
As part of our regulatory role, the HPRA inspects 
relevant establishments, organisations and centres 
to monitor compliance with applicable EU guidelines 
on the quality and safety of blood, blood products, 
tissues and cells, and human organs intended for 
transplantation.
Our inspection programme in 2016 consisted of:
- Fifteen tissue establishment inspections of which 
eight were non-routine; 
- Seven routine inspections of blood establishments; 
and
- Four non-routine inspections of organ procurement 
organisations / transplantation centres. 
Legislation and Regulation
Tissues and Cells: New Commission 
Directives 
Two Commission Directives were published during 
2015. These were:
- Directive (EU) 2015/565, amending Directive 
2006/86/EC: The purpose of this Directive is to 
improve the traceability of human tissues and 
cells from procurement to human application or 
disposal. It obliges tissue establishments to affix 
a single European code (SEC) on tissues and cells 
distributed for clinical application in the EU; 
- Directive 2015/566, implementing Directive 
2004/23/EC: The purpose of this Directive is to 
ensure that tissues and cells imported into the 
EU from third countries meet quality and safety 
standards equivalent to those tissues and cells 
procured, processed and distributed in the EU. 
The HPRA continued to prepare for the implementation 
of the new Directives which are due to come into force 
throughout the EU on or before 29 April 2017.
46
HPRA Annual Report 2016
26
inspections of relevant 
establishments, 
organisations and 
centres
Stakeholders and Partners
Contributing to the European 
Regulatory Network
VISTART
The key goal of the EU co-funded Joint Action on 
Vigilance and Inspection for the Safety of Transfusion, 
Assisted Reproduction and Transplantation (VISTART) 
is to promote and facilitate the harmonisation of 
inspection, authorisation and vigilance systems in the 
EU for blood, tissues and cells used in transfusion, 
transplantation and assisted reproductive technology 
(ART). It is a crucial step towards increasing both 
collaboration among EU member states and mutual 
confidence in their respective systems, thus ensuring an 
equivalent level of quality and safety for substances of 
human origin (SoHO).
VISTART is co-ordinated by the Italian National Blood 
Centre and the Italian National Transplant Centre. The 
HPRA is participating in five of the work packages and 
is leading one of these, which is a voluntary programme 
of inter-member state inspection system auditing.
Meetings with Stakeholders
We continued our regular interaction with the NHO 
during 2016, including discussion of issues of mutual 
interest and concern at bilateral quarterly meetings.
Information Seminars and Training
Training and updates on the coding and import 
Directives for human tissue and cells were provided to 
tissue establishments and the presentations provided 
were also published on our website.
Presentations
We invest significant time at the HPRA in delivering a 
programme of presentations and talks at a range of 
external stakeholder events such as meetings, seminars, 
conferences and training courses. Such presentations 
contribute to the HPRA goal of providing stakeholders 
such as healthcare professionals and regulatory 
professionals with access to relevant, up-to-date 
information. Details of presentations delivered during 
2016 relevant to blood, tissues and organs are provided 
in Appendix 2.
Publications
Guidance Documents
HPRA guidance documents provide stakeholders, 
primarily from the industry sectors we regulate, with 
advice and direction in respect of legislation and 
regulatory requirements. In January 2016, we published 
a new guide entitled Serious Adverse Reaction / 
Event Reporting for Human Organs Intended for 
Transplantation. All of the HPRA guidance documents 
can be accessed via the publications section of  
www.hpra.ie.
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The role of the HPRA is to regulate the manufacture, 
sale and supply of cosmetic products in Ireland. We 
identify and address cosmetic product quality and 
safety issues, in conjunction with the HSE, so that 
a cosmetic product will not compromise the health 
and safety of the consumer or the person applying 
the product.
Authorisation and Registration
Free Sale Certificates 
Cosmetic companies exporting to third countries may 
require a certificate of free sale as part as their export 
dossier. A certificate issued by the HPRA indicates that 
the product intended to be imported is compliant with 
EU regulations.
During 2016, there were 369 certificates issued in 
respect of cosmetic products representing an increase 
of over 70% compared with the previous year.
Safety and Quality
Market Compliance of Cosmetics
Proactive Market Surveillance
Post-market surveillance of cosmetic products includes 
a national sampling and analysis programme and 
involves close co-operation between the HPRA and the 
HSE’s Environmental Health Service and Public Analyst 
Laboratories in Galway, Cork and Dublin. 
During the past year, 471 cosmetic products were 
sent for laboratory testing with 54 (11%) found to be 
non-compliant. The largest areas of non-compliance 
included microbial contamination of talcum powders 
and face paints, heavy metals in make-up and children’s 
products, phenol in henna products and the presence 
of kojic acid not declared on the labelling of some 
skincare creams. 
Reactive Market Surveillance
Reactive surveillance includes investigation of quality-
related complaints (compliance cases), reports of 
adverse events relating to the use of cosmetics 
(vigilance cases) and RAPEX serious risk alerts. There 
were 163 compliance cases opened of which 150 
involved cosmetic products that were deemed to be 
non-compliant with EU regulations. The majority of non-
compliances were in the areas of labelling, the presence 
of prohibited substances, contamination (mainly 
microbiological or heavy metals) and unsupported 
efficacy claims. There were five withdrawals from 
the Irish market as a result of non-compliances due 
to issues such as microbiological contamination, 
counterfeiting and labelling issues. 
During the year, 13 vigilance cases (undesirable 
effect reports) were investigated. These related to 
hair products, creams, lotions, make-up products and 
others. A total of 110 RAPEX serious risk alerts were 
received from other European member states regarding 
non-compliant cosmetic products. Five of these 
products were found on the Irish market and removed 
from sale.
Cosmetics
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Stakeholders and Partners
Regulatory Information Seminars and 
Training
We provided training and support for HSE 
environmental health officers (EHOs) and Public 
Analyst’s Laboratories in the monitoring of retailers of 
cosmetic products. The training and support included 
hosting the National Cosmetics Surveillance Forum 
and Open Cases meeting as well as presenting at two 
training days for EHOs. 
The first of these was for training of the newly 
appointed steering committee of the Environmental 
Health Service on the cosmetic regulations, focusing on 
the compliance notice process. 
The second training day was open to the wider group 
of EHOs and focused on the cosmetic regulations and 
market surveillance of retailers. 
We also hosted an information stand at the Professional 
Beauty Show held in the RDS, Dublin in October. We 
provided information on the regulatory requirements 
for cosmetics to beauty professionals both participating 
in and attending the event.
Publications and Information
Guidance Documents
We developed a Guide to Essential Oils in Cosmetics 
on behalf of the Council of Europe.
Presentations
Presentations enable the HPRA to provide cosmetic 
stakeholders with relevant, up-to-date regulatory 
information. We presented at two cosmetic products 
conferences in 2016. A full list of all presentations 
delivered by the HPRA during the year is provided in 
Appendix 2.
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cosmetic products sent 
for laboratory testing
Reactive Market Surveillance 2014 2015 2016
Compliance cases opened 105 107 163
Compliance cases closed 109 99 171
Vigilance cases opened 21 11 13
Vigilance cases closed 14 20 14
RAPEX alerts received 100 56 110
Recalls/withdrawals from the Irish market 1 4 5
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Authorisation and Registration
Processing of Applications for Licences 
and Registrations
Controlled Drugs
Import, export and holding of controlled drugs (for 
legitimate purposes) are subject to licensing. The 
Department of Health is the licensing authority while 
the HPRA handles the administrative aspects of the 
application and licensing process.
Licensing activity consists primarily of export and import 
licences, and letters of no objection. Data for the past 
five years are outlined in the accompanying table. 
Precursor Chemicals 
Precursor chemicals are substances which are used in 
a wide variety of industrial processes and consumer 
products, such as medicines, flavourings and fragrances 
but additionally have the potential to be diverted for 
use in the chemical synthesis of illicit substances.
The HPRA has been the licensing authority for precursor 
chemicals since 2010. These are subject to different 
licensing requirements, dependant on the category. 
Precursor Chemicals 
Licensing Activity 
2012 2013 2014 2015 2016
Total 70 27 46 32 16
Controlled 
Substances
2,500
2,000
1,500
1,000
500
0
Controlled Drugs Licensing Activity
2,034 2,055 2,130
2,363 2,343
2012 2013 2014 2015 2016
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Legislative Developments 
Misuse of Drugs
The Misuse of Drugs (Amendment) Act 2016 was 
passed by the Oireachtas in July. The primary purpose 
of the Act is to protect public health by bringing certain 
substances which are open to misuse and known to 
be traded on the illicit market, under the scope of 
the Misuse of Drugs legislation, thereby aiding the 
law enforcement activities of An Garda Síochána and 
Revenue’s Customs Service. The Act will come into 
operation on foot of commencement orders and 
will enable the Minister for Health to introduce new 
regulations.
Stakeholders and Partners
Contributing to the European 
Regulatory Network
We were involved in the development of a European 
Guidance for Operators that is aimed at stakeholders 
involved in the distribution of precursor chemicals.
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The number of controlled 
drug licences processed 
in 2016
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Scientific 
Animal 
Protection
The HPRA is the competent authority in Ireland 
responsible for the implementation of EU legislation 
(Directive 2010/63/EU) for the protection of animals 
used for scientific purposes. We are committed 
to ensuring that the care and use of animals for 
scientific purposes is in line with the 3Rs principles 
(replacement, reduction and refinement).
Authorisation and Registration
Authorisations of Establishments, 
Projects and Individuals 
One of the primary functions of the HPRA is to perform 
evaluations of applications for the authorisation of 
research establishments and projects. The HPRA also 
evaluates applications from individuals to allow them to 
conduct procedures or euthanasia of animals. 
During the past year, the total number of new 
individual and project authorisations granted decreased 
somewhat when compared to 2015. Please note that 
the higher level of individual authorisations during 
the previous two-year period was due to the legal 
requirement for existing establishment personnel to 
apply for individual authorisations before the end of 
2014. Hence, there were a large number of applications 
for individual authorisations, which are valid for five 
years, in that period. It is likely that the application 
numbers for 2016 and 2015 mainly reflect new 
individuals joining the sector.
We also processed 277 amendments to existing 
authorisations throughout the year. The majority of 
these amendment applications (170) were for project 
authorisations, which, depending on the nature of 
the amendment requested, may involve significant 
assessor input. The remaining amendment applications 
Individuals
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were for individual authorisations (97) and breeder / 
supplier / user establishment authorisations (10). There 
were 16 renewal applications processed. Two of these 
were to renew breeder / supplier / user establishment 
authorisations while 14 were to renew project 
authorisations. 
National Statistical Report
In July, the HPRA published its third annual statistical 
report on the use of animals for scientific purposes in 
Ireland. We are required to collect and make publicly 
available, on an annual basis, statistical information on 
the use of animals in procedures, including information 
on the actual severity of the procedures. 
Safety and Quality
Inspection Programme
The second key component of our work involves 
the inspection of animal facilities to monitor animal 
welfare standards and compliance with legislation. Our 
inspections, an increasing percentage of which have 
been unannounced, follow a risk-based approach with 
a focus on the welfare of animals used for scientific 
purposes. Inspections also allow us to verify compliance 
with the scientific animal protection legislation.
During 2016, there were a total of 33 inspections 
performed, 48% of which were unannounced. This 
compares with 2015 when 28% of the 29 completed 
inspections were performed on an unannounced basis. 
Stakeholders and Partners
Contributing to the European 
Regulatory Network
In relation to the EU network on scientific animal 
protection, the HPRA contributed to deliberations in 
respect of a number key topics and played an active 
role as part of the European Commission’s National 
Contact Point Network for the implementation of 
scientific animal protection legislation.
Contributing to the National Initiatives 
We provided support to the National Committee for 
the Protection of Animals used for Scientific Purposes 
in relation to their role to nurture the creation of a 
culture of care at the establishments concerned. The 
committee met on two occasions during 2016.
We continued to liaise with Science Foundation Ireland 
and the Health Research Board to explore ways of 
raising awareness of the 3Rs amongst the research 
community in Ireland. One significant development 
was the agreement among our three agencies to host a 
conference focused on promoting awareness of the 3Rs 
amongst the research community in Ireland during May 
2017. Planning for the event, which was co-ordinated 
by the HPRA, commenced during the latter part of the 
year.
Presentations
We delivered six Laboratory Animal Science and 
Training (LAST) lectures in relation to EU legislation 
and the role of the HPRA. We also delivered a similar 
lecture to the Association for Veterinary Teaching and 
Research Work in UCD. 
Publications
Regulatory Updates 
These updates, which were issued on four occasions 
during the year, are intended to provide the research 
community in Ireland with updates on the latest 
developments, including:
- new and updated HPRA guidance documents, 
forms and procedures;
- information on education and training; 
- information on the 3Rs, best practices, compliance 
with the legislation and other relevant details.
 
33
The number of 
inspections of 
establishments 
completed in 2016
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The HPRA is committed to having the necessary 
corporate functions, systems and supports in place 
to deliver on our public health mission. We must 
ensure that our organisational capabilities continue 
to expand and evolve in line with regulatory and 
scientific developments and that we adapt to other 
changes in our operating environment. We must also 
apply and maintain the highest possible levels of 
corporate governance.
Organisation-Wide 
Programmes
Scientific Affairs 
Innovation Office
As part of our strategic goal to support innovation, 
the HPRA’s Innovation Office was launched in 2016. 
The main function of the office is to provide regulatory 
support and advice to individuals or groups who are 
developing innovative health products or technologies. 
Queries can relate to any area within the HPRA’s remit 
and can be submitted at any stage of development.
Although the Innovation Office was launched in late 
2016, by the end of the year nine queries had already 
been received. The queries related to novel medical 
devices and medicinal products, and to innovative 
manufacturing and testing technologies. Responses 
to all queries were issued within the standard 20 day 
timeframe.
Horizon Scanning
The HPRA has identified the need to perform 
horizon scanning to ensure that we are in a position 
to effectively and appropriately regulate innovative 
products and technologies that are currently under 
development and thereby support the advancement of 
novel approaches within the life sciences sector. 
To this end, we established an internal horizon scanning 
group to proactively identify such innovations and 
help to ensure that the HPRA is prepared for future 
developments within our remit. As part of its work, the 
group will consider whether changes to regulatory tools 
or approaches and / or the development of additional 
knowledge and expertise within the HPRA is required. 
This group held its first meeting in 2016 and will 
continue its work in 2017.
Communications
Communications Strategy 2016 – 2020
At the beginning of the year, the Authority of the HPRA 
approved the Communications Strategy 2016 – 2020. 
The communication activities identified in the strategy 
are intended to support the successful delivery of our 
new strategic plan and, in particular, the goal to ensure 
that users of health products are as well informed as 
possible. Open and proactive communications will also 
be critical to maintaining public trust and confidence in 
the regulatory system. 
This strategy document sets out the HPRA’s approach 
to communications over the five year period and 
outlines our core communications objectives, the key 
Organisation-Wide  
Initiatives and 
Development
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target audiences we need to reach and the various 
channels and platforms we will employ to reach 
them. A particular focus in the coming years will be to 
increase public awareness of the HPRA and our role. 
There is also an emphasis on developing our consumer 
communications and patient engagement initiatives. 
Public Information Campaign
As part of our commitment to increasing consumer 
communications, we launched our first ever national 
public information campaign in September to raise 
awareness of the safe and effective use of medicines. 
Entitled ‘For the full benefit, take three minutes’, 
the campaign was officially launched by Minister for 
Health, Simon Harris TD, and ran over six weeks across 
national and regional radio as well as digital and print 
media. The focus of the adverts was to advise members 
of the public that to get the most benefit from their 
medicine, they should take the time to always read 
the information printed on the packaging and / or the 
product leaflet. This information includes essential 
details such as the correct dose, instructions for use and 
potential side effects. 
The campaign was developed in response to our 
ongoing research programme which shows a worrying 
downward trend in the number of consumers not 
reading product information both for over-the-counter
 
and prescription only medicines. Data published by 
the HPRA in 2016 showed that one in four (26%) adults 
admit that they never read the product information 
for an over-the-counter medicine with one in five 
(21%) never reading the information for a prescription 
only medicine. The corresponding figures from the 
same survey conducted in 2010 were 14% and 12% 
respectively.
The campaign will be repeated on a number occasions 
during 2017.
Market Research
During 2016, we published results and findings from 
a series of national consumer surveys. Our research 
programme assists us in better understanding the 
general public’s views, opinions and behaviours 
in respect of the range of health products that we 
regulate.
Where necessary and appropriate, we will respond to 
specific findings by changing current HPRA practices 
or by developing new initiatives and campaigns 
focused on consumers. An example of this was the 
development of our public information campaign to 
address the fact that fewer Irish adults are reading 
the product information that comes with a medicine. 
This finding was highlighted in the results of a survey 
to examine how Irish consumers source information 
about health in general and, more specifically, the 
medicines that they take. The results of this research, 
which also examined the use of the internet as a source 
of medicines information and supply, were published in 
May.
Additional research published during 2016 included:
- Human medicines: Further research examining the 
extent to which members of the public read specific 
sections of the product information leaflet such as 
the directions for use and the potential side effects.
- Veterinary medicines: The levels and nature of pet 
ownership in Ireland as well as the extent to which 
owners purchase medicines for their animals. This 
research also focused on the percentage of pet 
owners reading the printed information supplied 
with veterinary medicines.
- Sunscreens: The extent to which consumers 
understand the terminology and symbols printed 
on the labelling of sunscreens such as UVA and 
UVB, the two harmful rays from the sun, and the 
sun protection factor (SPF). This research also asked 
consumers to rank in order of importance the issues 
they take into consideration when choosing to 
purchase a specific sunscreen product. 
Summary results from all the research published by the 
HPRA during 2016 is available from our website.
Media Communications
Throughout the year, we continued our media 
communications programme to proactively 
communicate important safety messages and to build 
awareness of the role of the HPRA. We issued 23 
press releases and statements concerning safety and 
regulatory issues to ensure consumers, healthcare 
professionals and other stakeholders received timely 
and accurate information and advice. In a number 
of instances, these communications resulted in 
national and regional media interviews with a HPRA 
spokesperson. 
Among the issues highlighted via press releases during 
the past year were:
- HPRA launches strategic plan for 2016 to 2020
- New campaign urges people to Take 3 Minutes to 
get full benefit of medicines
- HPRA consumer research reveals fewer Irish adults 
reading important product information
- Almost 750 potentially life-saving defibrillators 
require urgent updates
- Global operation targeting falsified medicines – 
Over 60,000 units of illegal prescription medicines 
detained in Ireland
- Majority of pet owners take great care when giving 
medicines to their pets
- Sunscreens - the burning questions: HPRA national 
survey findings on consumer understanding of 
sunscreens
We also published a number of press releases to 
highlight successful prosecutions related to the illegal 
supply of unauthorised medicines.
In addition, we responded to more than 440 initial and 
follow-up queries from national, local and specialist 
media during the year. Drafting responses to such 
queries involves subject matter experts from across the 
organisation. 
Awards for Excellence in Public Relations
In July, the HPRA was confirmed as one of the winners 
of the Awards for Excellence in Public Relations 
2016. Along with our public relations advisor, Weber 
Shandwick, we received the Best Healthcare Campaign 
award for our work in promoting the safe use of 
cosmetic products. These annual awards are considered 
a benchmark for excellence in public relations and 
showcase the very real value of proactive and planned 
media engagement.
The HPRA campaign, which was developed by a cross-
functional team and phased throughout the second 
half of 2015, was based around the seasonal use of 
a number of specific cosmetic products. In addition 
to highlighting important consumer safety advice, 
the campaign also served to build awareness of our 
regulatory role in respect of cosmetic products.
Online and Digital Communications
Website
The HPRA website – www.hpra.ie – is a key 
communications channel. The site outlines our primary 
functions and activities and enables the dissemination 
of information to a wide variety of audiences including 
healthcare and industry professionals as well as patients 
and other members of the public. As new content is 
regularly added to the website, we are focused on its 
continued development and enhancement to ensure it 
remains an attractive and user-friendly resource.
Developments in respect of the HPRA website during 
2016 included the following:
- Implementation of a pay-per-click (PPC) campaign. 
PPC is an internet advertising model used to direct 
traffic to a website rather than relying solely on 
organic visits. 
- Development of new pages and content to support 
the launch of our public information campaign. 
-  Increased new outgoing MRP/DCP web content for 
relevant veterinary stakeholders.
- Launch of a new section promoting the HPRA’s 
Innovation Office and incorporating an online query 
form.
- Design and publication of a series of infographics 
and other images to highlight and simplify 
the presentation of key safety and regulatory 
information. 
We continuously monitor and analyse key statistics in 
respect of the website including overall visitor numbers 
and the most widely viewed pages. Among the key 
findings from 2016 were:
- Almost 284,000 unique visitors accessed our 
website during the past twelve months representing 
a 38% increase compared to 2015. There were in 
excess of 682,000 visits in total in 2016.
- Of those who accessed the site, 40% were new or 
first time users. 
- As in previous years, the most popular sections 
of the website were the human and veterinary 
medicines listings, and the medicines regulatory 
information sections (which include publications 
and forms).
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Twitter
In November, we launched our @TheHPRA Twitter 
account. Social media is a key tool in supporting our 
communications activities and also serves to direct 
additional traffic to the HPRA website. 
Our Twitter content incorporates tweets in respect 
of all products and areas that we regulate. There is a 
particular focus on urgent safety updates and recall 
notices, especially where these contain safety advice 
for patients and members of the public, HPRA events 
and consultations, publications and media / news 
announcements.
We also retweet content from other public sector 
bodies and organisations if we feel it will be of interest 
to our followers. We are committed especially to 
prompting important public health initiatives and 
messages. 
A HPRA Twitter policy was published to coincide with 
the launch of @TheHPRA and this document explains to 
users how we manage our Twitter presence and how we 
engage with followers.
Publications
Innovation Office Leaflet 
In addition to the product specific publications 
highlighted earlier in this report, we also designed and 
published an information leaflet entitled Supporting 
Innovation through Regulation and Science. The leaflet, 
which highlights the activities of the HPRA’s Innovation 
Office, is in a question and answer format and outlines 
the nature of the innovation support we can provide 
in addition to the process our stakeholders can use for 
submitting queries. 
Public Consultations
Public consultations enable the HPRA to identify the 
needs and expectations of stakeholders so that we may 
incorporate their views into the way our services are 
planned and delivered.
During 2016, we completed our annual consultation 
in respect of the regulatory fees proposed for the 
coming year. We also published the outcome of the 
consultation (which commenced in 2015) on the 
introduction of a fee based funding model to support 
the conduct of medical device regulatory activities by 
the HPRA.
We also make submissions to third party consultations 
where the topic is related to or impacts our regulatory 
functions and the broader public health agenda. In 
2016, we provided comments in respect of 15 public 
consultations from the Department of Health, the 
Department of Jobs, Enterprise and Innovation, the 
European Commission, the Royal College of Physicians 
of Ireland and from a number of other national 
agencies.
Event Management
Information and Training Events
HPRA information days, seminars and training 
workshops provide regulatory guidance and updates 
to a range of stakeholders. We held nine events in 
2016 all of which were organised and managed in-
house. This approach ensures cost-effective delivery of 
events while also allowing HPRA staff to deal directly 
with stakeholders. This has resulted in very positive 
feedback from attendees via event questionnaires.
As well as presentations from our staff and, where 
appropriate, external contributors, the events enable 
all attendees to submit questions, seek clarifications 
and network with colleagues. While additional details 
concerning a number of these events are provided 
in earlier sections of this report, the following is a 
summary of the HPRA organised information sessions 
and meetings held during 2016:
- Four workshops focused on the requirement for 
manufacturers / MAHs to add safety features to the 
outer packaging of specified medicines for human 
uses were hosted in Athlone, Cork and Dublin 
during May. 
- A training workshop for clinical / safety assessors 
was organised in September in collaboration with 
the EU Network Training Centre (EU NTC). 
- Advanced Quality Risk Management (QRM) 
training, which was hosted in the offices of the EMA 
in September, was organised jointly by the HPRA 
and the Pharmaceutical Inspection Co-operation 
Scheme (PIC/S). 
- The HPRA hosted an informal meeting of the 
Committee for Advanced Therapies (CAT) in 
October on behalf of the Slovakian regulatory 
authority. 
- In November, the HPRA hosted an information 
day for the medical devices industry to provide 
an overview of the anticipated requirements for 
manufacturers under the new EU Regulations. This 
seminar, which included a number of external guest 
speakers, was attended by approximately 250 
delegates. 
- A meeting was held in November under the Joint 
Action on Market Surveillance of Medical Devices 
(JAMS). 
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BT Young Scientist and Technology 
Exhibition 2016
Thousands of students as well as teachers, parents and 
members of the general public from all over Ireland 
again visited the HPRA’s exhibition stand at the annual 
BT Young Scientist and Technology Exhibition. The 
exhibition took place in mid-January in the RDS, Dublin. 
Our stand highlighted the importance of the safe and 
appropriate use of medicines, medical devices and 
cosmetic products. We also sponsored and presented a 
special award focused on health product safety.
Customer Services
Almost 3,000 queries were received and actioned 
by the customer services team during 2016. These 
included queries from industry representatives, 
healthcare professionals and members of the public. 
A large proportion of the queries received related to 
compliance issues, product variations and the product 
information for medicines. Queries were received 
primarily via email and by phone. In addition to the 
queries managed by customer services staff, a range 
of stakeholder queries are addressed by specialist staff 
across the organisation. Many of these queries come 
from healthcare professionals requesting information 
about specific medicines. 
Information and Transparency
Freedom of Information
The HPRA is subject to the Freedom of Information 
Act 2014. The Act asserts the right of members of the 
public to obtain access to official information to the 
greatest extent possible consistent with public interest 
and the right to privacy of individuals. During 2016, the 
HPRA received 26 Freedom of Information requests. 
Of these, three were requests for personal information. 
The HPRA has a policy of posting a disclosure summary 
of non-personal FOI requests on our website for 
reference purposes. The 2016 summary can be viewed 
on www.hpra.ie. 
Protected Disclosures
During 2016, there were concerns raised by external 
persons in relation to organisations regulated by the 
HPRA. These concerns were handled under the HPRA’s 
process for protected disclosures. All eight were 
investigated, of which three are still ongoing and five 
have concluded. Any matter arising from the
investigations was addressed, and the outcomes were 
communicated to the discloser where known. 
During the same period, no disclosures under the 
Protected Disclosures Act were received from HPRA 
staff members.
Parliamentary Questions and 
Requests for Information
The HPRA received and responded to 53 parliamentary 
questions. There were also a further 116 requests for 
information received from the Department of Health, 
other government departments or members of the 
Oireachtas during the year. Of the total number of 
queries (169), the largest category related to human 
medicines (111) and concerned topics such as adverse 
reactions, the availability or supply of medicines, 
reclassification / switching, clinical trials and counterfeit 
products.
Data Protection
The HPRA is subject to the Data Protection Acts 1988 
and 2003. The Acts gives individuals the right to obtain 
a copy, clearly explained, of any personal information 
relating to them kept on computer or in a structured 
manual filing system or intended for such a system by 
any entity or organisation. During 2016, we received 
one data access request.
Complaints
No complaints regarding the standard of service 
provided by the HPRA were received during the year.
Authority and Committees
The corporate affairs section provides secretarial 
support to the Authority and committees of the HPRA 
and ensures adherence to best practice in the area of 
corporate governance.
- The Authority of the HPRA met seven times in 
2016 and considered a number of strategic matters 
including corporate policy, planning and finance 
matters. The latter included monthly management 
accounts, annual budgets and the financial 
statements for 2015. The Authority also reviewed 
update reports from the Statutory Advisory 
Committees and the Audit Committee. In addition, 
it reviewed the licences for all medicinal healthcare 
products as approved by the Management 
Committee.
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The number of meetings attended by each Authority 
member during 2016 was as follows:
Authority 
Member
Number of 
meetings held 
during the period 
the member was 
on the Authority
Number of 
meetings 
attended during 
the period the 
member was on 
the Authority
Ms. Ann Horan 
(Chairperson)
7 7
Mr. Pat Brangan 7 7
Mr. Wilf Higgins 7 6
Mr. David 
Holohan
6 6
Prof. Mary Horgan 7 5
Mr. Brian Jones 6 5
Prof. Elizabeth 
Keane
7 7
Prof. Caitriona 
O’Driscoll
7 7
Dr. Diarmuid 
Quinlan
7 5
- The Audit Committee, a subcommittee to the 
Authority, met four times in 2016. Further details 
are provided in the HPRA’s Financial Statements. 
- The Advisory Committee for Veterinary Medicines 
met twice as did the Advisory Committee for 
Medical Devices.
- The Herbal Medicines Sub-Committee, a sub-
committee to the Advisory Committee for Human 
Medicines, met once. The Clinical Trials Sub-
Committee is also a sub-committee to the Advisory 
Committee for Human Medicines and it met 12 
times in the past year.
- The National Committee for the Protection of 
Animals Used for Scientific Purposes, a statutory 
committee to provide guidance to the regulator 
and those working in this area, met twice in 2016.
Decisions of the Authority 
The terms of reference of the Authority, which are 
published on the HPRA website, include an overview of 
how the Authority operates, an overview of all decisions 
taken by the Authority and those devolved to the 
Management Committee. 
The following decisions are reserved functions of the 
Authority: 
- The Authority takes decisions relating to very 
significant and serious public and/or animal 
health matters except in circumstances where a 
meeting of the Authority cannot be convened, 
in which case the Management Committee takes 
the decision and informs the Chairperson at the 
earliest opportunity and the Authority as soon as is 
practical.
- The Authority refuses applications, or suspends, 
revokes or terminates authorisations as set out in 
legislation except in circumstances where: 
a) the urgency is such that a meeting of the 
Authority cannot be convened, or
b) the application or authorisation is subject to a 
binding European decision, or
c) the application or authorisation is for a clinical 
trial or clinical investigation;
 in which case the Management Committee takes 
the decision and informs the Authority.
- Through its Audit Committee, the Authority 
approves the internal financial controls and the 
financial audit function and satisfies itself that the 
financial controls and systems of risk management 
are robust and defensible. The Authority appoints 
the internal financial auditor.
- The Authority approves the investment policy, 
major investments, capital projects and the terms of 
major contracts.
- Significant acquisitions and the disposal or 
retirement of assets above a threshold set by the 
Authority are subject to Authority approval.
- The Authority approves treasury policy and risk 
management policies.
- The Authority approves corporate plans as 
required.
- The Authority approves the annual budget, 
monitors expenditure and supervises the 
preparation and submission of the annual statutory 
accounts.
- The Authority makes an annual report on the 
activities of the HPRA, including a financial 
statement, to the Minister for Health. This report is 
then published.
- The Authority selects and appoints the Chief 
Executive, with the consent of the Minister for 
Health. The terms of office and the remuneration 
of the Chief Executive are determined by the 
Minister for Health, after consultation with the 
Authority and with the consent of the Minister for 
Finance. The Authority, through its Performance 
Review Committee, conducts a process of annual 
performance appraisal of the Chief Executive. 
Succession planning for the role of Chief Executive 
is also undertaken by the Authority.
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Human Resources and Change
In line with the HPRA’s strategic focus on the 
development of internal capabilities, the launch of the 
Human Resources and Change Strategy 2016-2020 was 
a significant deliverable in 2016. Using a framework of 
six core themes, the strategy identifies and delivers key 
supports required by the organisation to achieve its 
goals over this five year period. Under each theme, an 
action plan for 2016 highlighted the main priorities for 
the year. 
As part of the development and launch of the 
strategy, a branding exercise was completed to create 
an internal human resources and change logo. An 
organisational communications programme, which 
included an online introductory video, was also 
implemented.
Retention and Engagement
The ability to retain and engage highly skilled staff in 
light of improvements in the economy and ongoing 
developments in the sectors we regulate continues 
to present a challenge for the HPRA. As part of our 
ongoing initiatives to foster high levels of engagement, 
and therefore ensure the retention of our staff, we 
continued throughout 2016 to deliver our core range of 
programmes such as our;
- Health and wellbeing and lunchtime learning 
programmes which are focused on five main 
areas; physical, financial, nutritional, emotional, 
and general health and wellbeing. We continue to 
carry out research into how to further develop and 
enhance these offerings using survey feedback. The 
receipt of a Silver Active@Work Award was a key 
achievement in 2016 and recognition of our work in 
this area in recent years;
- Suite of management development supports 
and initiatives including; new manager training, 
coaching and mentoring, developing others 
training, and performance development 
programme (PDP) training for managers.
With a view to extending our retention and 
engagement programme, among the research activities 
conducted in 2016 for future initiatives were;
- Completion of a number of employee surveys, 
workshops and focus groups to gain insight 
into areas such as flexible working patterns and 
management competency frameworks;
- Commencement of research into the development 
of a tailored management development 
programme to further support and promote 
management and leadership skills;
- Continuation of research into the optimum 
approach to establish engagement levels.
Organisation Design
To support our focus on cross-department engagement 
and knowledge sharing, we continued to successfully 
deliver our organisational awareness programme during 
2016. There was a total attendance of 333 staff across 
16 separate events. Externally, we continued to support 
knowledge sharing and cross-fertilisation  of skills by 
keeping up-to-date with the ongoing work of the EU 
Network Training Centre.
Career Development
Succession planning was an area of major focus in 
2016. A comprehensive review of succession planning 
frameworks resulted in agreement to take a risk-
based approach to this key component of career 
development. The required tools to complete the 
planning process were developed for implementation 
in 2017.
With a view to establishing specific roles that 
employees can develop into over time, on the basis of 
the acquisition of related skills and experience, an initial 
step in 2016 was the commencement of a research 
project to determine the value and feasibility of 
introducing a formal graduate recruitment programme 
in the HPRA.
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Change Management
The Human Resources and Change department 
continued to provide change management support to 
two significant organisation-wide projects:
- Health Systems Strengthening Programme: The 
HPRA is providing technical assistance to the 
Zambia Medicines Regulatory Authority (ZAMRA) 
under the EU funded Health Systems Strengthening 
(HSS) programme. The change management team 
maintained a lead role in planning for the delivery 
of regulatory and capacity building support to 
ZAMRA during 2016. The main areas of work 
involved supporting the identification and provision 
of short term experts in addition to facilitating a 
week-long study visit from a Zambian delegation to 
the HPRA in November. 
- EOLAS: As well the provision of ongoing support 
as project lead in the area of change management, 
leadership and development support, the 
department was also allocated to assist with the 
development of training that is required for the 
introduction of phase one.
The public sector reform agenda continues to have a 
direct impact on employment terms and conditions. 
In this regard, a comprehensive communications 
programme outlining the associated impact on 
individual employees was delivered during 2016.
Talent Management 
The HPRA takes an integrated approach to correctly 
identifying our resource requirements. Our focus is on 
recruiting the right people with the right skills at the 
right time while also ensuring we develop our talent to 
maximise effectiveness. This was an area of significant 
activity during 2016 with a particular focus on:
- Working with the organisation to maintain resource 
requirements through internal redeployment, 
training development and recruitment activities 
as required, while operating within public sector 
employment control frameworks;
- The delivery of the leadership and development 
programme of activities to support staff in their 
roles. This included the provision of internal training 
such as personal effectiveness, time management 
and telephone techniques, facilitating expert 
witness training in-house and providing access to a 
range of activities externally;
- The completion of research to identify the 
optimum approach to, and key requirements for, a 
technology-based learning system.
HR and Change
In the development of its strategy for 2016-2020, the 
Human Resources and Change department continued 
to focus on how we can add value, operating as internal 
experts to the business. Helpful in this regard was the 
identification of our vision ‘to enhance organisational 
performance by developing and delivering innovative 
solutions’ and our mission ‘to work in partnership with 
the organisation delivering a range of supports and 
services that maximise positive outcomes for all in the 
HPRA’. 
Information Technology and Business 
Services 
The Information Technology and Business 
Services department is responsible for all 
aspects of organisational technology, data and 
telecommunications. The department also manages the 
business services unit that is responsible for delivering 
specialist business services to the organisation, 
including business analysis and project management for 
both internal and external stakeholders. A core function 
of the business services unit is the management of 
the organisational Project Management Office (PMO) 
that formally manages projects and provides HPRA 
management with the necessary information to support 
the planning process while ensuring that organisational 
initiatives are fully aligned with corporate strategy.
Technology is recognised as a key component in 
supporting regulatory activities at both national 
and European levels and during 2016 a number of 
significant projects and initiatives were progressed.
Extensive work continued on the development of the 
HPRA’s new workflow technology solution, EOLAS, 
which will provide the organisation with a single 
workflow and data management system to support its 
regulatory activities. The phased development of the 
system will coincide with the implementation of new 
EU standards for regulatory data management and will 
commence with the implementation of the system in 
the Veterinary Sciences department in 2017. 
There was also significant work carried out on the 
internal information technology infrastructure, making 
it more reliable and robust to support the requirements 
of the organisation. These improvements included our 
backup and recovery capabilities, system security and 
disaster recovery.
In addition, as outlined earlier in this report, the 
HPRA contributed IT support in connection with 
a range of national and European initiatives and 
platforms. Nationally, this included the launch of 
the new Emergency Medicines Registration System, 
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the provision of hosting services to a number of 
organisations and contributing to the development of 
data set standards for ePrescribing and an electronic 
medicinal product reference catalogue. We also 
continued to support the exchange of information 
between stakeholders in areas such as the medical 
products database for both human and veterinary 
products, interchangeable medicines and data for 
clinical and pharmacy systems. 
At a European level, the HPRA again played a 
significant role in the development of European 
telematics strategies, standards and technologies. 
We were members of the EU telematics management 
board, the network data board and the e-submissions 
group and led on a number of key initiatives relating 
to single submission portals and data standards. 
The HPRA also participated, as part of a European 
consortium, in the European Commission’s Horizon 
2020 research programme on the openMedicine 
project. We continued the development and 
management of the Common Electronic Submission 
Portal (CESP) on behalf of the wider EU regulatory 
community in addition to assisting the medicines 
authority in Malta with the development of a 
new regulatory management system for product 
authorisation.
Quality Management
During 2016, the HPRA’s quality management system 
continued to be extended with the deployment of 
policies and procedures for cosmetics regulation, 
retail sales compliance and ‘risk-based’ approaches to 
regulatory activities. 
As part of the development of EOLAS, the new 
workflow and case management system, we continued 
working on a new management policy and procedures 
document. In addition, we completed the document 
tagging structure and began preparing some standard 
document templates for use in the new system.
Finance
The HPRA’s finance section is responsible for managing 
and safeguarding the finances of the HPRA. It must 
ensure that the organisation fulfils its legislative 
requirements and applies best practice to the 
governance of its affairs. All procedures are carried out 
using standard operating procedures under the quality 
management system. The 2016 financial statements 
presented in this report were prepared by the finance 
section and submitted for audit to the Comptroller and 
Auditor General. All financial transactions during the 
period under review are reflected and reported upon in 
these statements as is our commitment to the highest 
standards of corporate governance.
During 2016, as part of an on-going programme to 
integrate and streamline HPRA internal corporate 
processes, we implemented a new IT system for 
financial management and control.
Legal
Throughout 2016, the legal section advised on the 
implementation of new legislation in addition to other 
relevant issues. The section dealt with various legal 
queries from across the organisation. It also attended 
and presented at the European meeting of lawyers held 
under the European Presidency.
Overview of Energy Usage in 2016
Since 1 January 2011, the HPRA, as a public sector 
body, is required to report annually on its energy usage 
and actions taken to reduce consumption in accordance 
with the European Union (Energy Efficiency) Regulations 
2014 (S.I. No. 426 of 2014). As an organisation, we use 
electricity for lighting, air conditioning or heating as 
required and the provision of hot water. Natural gas is 
used for central heating.
In 2016, the HPRA consumed 1040 MWh of energy 
consisting of: 
- 708 MWh of electricity; 
- 332 MWh of fossil fuels;
- 0 MWh of renewable fuels.
Actions Undertaken in 2016
In the past year, we continued to focus on energy 
performance by maintaining framework agreements 
for the supply of both electricity and natural gas. Both 
of these framework agreements were established by 
the Office of Government Procurement for the supply 
of electricity and natural gas to the Irish public sector. 
The agreements are intended to maximise volume 
discounts and provide for reductions in administrative 
and transaction costs for suppliers and public sector 
purchasers. During 2016, HPRA cost savings were in the 
region of 2.7% for electricity and 5% for gas (compared 
to the cost of going directly to the market).
Also in 2016, we formed a partnership with the Office 
of Public Works (OPW) in relation to the Optimising 
Power @ Work initiative to effect energy savings 
through staff engagement. We also partnered with the 
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Sustainable Energy Authority of Ireland (SEAI) to focus 
on energy saving through the Energy Map programme. 
As part of these initiatives, the HPRA has set up an 
in-house Energy Efficiency Project Team, sponsored 
by the Deputy Chief Executive, to maintain focus on 
energy reduction.
Total Energy Savings
The HPRA has been highly focussed on reducing 
energy usage for the past number of years. This is 
evidenced by the 2016 SEAI report for the HPRA which 
confirmed that as an organisation we have improved 
our energy usage by 27.1% since 2009. As a result 
of our partnership with the OPW Optimising Power 
@ Work initiative, which was launched in the HPRA in 
October 2016, we had reduced energy usage by up 
to a further 2.7% by the end of 2016 progressing the 
organisation ever nearer to the 2020 public sector 33% 
energy reduction target.
Actions Planned For 2017
We are committed to reducing our energy usage by 
33% by 2020 in accordance with S.I. No. 426 of 2014, 
the National Energy Efficiency Action Plan 2014 and 
the European Energy Efficiency Directive (2012/27/
EU). As a result, we will maintain our focus in 2017 on 
our partnership agreements with the OPW and the 
SEAI. We also intend to maintain energy performance 
by continuing our participation in newly contracted 
framework agreements for the supply of both electricity 
and natural gas to the public sector. It is anticipated 
that both these framework agreements, accessed via 
the Office of Government Procurement, will deliver 
savings when compared to the costs of going directly 
to the market. It is important to note that the Office of 
Government Procurement contract rates are fixed until 
early 2019 for electricity and gas.
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The Health Products Regulatory Authority (the HPRA) 
was established under the terms of the Irish Medicines 
Board Act, 1995 (as amended), and is governed by 
an Authority which was appointed by the Minister 
for Health. The Authority of the HPRA (the Authority) 
consists of a chairman and eight unremunerated non 
executive members. On 1 July 2014, the organisation 
changed its name from the Irish Medicines Board, as 
provided for in Section 36 of the Health (Pricing and 
Supply of Medical Goods) Act 2013 and SI (205/2014) 
Health (Pricing and Supply of Medical Goods) Act 
2013 (Commencement) order 2014. 
The HPRA is committed to the highest standards 
of Corporate Governance and has implemented 
the “2009 Code of Practice for the Governance of 
State Bodies” issued by the Department of Public 
Expenditure and Reform. This Code of Practice 
incorporates many of the principles under which the 
HPRA operates, taking account of the size and legal 
nature of the organisation.
For the year ended 31 December 2016, the HPRA 
was in compliance with the 2009 Code of Practice. 
A revised Code of Practice was issued in August 
2016 and applies to all financial reporting periods 
beginning on or after 1 September 2016. The HPRA 
will comply with the revised Code in respect of its 
2017 financial statements. 
The HPRA has in place an extensive Code of Conduct 
and conflicts of interest policy for all staff, committees 
and Authority members. The HPRA applies the 
highest standards of disclosure and transparency in 
respect of interests held by staff, committees and 
Authority members.
Audit and Risk Committee
The HPRA has an audit and risk committee comprising 
three Authority members, which met on four 
occasions during 2016. This committee is responsible 
for reviewing internal control matters, together with 
any other issues raised by the external auditors, 
the Authority or management. The external auditor 
is invited annually to meet with the audit and risk 
committee to brief them on the outcome of the 
external audit, and the audit and risk committee also 
meets annually with the internal auditor. During 2016, 
the internal auditor carried out internal audits on the 
areas of fixed assets and budgeting. The audit and 
risk committee has also been involved with the review 
of the quality systems as described below.
Quality Systems
During 2016, the finance section of the HPRA 
continued the process of implementing and reviewing 
standard operating procedures (SOPs) under the 
quality management system. This process involved 
a critical review and analysis of internal controls and 
processes throughout the section with particular 
emphasis on risk management. This system now 
underpins the internal control environment and feeds 
into the internal audit process and ultimately into the 
audit and risk committee.
Remuneration Policy - Authority Members 
and Executive Directors
Remuneration and travel expenses paid to Authority 
members are disclosed in note 17 to the financial 
statements. The Chairman receives remuneration 
as directed by the Minister for Health in accordance 
with the Irish Medicines Board Act, 1995. Other 
Authority members receive travel expenses in 
accordance with circulars issued by the Department 
of Health. The Chief Executive is remunerated in 
accordance with guidelines issued from Government 
and other Executive Directors are paid in accordance 
with Department of Health pay scales. The Chief 
Executive’s remuneration is disclosed in note 18 to the 
Financial Statements.
Internal Control
The Authority is responsible for the HPRA’s systems 
of internal control. Such systems can only provide 
reasonable and not absolute assurance against 
material misstatement or loss. The systems of internal 
controls in use in the HPRA are described more fully in 
the Chairman’s report on page 66.
Corporate Governance
1. I, as Chairman, acknowledge that the Authority 
is responsible for the body’s system of internal 
financial control.
2. The HPRA system of internal financial control 
can provide only reasonable and not absolute 
assurance against material error, misstatement or 
loss.
3. The Authority confirms that there is an ongoing 
process for identifying, evaluating and managing 
the significant risks faced by the HPRA. The HPRA 
maintains a risk register which is reviewed and 
updated by management, considered by the 
audit and risk committee and presented to the 
Authority.
 Management are responsible for the identification 
and evaluation of significant risks applicable to 
their areas of business together with the design 
and operation of suitable internal controls. These 
risks are assessed on a continuing basis and may 
be associated with a variety of internal or external 
sources including control breakdowns, disruption 
in information systems, natural catastrophe and 
regulatory requirements. These risks are recorded 
in the risk register.
 Management reports fortnightly on operational 
issues and risks and how they are managed to 
the Management Committee. The Management 
Committee’s role in this regard is to review on 
behalf of the Authority the key risks inherent in 
the affairs of the HPRA and the system of actions 
necessary to manage such risks and to present 
their findings on significant matters via the Chief 
Executive to the Authority.
 The Chief Executive reports to the Authority 
on behalf of the executive management on 
significant changes in the work of the HPRA 
and on the external environment, which affects 
significant risks. The Deputy Chief Executive 
provides the Authority with monthly financial 
information, which includes key performance 
indicators. Where areas for improvement in the 
system are identified, the Authority considers the 
recommendations made by the Management 
Committee.
 An appropriate control framework is in place 
with clearly defined matters which are reserved 
for Authority approval only or, as delegated 
by the Authority, for appropriate Management 
Committee approval. The Authority has delegated 
the day-to-day management of the HPRA and 
established appropriate limits for expenditure 
authorisation to the Management Committee. The 
Chief Executive is responsible for implementation 
of internal controls, including internal financial 
control.
 The system of internal financial control is 
monitored in general by the processes outlined 
above. In addition, the Audit and Risk Committee 
of the Authority reviews specific areas of internal 
control. The HPRA has outsourced the internal 
audit function to an independent professional 
firm. During 2016 two reviews were conducted. 
The Audit and Risk Committee considers reports 
from internal audit and recommendations from 
the Comptroller and Auditor General arising as a 
result of the external audit.
4. The Authority have carried out a review of the 
effectiveness of internal financial control, in order 
to demonstrate compliance with the 2009 Code of 
Practice. This review was carried out at its meeting 
on 15 March 2017. 
Ms. Ann Horan 
Chairman to the Authority
Date: 16 June 2017
Statement on Internal  
Financial Control
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The Authority is required by the Irish Medicines Board 
Act, 1995 to prepare financial statements for each 
financial year which give a true and fair view of the 
state of affairs of the HPRA and of its surplus or deficit 
for that period.
In preparing those statements the Authority is 
required to:
• select suitable accounting policies and apply them 
consistently;
• make judgements and estimates that are 
reasonable and prudent;
• disclose and explain any material departures from 
applicable accounting standards; and
• prepare the financial statements on a going 
concern basis unless it is inappropriate to 
presume that the HPRA will continue in existence.
The Authority is responsible for keeping proper 
accounting records which disclose with reasonable 
accuracy at any time the financial position of the 
HPRA and which enable it to ensure that the financial 
statements comply with the Irish Medicines Board 
Act, with accounting standards generally accepted 
in Ireland and with accounting directions issued 
by the Minister for Health. It is also responsible for 
safeguarding the assets of the HPRA and hence 
for taking reasonable steps for the prevention and 
detection of fraud and other irregularities. 
 
On behalf of the Authority: 
 
 
Ms. Ann Horan
Chairman
Date: 16 June 2017
Statement of Authority  
Members’ Responsibilities
Mr. David Holohan
Authority Member
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I have audited the financial statements of the Health 
Products Regulatory Authority for the year ended 
31 December 2016 under the Irish Medicines 
Board Act, 1995. The financial statements comprise 
the statement of income and expenditure and 
retained revenue reserves, the statement of financial 
position, the statement of cash flows and the 
related notes. The financial statements have been 
prepared in the form prescribed under Section 18 of 
the Act, and in accordance with generally accepted 
accounting practice as modified by the Minister for 
Health in relation to accounting for superannuation 
costs.
 
Responsibilities of the Board of the 
Authority
The Board of the Authority is responsible for the 
preparation of the financial statements, for ensuring 
that they give a true and fair view and for ensuring 
the regularity of transactions.
 
Responsibilities of the Comptroller and 
Auditor General 
My responsibility is to audit the financial statements 
and report on them in accordance with applicable 
law.
My audit is conducted by reference to the special 
considerations which attach to State bodies in 
relation to their management and operation.
My audit is carried out in accordance with the 
International Standards on Auditing (UK and Ireland) 
and in compliance with the Auditing Practices 
Board’s Ethical Standards for Auditors.
Scope of audit of the financial 
statements
An audit involves obtaining evidence about the 
amounts and disclosures in the financial statements, 
sufficient to give reasonable assurance that 
the financial statements are free from material 
misstatement, whether caused by fraud or error. 
This includes an assessment of
• whether the accounting policies are appropriate 
to the Authority’s circumstances, and have been 
consistently applied and adequately disclosed.
• the reasonableness of significant accounting 
estimates made in the preparation of the 
financial statements, and
• the overall presentation of the financial 
statements.
I also seek to obtain evidence about the regularity 
of financial transactions in the course of audit.
In addition, I read the Authority’s annual report to 
identify material inconsistencies with the audited 
financial statements and to identify any information 
that is apparently materially incorrect based on, 
or materially inconsistent with, the knowledge 
acquired by me in the course of performing the 
audit. If I become aware of any apparent material 
misstatements or inconsistencies, I consider the 
implications for my report.
Comptroller and Auditor General Report  
for Presentation to the Houses of the Oireachtas
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Opinion on the financial statements
In compliance with the directions of the Minister 
for Health, the Authority accounts for the costs of 
superannuation entitlements only as they become 
payable. This basis of accounting does not comply 
with Financial Reporting Standard 102 which 
requires such costs to be recognised in the year the 
entitlements are earned. 
In my opinion, except for the accounting treatment 
of the Authority’s superannuation costs and liabilities, 
the financial statements, have been properly prepared 
in accordance with generally accepted accounting 
practice in Ireland and give a true and fair view of the 
state of the Authority’s affairs at 31 December 2016 
and of its income and expenditure for 2016.
In my opinion, the accounting records of the Authority 
were sufficient to permit the financial statements to be 
readily and properly audited. The financial statements 
are in agreement with the accounting records.
Matters on which I report by exception
I report by exception if I have not received all the 
information and explanations I required for my audit, 
or if I find
• any material instance where money has not been 
applied for the purposes intended or where the 
transactions did not conform to the authorities 
governing them, or
• the information given in the Authority’s annual 
report is not consistent with the related financial 
statements or with the knowledge acquired by me 
in the course of performing the audit, or
• the statement on internal financial control does 
not reflect the Authority’s compliance with the 
Code of Practice for the Governance of State 
Bodies, or
• there are other material matters relating to 
the manner in which public business has been 
conducted.
I have nothing to report in regard to those matters 
upon which reporting is by exception.
 
Patricia Sheehan 
For and on behalf of the
Comptroller and Auditor General 
29 June 2017
69
HPRA Annual Report 2016
 Note  2016  2015
  € €
Fee Income  3  21,461,418  21,654,894
Department of Health Funding 3  3,916,000  3,916,000
Other Income  4  1,090,096  585,872
   
  26,467,514  26,156,766 
Salaries and Wages  5, 24  18,684,512  18,285,952
Other Operating Costs  6  5,138,378  5,486,959
Depreciation  2  2,099,770  1,648,765
   
  25,922,660 25,421,676
 
Surplus for the year before write
back of Superannuation contributions   544,854  735,090
 
Staff Superannuation Contributions  24 746,723  800,890
 
 
Surplus for the year   1,291,577  1,535,980
 
Balance brought forward    27,398,177  25,862,197
 
Balance carried forward  12  28,689,754  27,398,177
 
 
 
All income and the surplus for the year arises from continuing activities.
 
 
 
 
 
 
 
STATEMENT OF INCOME AND EXPENDITURE AND RETAINED REVENUE RESERVES
For the year ended 31 December 2016
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Ms. Ann Horan
Chairman
Date: 16 June 2017
The notes on pages 73 to 82 form part of the financial statements.
Mr. David Holohan
Authority Member
 Note  2016  2015
   as restated
  € €
Fixed Assets  
Property, plant and equipment  2  26,039,261  25,665,558
 
Current Assets
Debtors and Prepayments 7  1,129,190 1,191,666
Inventory of Stationery  5,029  2,077
Cash at Bank and in Hand   1,989,592  475,265
Short Term Deposits 10 14,308,652  15,991,441 
  17,432,463  17,660,449
Creditors - Amounts falling
due within one year
Creditors and Accruals  8  8,435,294  8,787,819
Mortgage  13  793,332  793,332
   
  9,228,626  9,581,151
 
Net Current Assets   8,203,837  8,079,298
 
Creditors - Amounts falling 
due after more than one year
Mortgage  13  5,553,344  6,346,679
 
 
NET ASSETS   28,689,754  27,398,177
 
 
Reserves
Income and Expenditure Reserve  12  28,689,754  27,398,177 
  
  28,689,754  27,398,177
 
 
 
 
STATEMENT OF FINANCIAL POSITION
As at 31 December 2016
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Ms. Ann Horan
Chairman
Date: 16 June 2017
The notes on pages 73 to 82 form part of the financial statements.
Mr. David Holohan
Authority Member
 Note  2016  2015
  € €
Cash flows from Operating Activities
 
Surplus/(Deficit) for financial year   1,291,577  1,535,980
Depreciation of property, plant and equipment  2,099,770  1,648,765
(Profit)/Loss on Disposal of property, plant and equipment  (20)  156
(Increase)/Decrease in Debtors  62,476 (464,637)
(Increase)/Decrease in Stock  (2,952) 182
Increase/(Decrease) in Creditors - amounts  
falling due within one year  (352,528) 425,107
Deposit Interest   (35,829)  (79,548)
Bank Interest  222,798 243,288
Cash from Operations  3,285,292  3,309,293
Bank Interest Paid   (222,798) (243,288)
Net Cash generated from Operating Activities  3,062,494 3,066,005
Cash flows from Investing Activities  
Deposit Interest Received  35,829 79,548
(Increase)/Decrease in Bank Deposits   2,058,857 (2,126,720)
Payments to acquire property, plant and equipment   (2,473,473)  (1,740,789)
Receipts fom sales of property, plant and equipment  20  352
 
Net cash from Investing Activities  (378,767) (3,787,609)
Cash flows from Financing Activities
Repayment of Borrowings  (793,332)  (793,332)
Net cash used in Financing Activities  (793,332)  (793,332)
 
Net increase/(decrease) in Cash and Cash Equivalents  1,890,395 (1,514,936)
Cash and Cash Equivalents at beginning of year  2,102,133  3,617,069
 
Cash and Cash Equivalents at end of year 9  3,992,528 2,102,133
The notes on pages 73 to 82 form part of the financial statements.
 
 
STATEMENT OF CASH FLOWS 
For the year ended 31 December 2016
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1. Accounting Policies
A. General information
The Health Products Regulatory Authority (HPRA) is a public statutory body established under the Irish 
Medicines Board Act 1995 (as amended). The principal place of business is at Earlsfort Centre, Earlsfort 
Terrace, Dublin 2. The Health Products Regulatory Authority is the competent Authority for the 
regulation of medicines, medical devices and other health products in Ireland.
B. Compliance with FRS 102
The financial statements of the HPRA for the year ended 31 December 2016 have been prepared in 
accordance with FRS 102, the financial reporting framework applicable in the UK and Ireland, with the 
exception of superannuation. By direction of the Minister for Health, the provisions of FRS 102 in 
relation to retirement benefits are not being complied with. In all other respects the financial statements 
comply with FRS 102. The date of transition to FRS 102 is 1 January 2014.
C. Basis of preparation
The financial statements have been prepared under the historical cost convention. The following 
accounting policies have been applied consistently in dealing with items which are considered material 
in relation to the Health Products Regulatory Authority’s financial statements.
D. Critical accounting estimates and judgements
The preparation of the financial statements requires management to make judgements, estimates and  
assumptions that affect the amounts reported for assets and liabilities as at the balance sheet date and 
the amounts reported for revenues and expenses during the year. However, the nature of estimation 
means that actual outcomes could differ from those estimates. The following may involve a higher 
degree of judgement and complexity:
(a)  Provisions
 Provisions for legal obligations which it knows to be outstanding at the period-end date. These 
provisions are generally made based on historical or other pertinent information, adjusted for 
recent trends where relevant. However, they are estimates of the financial costs of events that may 
not occur for some years. As a result of this and the level of uncertainty attaching to the final 
outcomes, the actual outturn may differ significantly from that estimated.
NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2016
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E. Revenue recognition
Revenue is measured at the fair value of the consideration received.
-  In the case of applications for marketing authorisations (new applications, variations to existing authorisations,  
or transfers) and clinical trial applications, income is recognised on a straight line basis over the specified timeline 
for the processing of the application by the Authority.
-  In the case of wholesale and manufacturing licences and maintenance of marketing authorisations, fees are 
payable annually and a full year’s income is accrued in each financial year.
F. Expenditure recognition
Expenditure is recognised in the financial statements on an accruals basis.
G. Reporting currency and currency translation
The financial statements are prepared in euros. Transactions in currencies other than euro are recorded 
at the rates ruling at the date of the transactions or at a contracted date. Monetary assets and 
liabilities are translated into euro at the balance sheet date or at a contracted date. Exchange 
differences are dealt with in the statement of income and expenditure.
H. Property, plant and equipment
Plant and equipment excluding Premises
Plant and equipment excluding premises are stated at cost less accumulated depreciation. 
Depreciation is calculated in order to write off the cost of property, plant and equipment to their 
estimated residual values over their estimated useful lives by equal annual instalments.
The estimated useful lives of property, plant and equipment by reference to which depreciation has 
been calculated are as follows:
 Fixtures and Fittings :  5 years 
 Computer Equipment :  3 years 
 Improvements to Premises :  10 years
 
Premises
The HPRA purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2 
on 22 December 2004. The value capitalised was equal to the purchase price plus those costs directly 
attributable to bringing the asset into use.
No depreciation has been calculated on the value of premises, as the remaining useful economic life is 
estimated to be greater than 50 years.
I. Taxation
The HPRA is exempt from liability to Corporation Tax under Section 227 of the Taxes Consolidation Act, 1997.
NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2016
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J. Debtors
Known bad debts are written off and specific provision is made for any amount the collection of which is considered 
doubtful.
K. Superannuation
The superannuation scheme operated by the HPRA is in accordance with the Local Government (Superannuation Re-
vision) (Consolidation) Scheme, 1986. It is an unfunded statutory scheme and benefits are met from current income 
as they arise.
The charge to salaries and wages is stated gross of superannuation deductions of €746,723 (2015 - €800,890). The 
surplus for the year on page 70 is then shown both before and after superannuation deductions. The income and 
expenditure reserve on the statement of financial position is split between retained reserves and superannuation re-
serves in note 12. The balance on the superannuation reserve represents the cumulative superannuation deductions 
made since 1996.
By direction of the Minister for Health, the provisions of FRS 102 Section 28 Retirement Benefits are not being  
complied with.
L. Provisions
A provision is recognised when the HPRA has a present obligation as a result of a past event, it is probable that this 
will be settled at a cost to the HPRA and a reliable estimate can be made of the amount of the obligation.
M. Library
No value has been placed on the books, audio-visual resources and electronic databases in the library. Expenditure 
on these items is written off in the year in which it is incurred.
N. Leases
All leases are treated as operating leases and the rentals thereunder are charged to the Income and Expenditure 
account on a straight line basis over the lease period.
O. Loans
Loans are recognised initially at the transaction price (present value of cash payable, including transaction costs). 
Loans are subsequently stated at amortised costs. Interest expense is recognised on the basis of the effective interest 
method and is included in finance costs.
Loans are classified as current liabilities unless there is a right to defer settlement of the loan for at least 12 months 
from the reporting date.
NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2016
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NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2016
2. Property, plant Fixtures and Computer  Leasehold Improvements Premises Total 
 and equipment Fittings Equipment Improvements To Premises   
  € € € € € €
  Cost
  Balance as at  1,203,630  12,230,293 502,445  4,362,218  23,156,037  41,454,623
  1 January 2016  
  Additions for the year  16,247  2,455,246 -  1,980  -  2,473,473
  Disposals for the year (14,284) (95,231) -  -  -  (109,515)
  As at 31 December 2016  1,205,593 14,590,308  502,445  4,364,198  23,156,037  43,818,581
  Depreciation
  Balance as at  1,080,341 10,815,009  502,445  3,391,270  -  15,789,065 
 1 January 2016
  Charge for the year  52,949  1,688,829 -  357,992  -  2,099,770
  Disposals for the year  (14,284) (95,231) -  -  -  (109,515)
  As at 31 December 2016  1,119,006 12,408,607  502,445  3,749,262  -  17,779,320
  Net Book value at  
 31 December 2016  86,587  2,181,701  -  614,936 23,156,037  26,039,261
  Net Book value at 
  1 January 2016  123,289  1,415,284  - 970,948  23,156,037  25,665,558
3. Income
  2016  2015
  €  €
 Fee Income
 Clinical Trials  181,082  175,148
 Human Medicine - National Fees  6,324,512  6,439,762
 Human Medicine - European Fees  6,853,136  6,835,197
 Veterinary Medicine - National Fees  1,650,596  1,492,613
 Veterinary Medicine - European Fees  1,288,314  1,302,720
 Compliance Department  4,593,694  5,067,354
 Medical Devices  400,817  403,392 
  
  21,292,151  21,716,186
 Movement in deferred revenue 169,267  (61,292)
  21,461,418  21,654,894
 Dept Of Health Funding (Vote 38 Subhead E1)  3,916,000 3,916,000 
 Other Income (Note 4)  1,090,096 585,872
  
 Total Income  26,467,514 26,156,766
 
 Certain fees received by the Authority under the Irish Medicines Board Act 1995 (as amended), totalling €16,382,593 
 in 2016, shall be paid into or disposed of for the benefit of the Exchequer in such manner as the Minister for Public 
 Expenditure and Reform directs. 
76
HPRA Annual Report 2016
NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2016
4. Other Income
  2016  2015
  €  €
  
 Conference Fee Income  134,355  1,850
 Deposit Interest  35,829  79,548
 (Loss)/Gain on Disposal of Fixed Assets  20 (156)
 IT Income  876,283 504,630
 Zambia Project Income 43,609 -
   
  1,090,096 585,872
5. Salaries and Wages 
 Note  2016  2015
  as restated
  €  €
     
 Salaries and Wages    16,353,458  15,965,979
 Pensions  24 739,910  828,682
 Social Welfare Costs  1,591,144  1,491,291
   
  18,684,512  18,285,952
 
  
 The average number of staff employed during the year was 312 (2015 - 298). 
 Payroll numbers at 31 December 2016 can be analysed across the following departments : -
 
 Chief Executive  2  11
 Compliance  67  64
 Finance, Corporate & International  21  20
 Human Products Authorisation & Registration  111  103
 Human Products Monitoring  48  47
 Human Resources & Change  7  8
 IT & Business Services  21  19
 Quality, Scientific Affairs & Communications 11  1
 Veterinary Sciences  29  25
 Staff  317  298
 Pensioners  34  34
   
  351  332
 
 
 Pension related deductions for Public Servants of €809,795 were deducted from staff 
 during the year and paid over to the Department of Health.
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NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2016
 While the HPRA does not consider that Circular 13/2014 “Management and Accountability for Grants from  
 Exchequer  Funds” applies to HPRA, in the interests of transparency we are disclosing salary breakdowns  
 required under that circular: 
  Salary Band   2016  
  
 €0 to €60,000    214  
 €60,001 to €70,000    50  
 €70,001 to €80,000    9  
 €80,001 to €90,000    26  
 €90,001 to €100,000    9  
 €100,001 to €110,000    5  
 €110,001 to €120,000    2  
 €120,001 to €130,000    1  
 €140,001 to €150,000    1  
   
    317  
  
 Average Salary    €51.7K  
 
 Higher salaries relate primarily to scientific and other professional staff e.g. clinicians, pharmacists,
 veterinarians, lawyers etc. and are in accordance with Department of Health salary scales. 
 
6. Operating Costs
  2016  2015
  €  €
  
 Accommodation Costs  1,186,524  1,059,592
 Travel, Representation and Training  859,595  939,155
 Bank Charges and Interest  229,547  246,447
 Legal & Professional Fees  257,284  427,161
 Stationery, Publications, Postage and Communications 698,613  458,007
 Other Operating Costs  1,906,815  2,356,597
   
  5,138,378 5,486,959
  
  
 Operating costs of €5,138,378 includes an amount of €13,899 related to staff hospitality.
 
7. Debtors (all due within one year) 
 
 Trade Debtors  917,685  1,013,810
 Prepayments  181,669  26,339
 Other Debtors  29,836  151,517
   
  1,129,190  1,191,666
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NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2016
8. Creditors (amounts falling due within one year)  2016  2015
  €  € 
 
 
 Trade Creditors  191,082  367,776
 Accruals  6,508,352  6,554,867
 Deferred Revenue  1,102,945  1,272,212
 Revenue Commissioners  632,915  592,964 
  
  8,435,294  8,787,819
9. Cash and Cash Equivalents  As At   As At
  01/01/2016  Cashflow  31/12/2016 
  
  
 Cash at Bank and in Hand  475,265  1,514,327 1,989,592
 Demand Deposits  1,626,868  376,068  2,002,936
 
  2,102,133  1,890,395  3,992,528
 
10. Short Term Deposits    2016  2015
   €  € 
 
 
 Demand Deposits (convertible to cash on demand) 2,002,936  1,626,868
 Short Term Deposits (not immediately convertible to cash) 12,305,716  14,364,573 
  
  14,308,652  15,991,441
 
11. Administration Expenses    
 
 Surplus for the year was calculated having charged : -   
 Auditor’s Remuneration   16,000  16,000
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NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2016
12. Movement on Income  As At   As At
and Expenditure Reserves 01/01/2016  Movement  31/12/2016 
  €  € € 
  
Retained Reserves  19,288,937  544,854  19,833,791
Staff Superannuation Contributions 8,109,240  746,723  8,855,963
 
  27,398,177  1,291,577 28,689,754
 
13. Long Term Liabilities   
    
  Mortgage
  On 22 December 2004 the HPRA purchased its premises at Kevin O’Malley House, Earlsfort  
  Centre, Earlsfort Terrace, Dublin 2. The purchase was financed by way of a mortgage, secured 
  on the premises of €20,400,000 over 20 years from Bank of Ireland Corporate Lending.
  
  The HPRA is committed to making the following capital repayments on its mortgage : 
       
 
  - within one year    793,332  793,332
  - between one and five years    3,173,328  3,173,328
  - after five years    2,380,016  3,173,351
   
     6,346,676  7,140,011
14. Interest Rate Exposure    
 
 The HPRA have taken all necessary steps to minimise its interest rate exposure by fixing 2/3s  
 of the borrowings for the mortgage duration. The balance of the borrowings are fully offset 
 by cash reserves. As the mortgage is at a fixed rate, the Authority has no interest rate exposure. 
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NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2016
15. Financial Commitments
 Accommodation Costs (Note 6) includes expenditure of €285,984 in relation to operating leases. 
 
 On 28 January 2005 the HPRA signed a leasehold interest in respect of the 5th floor, Alexandra
 House Earlsfort Centre, Dublin 2. At 31 December 2016 this lease had 5 years and four months remaining. 
   
    
  2016  2015
   €  €
 The amounts due under this lease are as follows:
 - within one year 285,984  285,984
 - between one and five years  1,143,936  1,143,936
 - after five years  95,328  381,312
   
  1,525,248  1,811,232
16. Capital Commitments   
     
 Contracted For (Contract Signed)    2,094,971 1,877,410
 Not Contracted For  -  405,900
   
  2,094,971  2,283,310
 
17. Authority Remuneration
  
 Chairman’s Salary  11,970  20,520
 Authority Members’ Travel Expenses  8,284  9,106
   
  20,254  29,626
 Other than the Chairman, no other Authority Member receives a salary.
 
18. Staff Remuneration
    
 Chief Executive’s Total Remuneration
 Basic Salary  143,413  145,749
   
  143,413  145,749
  
  
 Mr. Pat O’Mahony served as Chief Executive during the period 1 January to 4 September 2015. 
 He received a salary of €99,535 during this period.
 Ms. Rita Purcell was appointed acting Chief Executive on 5 September 2015 and served in this
 capacity to 31 December 2015. Her salary for this period was €46,214.
 Ms. Lorraine Nolan was appointed Chief Executive on 1 January 2016.
 Mr. O’Mahony’s, Ms. Purcell’s and Ms. Nolan’s pension entitlements do not extend beyond the
 standard entitlements in the model public sector defined benefit superannuation scheme.
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NOTES TO THE FINANCIAL STATEMENTS 
For the year ended 31 December 2016
19. Related Party Transactions
  
 There have been no transactions with related parties which require disclosure under Financial
 Reporting Standard 102.
20. Prompt Payment of Accounts
  
 The Health Products Regulatory Authority (HPRA) confirms that it is complying with EU law
 in relation to prompt payments of account.
21. Exchange Rates
  
 The exchange rates used in preparing these financial statements were as follows : -
  
 2016 €1 = STG £0.85637
 2015 €1 = STG £0.73693
22. Provisions
  
 The HPRA has been notified of a number of legal proceedings or potential proceedings. The Authority 
 has provided in full for its ‘best estimate’ of the expenditure it is likely to incur in relation to those cases. 
 The Authority is availing of the reduced disclosures allowed by FRS 102 in instances where full 
 disclosure might prejudice seriously its position in a dispute with other parties on the subject matter 
 of the provision. 
23. Going Concern
  
 The HPRA has a reasonable expectation, at the time of appoving the financial statements, that 
 the HPRA has adequate resources to continue its operations. For this reason, the HPRA 
 continues to adopt the going concern basis in preparing the financial statements. 
 
24. Prior Year Adjustment
 
 In 2016, the Authority accounted for lump sum pension payments in Salaries and Wages. Staff 
Superannuation Contributions report gross contributions received. In 2015, the Authority had  accounted for 
such lump sums by netting the payments of €359,002 against superannuation contributions. 
The effects of this change in accounting treatment is to increase the 2015 Pension Costs by €359,002 and 
to increase the 2015 Staff Superannuation Contributions by €359,002. There is no overall effect on the 2015 
surplus.
25. Approval of Financial Statements
  
 The financial statements were approved by the Authority of the HPRA on 1 June 2017.
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Appendix 1 
2016 Committee Members
Management Committee
Dr. Lorraine Nolan  
Chief Executive 
Ms. Rita Purcell   
Deputy Chief Executive
Dr. Gabriel Beechinor  
Director of Veterinary Sciences
Dr. Jayne Crowe   
Director of Human Products 
Authorisation and Registration
Dr. Caitríona Fisher   
Director of Quality, Scientific Affairs 
and Communications
Dr. Joan Gilvarry   
Director of Human Products 
Monitoring
Mr. Kevin Horan
Director of Information Technology 
and Business Services 
Mr. John Lynch   
Director of Compliance
Ms. Lynsey Perdisatt   
Director Human Resources and 
Change
Authority
Ms. Ann Horan – Chairperson
Mr. Patrick Brangan
Mr. Wilfrid Higgins
Mr. David Holohan
Prof. Mary Horgan
Mr. Brian Jones
Prof. Elizabeth Keane
Prof. Caitriona O’Driscoll
Dr. Diarmuid Quinlan
Audit Committee
Mr. Patrick Brangan – Chair
Mr. David Holohan
Prof. Elizabeth Keane
Advisory Committee for 
Human Medicines
Prof. Mary Horgan – Chair
Dr. Kevin Connolly
Prof. Desmond Corrigan
Ms. Maria Egan
Prof. Tom Fahey
Prof. David Kerins
Ms. Fionnuala King
Prof. Patrick Murray
Dr. Fionnuala Ní Ainle
Dr. Brian O’Connell
Mr. Ronan Quirke
Dr. Patrick Sullivan
Advisory Committee for 
Veterinary Medicines
Mr. Patrick Brangan – Chair
Dr. Ruadhrí Breathnach 
Ms. Eugenie Canavan
Dr. Martin Danaher
Dr. Helena Kelly
Dr. Nola Leonard
Dr. Bryan Markey
Dr. Ciaran Mellet
Dr. Warren Schofield
Dr. Robert Shiel
Dr. Christina Tlustos
Advisory Committee for 
Medical Devices
Mr. Wilfrid Higgins – Chair
Prof. David Barton
Dr. Vivion Crowley
Mr. Ger Flynn
Dr. Fergal McCaffrey
Ms. Margaret O’Donnell
Prof. Martin O’Donnell
Prof. Richard Reilly
Prof. Mary Sharp
Mr. Sean-Paul Teeling
Prof. Sean Tierney
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Clinical Trial Sub-
Committee of Advisory 
Committee for Human 
Medicines
Dr. Patrick Sullivan – Chair
Dr. Liam Bannan
Dr. Geraldine Boylan
Dr. Paul Browne
Dr. Peter Crean
Prof. Lee Helman (CT Expert)
Dr. Filip Janku (CT Expert)
Dr. Catherine Kelly
Dr. Patrick Morris
Dr. Thomas Peirce 
Dr. Bryan Whelan
Dr. Jennifer Westrup
Advisory Sub-Committee 
for Herbal Medicines
Prof. Des Corrigan – Chair
Dr. James Barlow
Dr. Kevin Connolly
Mrs. Ingrid Hook
Ms. Claudine Hughes
Ms. Anna-Maria Keaveney
Dr. Celine Leonard
Dr. Donal O’Mathuna
Dr. Camillus Power
Dr. Helen Sheridan
Dr. Emma Wallace
Experts Sub-Committee of 
the Advisory Committee 
for Human Medicines
Prof. Mary Horgan – Chair
Dr. Linda Coate
Dr. Kevin Connolly
Dr. James Colville
Dr. Noreen Dowd
Dr. Stephen Eustace
Dr. Stephen Flint
Dr. Tim Fulcher
Dr. Joseph Galvin
Dr. Patrick Gavin
Dr. Paul Gallagher
Dr. Kevin Kelleher
Dr. Catherine Kelly
Dr. Mary Keogan
Prof. David Kerins
Dr. Mark Ledwidge
Dr. Frank Murray
Dr. Yvonne O’Meara
Dr. Cormac Owens
Mr. Ashley Poynton
Dr. Brion Sweeney (resigned 
March 2016)
Dr. Jogin Thakore
Dr. Gerry Wilson
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Presentations 2016
85
Third Level / Professional Development Presentations and Training 
Institution Course Presentation Title
Athlone IT Veterinary Nursing Regulation of Veterinary Medicines 
BioPharmaChem Ireland CMC Regulatory Affairs Training Common Errors in Variations
BioPharmaChem Ireland CMC Regulatory Affairs Training Common Deficiencies in CMC Part of 
Application
BioPharmaChem Ireland CMC Regulatory Affairs Training Introduction to Regulatory Affairs – 
Module 3 of the CTD
CMG Reducing Medication Errors In 
Healthcare Services
Medication Errors – The Regulatory 
Role
DIT Pharmaceutical Quality Assurance The GMP Inspection Process
DIT Medical Device Decontamination Medical Device Legislation And 
Vigilance
Dundalk IT Veterinary Nursing Regulation of Veterinary Medicines 
EU Network Training Centre Clinical Trials – General Regulation Safety Issues and Regulatory Action
EU Network Training Centre Clinical Trials Safety Safety Reporting Routes
EU Network Training Centre Clinical Trials Safety Reference Safety Information
EU Network Training Centre Clinical Trials Safety DSUR Assessments
EU Network Training Centre Clinical Trials - Clinical Assessment Introducing the Part I AR Template
Hospital Pharmacists Association of 
Ireland 
Intern Study Day The Role of the HPRA’s Health 
Product Distribution Section
Irish Association of Physicists in 
Medicine
Radiation Safety Course: Dental 
Radiology Equipment 
CE Marking
LAST Laboratory Animal Science and 
Training (multiple courses)
Implementation of Scientific Animal 
Protection Legislation 
Letterkenny IT Veterinary Nursing Regulation of Veterinary Medicines 
Medicademy Regulatory Affairs – Module 10 Biosimilars – Quality, non-clinical and 
clinical requirements
Medicademy Regulatory Affairs – Module 14 Detail and Critical Summaries
Medicademy Regulatory Affairs – Module 14 Special Cases: Cascade, MUMS, 
GMOs etc.
PIC/S Expert Circle on Quality Risk 
Management
Advanced Quality Risk Management 
Training
Use of QRM to support a PAT 
Change Control
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PIC/S Expert Circle on Quality Risk 
Management
Advanced Quality Risk Management 
Training
Risk-based Classification of GMP 
Deficiencies
PIC/S Expert Circle on Quality Risk 
Management
Advanced Quality Risk Management 
Training
Formal vs. Informal Quality Risk 
Management
PIC/S Expert Circle on Quality Risk 
Management
Advanced Quality Risk Management 
Training
Risk-based GMP Inspection Planning
PLS Pharma Responsible Person Forum Responsible Person – A Regulators 
Perspective
QQI Retail, Sale and Supply of Animal 
Remedies
Presentation to Graduates
RCSI Pharmacy Quality Defect Investigations and 
Product Recalls
RCSI Pharmacy Regulation of Biological Medicinal 
Products
RCSI Nurse / Midwife Prescribing (1) The Role of the HPRA and (2) 
Pharmacovigilance
RCSI Pharmacy Regulatory Affairs and Regulatory 
Authorities
Sligo IT Medical Biotechnology and  
Pharmaceutical Science 
Quality Defects / Pharmacovigilance
St. Johns, Cork Veterinary Nursing Regulation of Veterinary Medicines 
TCD Centre for Health Sciences: 
Regulatory Affairs Workshop
Medical Devices Legislation
TCD QP Forum HPRA - Overview of Strategy 2016-
2020
TCD Pharmaceutical Medicine Quality Aspects in the Regulation of 
Biologicals and ATMPs
TCD Pharmaceutical Medicine Product Recalls and MA Withdrawals
TCD Pharmaceutical Medicine Traditional Herbal Medicinal Products
TCD Pharmaceutical Medicine Collection and Reporting of Adverse 
Events in Clinical Trials
TCD Pharmaceutical Medicine Pharmacovigilance – Where Are We 
Now?
TCD Pharmaceutical Medicine Communication of Drug Safety Data
TCD Pharmaceutical Medicine Risk Management Plans
TCD Pharmaceutical Medicine International Quality 
Standards and Pharmacopoeias
TCD Pharmaceutical Medicine Falsified Medicines Directive
TCD Pharmaceutical Medicine Recent Developments in 
Pharmacovigilance – A Perspective 
from PRA
TCD Pharmaceutical Medicine Regulation of Medical Devices
TCD Pharmaceutical Medicine Application of Quality Risk 
Management to Quality Defects and 
Recalls 
TCD Pharmacy An Overview of Pharmacovigilance
TCD Pharmacy Investigation of Quality Defects
TOPRA Autumn Introductory Course Module 2 of the CTD
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UCC Medicine Notification of Adverse Reactions
UCC Pharmacy / Pharmaceutical 
Technology and Quality Systems
Quality Defect Investigations and 
Product Recalls
UCC Medicine Notification of Adverse Reactions
UCD Association for Veterinary Teaching 
and Research Work
Implementation of Scientific Animal 
Protection Legislation
UCD Veterinary Medicine / Veterinary 
Nursing
Regulation of Veterinary Medicines
UCD Nurse / Midwife Prescribing (1) The Role of the HPRA and (2) 
Pharmacovigilance 
UCD Clinical and Translational Research Medical Devices – Principles and 
Practices of Clinical Research (two 
presentations)
University of Hertfordshire Pharmacovigilance Update on the EU Pharmacovigilance 
Legislation
Event / Organiser Presentation Title
Advanced Manufacturing Ireland / Sligo IT Regulation of Medical Devices and Collaborative 
Robots
Animal and Plant Health Association: Animal Health 
Conference
Surveillance and Monitoring of Veterinary Medicines
Annual OMCL Network Meeting A New Risk-based Approach to Medicines 
Surveillance Testing (2 presentations)
Annual OMCL Network Meeting Work of the Communications Working Group
Association for Veterinary Teaching and Research Work Regulation of Animal Research using Non-Rodent 
Models
BioPharma Ambition Conference (IBEC) The Regulator’s Perspective on the future of 
Biopharma Manufacturing
Biosimilars 360° Symposium (RCPI) Evolving Landscape on Regulatory Data – 
Requirements to Demonstrate Biosimilarity  
China International Medical Device Regulators 
Conference
Regulatory developments in Europe and the new EU 
Regulations
Cosmetic, Toiletry and Perfumery Association 
Cosmetovigilance Seminar
Working with Regulation (EC) 1223/2009, as 
amended – A Regulator’s Viewpoint
Drug Information Association (DIA) International Regulatory Convergence, Collaboration 
and Cooperation
DIA Conference on Falsified Medicines Considerations related to Falsified Medicines 
DIA Workshop: Regulation of Veterinary Medicinal 
Products
Safety Surveillance in the Market: Pharmacovigilance
DIA Pharmaceuticals and Globalisation
EMA Focus Group on Anthelmintic Resistance Impact of Specific Formulations on Anthelmintic 
Resistance
Regulatory Presentations  
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EMA Tenth Stakeholder Forum on the 
Pharmacovigilance Legislation 
Pharmacovigilance Impact Evaluation – For Better 
Pharmacovigilance
European Validation Week Meeting Risk Based Validation Activities (two presentations)
Future Health Summit Regulation of Standalone Software as a Medical 
Device
French Refrigeration Association (AFF) Cold Chain 
Conference
Inspection Findings for Cold Chain Products
Health Research Board CRCI Official Launch HPRA – Supporting Clinical Research in Ireland
HSE Healthcare User Group Meeting Introduction to the new Medical Device Regulation 
and Unique Device Identification (UDI)
HSE National Distribution Centre Medical Devices Regulations: New Distributor 
Requirements 
HSE Workshops: Medical Device Equipment QA+I tool Medical Device Vigilance (multiple presentations)
ICMRA The EU System of Pharmacovigilance and Risk 
Management
IFPAC Cortona Conference Continuous Manufacturing – Some Assessment and 
GMP Considerations
IMSTA Distributor Breakfast Briefing Medical Device Distributor Pilot Inspections (two 
presentations)
Institute of Validation and Technology Complaints 
Congress and Recalls Summit
Application of Quality Risk Management to Quality 
Defect Investigations
International Development Ireland: Saudi Arabian 
Delegation
Regulation of Medical Devices in Ireland and Europe
International Society for Pharmaceutical Engineering 
(ISPE)
Continuous Manufacturing – Some Assessment 
Considerations
Irish Clinical Embryologists (ICE) Association Presentation on new Directive Requirements for 
Coding of Tissues
Irish Cardiac Society Medical Device Vigilance
Irish Decontamination Institute Best Practice in Decontamination
Irish Medtech Association Global Access Conference Overview of the International Medical Device 
Regulators Forum (IMDRF)
Irish Medtech Association Global Access Conference Introduction to new Regulations for Medical Devices 
and IVDs
Irish Medtech Association Additive Manufacturing 
Workshop
Regulation of Additive Manufacturing for Medical 
Devices
ISPE International Conference on 
Pharmacoepidemiology
PRAC Experience on Risk Management Plans
ISPE International Conference on 
Pharmacoepidemiology
Real World Effectiveness – How Effective is it?
ISPE International Conference on 
Pharmacoepidemiology
Pharmacoepidemiology and Risk Management 
Planning
Life Sciences Product Complaints Congress The Evaluation from a Quality Risk Management 
Perspective of Quality Defects
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Macedonian OMCL Quality Risk Management in the GMP Environment
Market Surveillance Forum Overview of new Regulations for Medical Devices 
and IVDs
Medtec Annual Conference Introduction to new Regulations for Medical Devices 
and IVDs
Medtech Week (RCSI and Irish Medtech Association) Clinical Research of Medical Devices
National Steering Group for Collaborative Robotics Regulation of Medical Devices and Collaborative 
Robots
Parenteral Drug Association (PDA) GMP Inspectors – Benefits of Interacting with 
Pharmaceutical Assessors
PDA Formal and Informal Quality Risk Management
Pharma-Bio Serv Human Error Workshop The Evaluation from a Quality Risk Management 
Perspective of Quality Defects
Pharmaceuticals and Medical Devices Agency, Japan GMP Inspection Planning using Risk-based Principles
Pharmaceuticals and Medical Devices Agency, Japan Performing a Mock GMP Inspection
Q1 Productions Conference Competent Authority Perspective – Medical Device 
Regulation
Regulatory Science Ireland Quality Defects Research Project
SCOPE Training: Lifecycle Pharmacovigilance Work Package 8: Practical Guidance on PSUR/
PSUSA assessment
SCOPE Workshop: Risk Communication Work Package 6, Topic 2: Impact Assessment
Society of Chief and Principal Dental Surgeons Medical Device Vigilance
Swissmedic Output of the Defect Best Practices Working Group
The Pharmaceutical Managers’ Institute The Role of the HPRA and our Key Areas of Focus
TOPRA Annual Symposium Authorisation of Veterinary Medicinal Products 
Containing (potential) PBT or vPvB Substances
Technology Sciences Group Europe Market Surveillance of Cosmetic Products in Ireland
WHO Workshop: Post-Market Surveillance of IVDs What is Expected of Regulators?
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Human Medicines Safety: 
Publications and Articles
Drug Safety Newsletters
Edition Topics
February 
73rd Edition
- Educational materials – Optimising the safe and effective use of medicinal products
- Adverse reaction reporting – A reminder 
- New Direct Healthcare Professional Communications published on the HPRA website
April 
74th Edition
- High strength insulin preparations
- Antiretroviral medicines – Updated advice on lipodystrophy and lactic acidosis
- Natalizumab (Tysabri) – Updates to progressive multifocal leukoencephalopathy (PML) risk 
minimisation measures
- Fingolimod (Gilenya) – Risks related to its immunosuppressive effects
- New Direct Healthcare Professional Communications published on the HPRA website 
May
75th Edition
- Withdrawal of fusafungine-containing medicinal products
- Updated advice on the risk of diabetic ketoacidosis during treatment with SGLT2 inhibitors
- Risk of pneumonia with inhaled corticosteroids for chronic obstructive pulmonary disease 
(COPD)
- Risk of hepatitis B reactivation with BCR-ABL Tyrosine Kinase Inhibitors (TKIs)
- Aflibercept (Zaltrap) – Minimising the risk of osteonecrosis of the jaw (ONJ)
- New Direct Healthcare Professional Communications published on the HPRA website
August 
76th Edition
- Valproate containing medicines – Additional educational materials available for healthcare 
professionals and patients
- Miconazole and warfarin – Reminder of the potential for interaction
- Levonorgestrel releasing intrauterine devices-Recommendation to prescribe by brand 
name
- Implanon NXT-Risk of migration in vasculature and lung 
- New Direct Healthcare Professional Communications published on the HPRA website
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October 
77th Edition
- Direct-acting antivirals for hepatitis C – Advice on interaction potential with warfarin and 
other vitamin K antagonists leading to a reduced international normalized ratio (INR)
- Advice on potential interaction between cobicistat-containing products and corticosteroids 
primarily metabolized by CYP3A – Risk of adrenal suppression
- Adverse reaction reporting during 2015
- New Direct Healthcare Professional Communications published on the HPRA website
December 
78th Edition
- Otezla (apremilast) – Important advice regarding suicidal ideation and behaviour
- Lenalidomide (Revlimid) – Advice regarding viral reactivation
- Levetiracetam 100mg/ml oral solution – Global reports of medication errors resulting in the 
administration of higher than intended doses of levetiracetam
- Improved access to educational materials on the HPRA website
- New Direct Healthcare Professional Communications published on the HPRA website
Articles in External Publications
Month Publication Topics
January MIMS - Bisphosphonates – Small risk of osteonecrosis of the external 
auditory canal
February IMF - Reminder – Oral methotrexate and risk of unintentional 
overdose due to medication errors
February MIMS / MIMS 
Respiratory 
Supplement
- HPRA commences publication of educational materials and 
tools for medicines
March MIMS / MIMS Cardiac 
Supplement
- Reminder – Oral methotrexate and risk of unintentional 
overdose due to medication errors
- Ibuprofen – Review confirms small increased cardiovascular risk 
with daily doses at or above 2400mg
April MIMS - High strength insulin preparations
May MIMS / MIMS 
Oncology Supplement
- Fingolimod (Gilenya) – Risks related to its immunosuppressive 
effects
- HPRA commences publication of educational materials and 
tools for medicines
June MIMS / MIMS 
Respiratory 
Supplement
- Withdrawal of fusafungine-containing medicinal products
- Risk of pneumonia with inhaled corticosteroids for chronic  
obstructive pulmonary disease (COPD)
July MIMS / MIMS 
Diabetes Supplement
- Risk of pneumonia with inhaled corticosteroids for chronic  
obstructive pulmonary disease (COPD)
August IMF - Valproate-containing medicines – New educational materials 
available for healthcare professionals and patients
92
HPRA Annual Report 2016
August MIMS - Miconazole and warfarin – Reminder of the potential for 
interaction
September MIMS / MIMS 
Rheumatoid Arthritis 
Supplement
- Valproate-containing medicines – Additional educational 
materials available for healthcare professionals and patients
- Reminder – Oral methotrexate and risk of unintentional 
overdose due to medication errors
October MIMS / MIMS 
Women’s Health 
Supplement
- Implanon NXT – Risk of device migration in vasculature and lung
November MIMS / MIMS 
Diabetes Supplement
- Fingolimod (Gilenya) – Risks related to its immunosuppressive 
effects
- High strength insulins
December MIMS / MIMS 
Compendium
- Direct-Acting Antivirals for Hepatitis C – Advice on interaction 
potential with warfarin and other vitamin K antagonists leading 
to a reduced international normalised ratio (INR)
- Valproate-containing medicines – Additional educational 
materials available for healthcare professionals and patients
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European and National  
Committee / Working Group 
Participation
Committee/Working Group Organisation Meetings 
in 2016
Competent Authorities for Medical Devices (CAMD) CAMD 2
Competent Authorities for Medical Devices – Executive Group CAMD 4
Medical Device Compliance and Enforcement Working Group 
(COEN)
CAMD 2
Notified Bodies Operations Group (NBOG) CAMD 2
Cross Border Controlled Drug Regulatory Meeting Care Quality 
Commission
4
Committee of Experts on Minimising Public Health Risks Posed by 
Counterfeiting of Medical Products and Similar Crimes 
Council of Europe 2
National Meeting on Endocrine Disruptors Department of 
Agriculture
1
Early Warning and Emerging Trends Department of Health 2
Medication Safety Forum Department of Health 3
Chemicals Interdepartmental / Agency group Department of 
Jobs, Enterprise and 
Innovation
2
Market Surveillance Forum Department of 
Jobs, Enterprise and 
Innovation
2
Active Pharmaceutical Ingredients (API) Working Group of the 
OMCL Network 
EDQM 1
Annual OMCL Network Meeting EDQM 1
Centrally Authorised Products (CAP)  OMCL Network Meeting EDQM 1
Counterfeit Products Working Group of the OMCL Network EDQM 2
MRP/DCP OMCL Network Meeting EDQM 2
OMCL Network Communications Group EDQM 2
Committee for Advanced Therapies (CAT) EMA 11
Committee for Herbal Medicinal Products (HMPC) EMA 6
Committee for Medicinal Products for Human Use (CHMP) EMA 11
Committee for Medicinal Products for Veterinary Use (CVMP) EMA 11
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Committee for Orphan Medicinal Products (COMP) EMA 11
GCP Inspectors Working Group EMA 4
GMDP Inspectors Working Group EMA 4
Heparin Working Group (Telecon) EMA 2
Immunological Working Party - Veterinary EMA 3
Paediatric Committee (PDCO) EMA 12
Pharmacovigilance Inspectors Working Group (Human and 
Veterinary)
EMA 3
Pharmacovigilance Risk Assessment Committee (PRAC) EMA 11
Pharmacovigilance Working Party - Veterinary EMA 6
Quality Defects / Rapid Alerts Meetings EMA 2
Quality Working Party EMA 4
Safety Working Party – Veterinary EMA 4
Scientific Advice Working Party – Veterinary EMA 11
Signal Management and Review Team (SMART) EMA 13
Statement of Non-compliance with GDP Process Drafting Group EMA 2
EU Pharmacovigilance Business Team EMA / National 
Competent Authorities
12
Health Advisory Committee Environmental 
Protection Agency
3
Clinical Investigation and Evaluation Working Group European Commission 4
Competent Authorities for Blood European Commission 2
Competent Authorities for Organs for human transplantation European Commission 1
Competent Authorities for Tissues and Cells European Commission 2
Cosmetic Standing Committee and Working Group European Commission 3
Drafting Group for GMP Guide for Advanced Therapy Medicinal 
Products (ATMPs) 
European Commission 17
Drug Precursor Working Group European Commission 2
European Commission Sub-working Group on Cosmetovigilance European Commission 1
In Vitro Diagnostic Technical Group (IVDTG) European Commission 2
MDR Eudamed Steering Committee European Commission 2
MDR/IVDR Implementing Legislation European Commission 2
Medical Device Expert Group (MDRG) – EU IMDRF Coordination European Commission 2
Medical Device Vigilance Experts Group European Commission 4
Medical Device Vigilance Monthly Teleconference European Commission 12
Meeting of Expert Group on Safety Features European Commission 4
Platform of European Market Surveillance Authorities for 
Cosmetics (PEMSAC) Market Surveillance
European Commission 1
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Platform of European Market Surveillance Authorities for 
Cosmetics (PEMSAC) Analytical Methods
European Commission 1
Precursor Drafting Group European Commission 2
Single European Code Working Group Meeting European Commission 2
VISTART Project on Guidance for Regulators of Blood, Tissues and 
Cells, and Organs
European Commission 7
SCOPE Work Package Meetings European Commission 
/ National Competent 
Authorities
22
Working Party on Pharmaceuticals and Medical Devices European Council 13
Food Fraud Task Force FSAI 1
Zika Scientific Advice Committee  Health Protection 
Surveillance Centre
4
Clinical Trials Facilitation Group (CTFG) HMA 6
Co-ordination Group for Mutual Recognition and Decentralised 
procedures – Human (CMDh)
HMA 11
Co-ordination Group for Mutual Recognition and Decentralised 
procedures – Veterinary (CMDv)
HMA 11
Drafting Group on Risk Based Surveillance Testing HMA 5
Meeting of Heads of Medicines Agencies under EU Presidency HMA 4
Pharmacovigilance Procedures Work Sharing Working Party HMA 8
Working Group of Communications Professionals HMA 2
Working Group of Enforcement Officers HMA 3
Working Group of Quality Managers HMA 2
National Cosmetics Surveillance Forum HPRA / HSE 3
National Blood Glucose Meter Guidelines Group HPRA / HSE / 
Pharmacists
4
Environmental Health Service Steering Committee and 
Operational Group
HSE Environmental 
Health Service
6
Sub-group for Drafting of ICH Q12 ICH 3
Supply Chain Integrity Drafting Group (Telecon) ICMRA 11
International Medical Device Regulators Forum (IMDRF) 
Management Committee
IMDRF 1
IIWA Organising Committee Interpol 1
Pangea Liaison Interpol 2
HPRA and UK Department for Business Innovation and Skills Ireland / UK Working 
Group
3
Forum on the Advertising of Medicines (FOAM) Network Meeting  MHRA 1
Cosmetic Standards Advisory Group NSAI 2
PIC/S Committee of Officials Meeting PIC/S 2
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PIC/S Executive Bureau Meeting PIC/S 2
PIC/S Quality Risk Management (QRM) Expert Circle PIC/S 1
National Immunisation Advisory Committee                RCPI 6
National Medicines Forum RCPI 1
Point of Care Consultative Group Meetings RCPI 4
Present and Future of Countering Pharmaceutical Crime – Project 
ALPhA
University of Osnabruck 1
Annual National Pharmacovigilance Centres Meeting WHO 1
Board of the WHO/UMC Collaborating Centre WHO 3
Member State Mechanism on Substandard / Spurious / Falsely-
labelled / Falsified / Counterfeit Medical Products
WHO 1
Notify Project Technical Meeting WHO / Italian National 
Transplant Centre 
1
97
Appendix 5 
Glossary
AED Automated External Defibrillator 
AMR  Antimicrobial Resistance
APMI Association of Pharmaceutical Manufacturers in Ireland 
ART  Assisted Reproductive Technology
BEMA Benchmarking of European Medicines Agencies
BPCI BioPharmaChem Ireland
CAMD Competent Authority for Medical Devices 
CD Controlled Drug 
CESP Common European Submission Portal
CHMP Committee for Medicinal Products for Human Use 
CMC Chemistry, Manufacturing, and Controls
CMD(h) Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human
CMD(v) Co-ordination Group for Mutual Recognition and Decentralised Procedures - Veterinary 
CMS Concerned Member State
COEN  European Compliance and Enforcement
CVMP  Committee for Medicinal Products for Veterinary Use 
DCP  Decentralised Procedure 
DHPC  Direct Healthcare Professional Communications
DJEI Department of Jobs, Enterprise and Innovation
EDQM European Directorate for Quality of Medicines 
EEA European Economic Area 
EMA European Medicines Agency 
EPA Environmental Protection Agency
EUDAMED European Database on Medical Devices
FOAM  Forum on the Advertising of Medicines
FVD Food and Veterinary Office
FSAI Food Safety Authority of Ireland
GCP Good Clinical Practice 
GDP Good Distribution Practice 
GMP Good Manufacturing Practice
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GVP Good Vigilance Practice 
HEA Healthcare Enterprise Alliance
HIQA Health Information and Quality Authority 
HMA Heads of Medicines Agencies
HMPC Committee on Herbal Medicinal Products 
HSE Health Service Executive
HSS Health Systems Strengthening
IAHS  Irish Association of Health Stores
IBTS Irish Blood Transfusion Service 
ICH International Conference of Harmonisation 
ICDA  Irish Cosmetics, Detergent & Allied Products Association
ICMRA International Coalition of Medicines Regulatory Authorities
ICSR Individual Case Safety Reports 
IDA Industrial Development Authority
IDMP  Identification of Medicinal Products
IGMA Irish Generic Medicines Association
IHTA  Irish Health Trade Association
IMDRF International Medical Device Regulators Forum
IMF Irish Medicines Formulary
IMSTA  Irish Medical and Surgical Trade Association
IMVO Irish Medicines Verification Organisation 
IPHA Irish Pharmaceutical Healthcare Association
IVD In-Vitro Diagnostics 
JAP Joint Audit Programme
JRC Joint Research Centre 
LDP Leadership Development Programme 
MAH Marketing Authorisation Holder 
MDSAP Medical Device Single Audit Program 
MHRA  Medicines and Healthcare products Regulatory Authority 
MIMS Monthly Index of Medical Specialities 
MS Member State
MRP Mutual Recognition Procedure 
NBOG  Notified Body Operations Group 
NCAR National Competent Authority Report
NHO National Haemovigilance Office
NSAI National Standards Authority of Ireland 
OMCL Official Medicines Control Laboratories 
OPW Office of Public Works
OTC  Over-the-Counter 
PASS  Post Authorisation Safety Studies 
PIP Paediatric Investigational Plans 
PDP Performance Development Programme
PHECC Pre-Hospital Emergency Care Council
PIC/S Pharmaceutical Inspection Co-operation Scheme 
PIP Paediatric Investigational Plan
PL Package Leaflet
PMO Project Management Office
PPC Pay-per-click
PRAC Pharmacovigilance Risk Assessment Committee
PSI Pharmaceutical Society of Ireland
PSUR Periodic Safety Update Report
PSUSA EU Single Assessment Procedures
QRM Quality Risk Management
RCPI Royal College of Physicians in Ireland
RMP Risk Management Plan 
RMS  Reference Member State 
RPS Regulated Product Submission
SCOPE Strengthening Collaboration for Operating Pharmacovigilance in Europe
SEAI Sustainable Energy Authority of Ireland
SI Statutory Instrument
SmPC Summary of Product Characteristics
THMP Traditional Herbal Medicinal Product
TOPRA The Organisation for Professionals in Regulatory Affairs
UMC Uppsala Monitoring Centre 
VFC Voluntary Formal Caution 
VHP Voluntary Harmonisation Procedure
VISTART       Safety of Transfusion, Assisted Reproduction and Transplantation
WHO World Health Organization 
ZAMRA  Zambian Medicines Agency 
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